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Abstract
Health-Related Quality of Life in Multiple Sclerosis: Measurement, Predictors and
Utilization in Routine Clinical Practice
Vivek S. Pawar
There are a large number of patient-reported questionnaires to assess health-related
quality of life (HRQoL) in patients with multiple sclerosis (MS). In order to make a
recommendation for use in clinical practice, a comparison of their psychometric properties is
necessary. In addition to accurate assessment, it is also necessary to identify factors that
have a significant impact on HRQoL. Further, lack of use of HRQoL information in clinical
practice warrants examination of attitudes and behavior of neurologists about HRQoL
assessment and their intention to consider incorporating HRQoL information in their decision
making. This study collected data from patients with MS as well as neurologists and
consisted of two phases. Phase I involved collection of primary data from noninstitutionalized patients with MS. Data from Phase I was used to measure HRQoL, identify
factors affecting HRQoL, and compare the measures on their psychometric properties. A
mail survey of neurologists was performed in Phase II. This data facilitated investigation of
factors that have a significant influence on neurologists’ intention to assess HRQoL
information in clinical practice. Possible predictors of intention such as: attitude, subjective
norms, perceived behavior control and practice characteristics were included. Based on
analyses of Phase I, no measure emerged clearly or consistently better or worse than the
others in terms of psychometric properties. Hence, a recommendation of one particular
measure for use in MS-related clinical practice cannot be substantiated. The choice of a
measure ultimately rests on the neurologist and may be related to their perception of its
usefulness and their intention to use such information in the routine care. With respect to
predictors of HRQoL, visual function among other factors was found to have a significant
and independent impact on HRQoL in patients with MS. This suggests that visual screening
should be performed periodically using patient-reported questionnaires in addition to
conventional tests of visual acuity. Over 90% of neurologists reported that they did not use
standardized HRQoL questionnaires in clinical practice. Organizations such as the American
Academy of Neurology and fellow neurologists can exert significant influence on
neurologists’ intention to assess HRQoL information in clinical practice.
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Chapter 1: Introduction and Study Objectives

Health-Related Quality of Life in Multiple Sclerosis
Multiple sclerosis (MS) being a progressive neurological disease with no cure, lends
itself as an important area for health-related quality of life (HRQoL) research. The available
treatments have only a modest effect on the course of the disease with MS patients reporting
lower satisfaction with life, not only compared to people without any disease, but also those
with chronic illnesses such as inflammatory bowel disease, rheumatoid arthritis, epilepsy,
and diabetes (Hermann et al., 1996; Rudick, Miller, Clough, Gragg, & Farmer, 1992). There
are several ways in which MS can have an impact on patients’ HRQoL. MS causes a
disturbance in normal physiological functioning due to symptoms such as motor sensory
impairments, ambulatory problems, bowel and bladder problems, cognitive disturbances,
sexual dysfunction, and vision problems. The progressive nature of the disease elicits a
pervasive impact on patients' lives, with substantial negative consequences for family and
working life, which can manifest during the most active and productive period of people's
lives (Solari & Radice, 2001).
Within 10 years of onset, half of all MS patients are unable to fulfill household and
employment responsibilities; within 15 years, half of the patients are unable to walk unaided;
and within 25 years half require a wheelchair (Confavreux, Vukusic, Grimaud, & Moreau,
1999). MS patients can be under immense social strain as the need for help, risk of divorce,
loss of contact with relatives, difficulty leaving the house, need for structural changes in the
house and need for pension can increase with worsening disability (Stenager, Stenager,
Knudsen, & Jensen, 1994). Since it usually occurs in young adults it can have an
overwhelming influence on future productivity and personal development. The
1

unpredictable course which the disease follows makes it very difficult for patients to
anticipate and deal with the periods of relapses and remissions (Benito-Leon).
Although no curative treatments exist for MS, a number of parenterally administered
immunological drugs have been developed to curb the progression of the disease. These
treatments however, are not without their shortfalls. Treatment with interferon beta which is
administered via injections can produce side effects that may have a deleterious effect on a
patient’s quality of life irrespective of whether it is given daily or once a week. In addition,
the side effects of this treatment seem to increase with time. Adverse effects such as
cutaneous ulceration and local pain at the injection site as well as flu like symptoms have
been reported in MS patients on interferon therapy (Logan-Club & Stacy, 1995; Inafuku,
Kasem Khan, Nagata, & Nonaka, 2004; Gottberg, Gardulf, & Fredrikson, 2000).
Skin reactions in response to disease modifying therapy have the potential to evolve
into serious lesions culminating in infection, necrosis, and in some circumstances requiring
surgical repair (Frohman et al., 2004). In addition to local skin reactions, therapy with
glatiramer acetate and mitoxantrone has also been associated with several adverse events.
Systemic adverse events such as flushing, chest-tightness, sweating, palpitations and anxiety
have been observed in patients on glatiramer acetate therapy (Munari, Lovati, & Boiko,
2004). Adverse events such as nausea, alopecia, infections, menstrual disorders, risk of
cardiotoxicity and malignancy may occur following administration of mitoxantrone (Edan,
Morrissey, & Le Page, 2004). Side-effects are rarely incorporated in the overall results of a
trial or intervention. They are either listed separately or often ignored.
Physicians generally lean towards assessing physical disability in MS patients, but are
skeptical about the additional benefits of measuring HRQoL (Barbotte, Guillemin, & Chau,
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2001). HRQoL in MS has been known to correlate with measures of impairment and
disability such as the Expanded Disability Status Scale (EDSS). However, this correlation
has been found to vary from 2% to 29% (on the correlation coefficient) depending upon the
presence of other influencing factors such as fatigue, cognition, mood disorders etc.
(Benedict et al., 2005; Patti et al., 2003; Fruehwald, Loeffler-Stastka, Eher, Saletu, &
Baumhackl, 2001). The EDSS has to be administered by the physician and as a result certain
patient-centered domains of health which may contribute to HRQoL may be overlooked.
This can be a problem because it has been noted that patients with multiple sclerosis and
possibly those with other chronic diseases are less concerned than their clinicians about
physical disability in their illness (Rothwell, McDowell, Wong, & Dorman, 1997).
MS patients identify role limitations, cognition and emotional problems as having a
significant influence on their HRQoL in addition to just the physical manifestations of the
disease. Murphy and colleagues have shown that these domains are substantially lower in
patients with MS compared with controls, and that these changes correlate poorly with
neurological impairment and disability as measured by the EDSS (Murphy et al., 1998).
Thus, assessment of quality of life during routine care of MS patients might alert health
professionals to less obvious burdens of the disease. These may include factors that are
affected by the disease process, are more closely related to overall HRQoL, and may also be
adversely affected by side effects of treatment.

3

Factors Affecting Health-Related Quality of Life in MS
Neuro-ophthalmologic manifestations are common and disabling in patients with MS.
Any area of the visual system can be affected, including the optic nerves, chiasm, tracts and
even optic radiations, leading to a variety of symptoms from blurring to distortion of vision
(Nordmann, Saraux, & Roullet, 1987; Warner & Lessell, 1994). Although visual symptoms
in MS may precede, occur at onset, or develop during the course of the disease, they may
represent the most prominent symptoms of MS from the patient’s point of view. Visual
symptoms may cause difficulties with activities used in day-to-day life such as dressing,
eating, writing, simple communications or interactions with others, and daily travel
(Stelmack, 2001; Keeffe, Lam, Cheung, Dinh, & McCarty, 1998). In addition to daily
activities and functional status, mood level and social relationships can particularly be
affected by visual impairment (Carabellese et al., 1993). Given the wide-spread impact, it is
not surprising that visual impairment has been found to be associated with overall HRQoL in
MS patients. This was noted in studies which used visual subscales of the general or
functional status measures to correlate with the overall quality of life scores (Rudick et al.,
1992; Fischer et al., 1999).
Objective measurements of vision impairments, particularly measures of visual acuity
and visual fields have also been commonly used to represent a patient’s functional
capabilities during treatment. The term objective is usually used when the variable is
manifest, that is, a publicly observable and quantifiable attribute or behavior. Since many
clinical treatment trials depend on such objective measures as primary study variables, there
is a growing demand to include subjective patient-based visual function assessments, which
can be accomplished with several questionnaires that have been developed exclusively for
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this purpose (Massof & Rubin, 2001; 1993; USDHHS, 1993). These instruments include the
Visual Function Index (VFI) (Bernth-Petersen, 1981), Activities of Daily Vision Scale
(ADVS) (Mangione et al., 1992), 14-Item Visual Functioning Index (VF-14) (Steinberg et
al., 1994), and the National Eye Institute’s Visual Functioning Questionnaire (VFQ)
(Mangione et al., 2001), among others.
Depression is one of the strongest predictors of HRQoL in patients with MS
(Lobentanz et al., 2004; Fruehwald et al., 2001). This can be due to several reasons
(Mitchell, Benito-Leon, Gonzalez, & Rivera-Navarro, 2005). It can impair motivation,
interest and concordance, thus retarding physical progress. It can also manifest itself at the
point where the patients have exhausted their resources to cope with the disease. Presence of
depression can distort an individual’s view of their surroundings as well as their health,
leading to a more negative assessment of quality of life. The association may also be due to
the fact that HRQoL and depression are both typically associated with similar facets of
experience such as distress and suffering. A strong inverse correlation of depression with
generic and MS-specific quality of life measures has been shown (Amato et al., 2001; Bakshi
et al., 2000).
In the study by Bakshi et.al., the association of depression with lower quality of life
scores remained significant after adjusting for other factors like severity of neurological
disability and fatigue. Depressed patients with MS have also scored worse on various scales
such as energy, mental health, cognitive function, overall quality of life, sexual and
emotional function compared with non-depressed MS patients (Wang, Reimer, Metz, &
Patten, 2000). Additionally, studies have tried to correlate neurological disability with
impaired HRQoL in MS patients. Results from these studies have shown that neurological
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disability has a significant influence on HRQoL (Brunet, Hopman, Singer, Edgar, &
MacKenzie, 1996; Modrego, Pina, Simon, & Azuara, 2001).

Problem Statement
In order to determine the relative advantages and disadvantages of various HRQoL
instruments, a comparison of their psychometric properties in the same population is
necessary. Although researchers have examined the psychometric properties of each of these
three health status measures to be compared, some limitations can be noted. Only three
studies have compared the properties of HRQoL measures on the same cohort of patients.
The Multiple Sclerosis Quality of Life – 54 items (MSQoL-54) was used in two of the three
studies which provided conflicting evidence regarding its superiority over its comparators
(Vickrey, Hays, Genovese, Myers, & Ellison, 1997; Nicholl, Lincoln, Francis, & Stephan,
2001). Moreover, neither of these studies evaluated the full spectrum of psychometric
properties, particularly ignoring responsiveness, for the included HRQoL measures.
One study performed a comparison of all psychometric properties among three
patient reported outcome (PRO) measures and found that the Multiple Sclerosis Impact Scale
(MSIS-29) performed better than Functional Assessment in Multiple Sclerosis (FAMS)
(Riazi, Hobart, Lamping, Fitzpatrick, & Thompson, 2003). The authors however,
acknowledged the need for further evaluation of their work owing to the small sample size of
the study. A number of instruments have been designed to measure HRQoL in MS patients
with many being published in recent years (Nortvedt & Riise, 2003; Solari, 2005). As a
result, physicians have a greater range of choices but limited information on which to base
the selection of health status measures. Hence, it is necessary to perform a rigorous and all-
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inclusive concurrent comparison of currently relevant MS-related HRQoL instruments for
use in routine clinical care. MSIS-29 is one such currently relevant measure which has been
validated in a number of settings and has been shown to have better psychometric properties
compared to other commonly used HRQoL measures. MSIS-29 however, measures only
physical and psychological impact of the disease and not HRQoL per se. Other relevant
measures include: the Hamburg Quality of Life Questionnaire in MS (HAQUAMS) which
was recently developed and is the only measure that addresses all domains relevant to
patients with MS; and the ubiquitous Medical Outcomes Survey – Short Form 36 Items (SF36) which has been extensively used in MS research.
In addition to accurate and efficient assessment of quality of life, it is also necessary
to identify and focus on factors that affect the quality of life of MS patients. A number of
studies have reported association of overall quality of life with impairment and disability as
measured by neurological symptoms or measures of disability (Miller, Rudick, Cutter, Baier,
& Fischer, 2000; Ozakbas, Cagiran, Ormeci, & Idiman, 2004; Janardhan & Bakshi, 2000;
Modrego et al., 2001). Others have demonstrated that variables such as fatigue, depression
and anxiety and disease course (Pfennings et al., 1999a) can also have an impact on quality
of life while some conflict exists regarding the impact of cognitive impairment (Benito-Leon,
Morales, & Rivera-Navarro, 2002; Kenealy, Beaumont, Lintern, & Murrell, 2002). Of these
variables, only neurologic disability, fatigue and depression have been shown to contribute
independently to overall HRQoL (Henriksson, Fredrikson, Masterman, & Jonsson, 2001;
Merkelbach, Sittinger, & Koenig, 2002a; Janardhan & Bakshi, 2002). However, no evidence
is available on whether visual impairment affects MS-related quality of life, irrespective of
disability, depression and other important clinical features of the disease. Since visual
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impairment is a common manifestation among MS patients and can have a significant impact
on HRQoL such information may be relevant in the routine care of patients.
The past decade has seen an increase in the number of MS-related clinical trials with
quality of life as one of the outcomes of interest (Leuschen, Filipi, & Healey, 2004; Panitch,
Miller, Paty, & Weinshenker, 2004; Patti et al., 2004a). A number of disease-specific quality
of life measures have also been developed for use in MS research (Solari, 2005; Nortvedt et
al., 2003). One of the major issues in HRQoL assessment is the transfer of newly developed
measures from medical research to clinical practice (Belli, Tamburini, & Paci, 1994). No
studies of the perspectives of neurologists on quality of life assessment in clinical practice
have been reported in the literature. Thus, in addition to developing HRQoL measures
appropriate for use in routine practice, more information is needed about the attitudes and
behavior of neurologists about HRQoL assessment and their intention to consider
incorporating HRQoL information in their decision making.
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Study Aims
PHASE I
Objective 1: To compare the HAQUAMS with the SF-36 and the MSIS-29 in terms of their
psychometric properties (scaling assumptions, acceptability, reliability, validity and
responsiveness) as well as the preference of MS patients for each of these instruments.
Objective 2: To investigate the impact of visual impairment, in addition to other possible
predictors such as disability and depression, on overall HRQoL in patients with MS.
Objective 3: To determine predictors (visual impairment, disability, depression, demographic
factors, duration of disease and comorbid conditions) of various MS-specific HRQoL
domains including fatigue, mobility, mood and social function, in patients with MS.

PHASE II
Objective 1: To compare neurologists’ preferences regarding the usefulness and practicality
of various MS-specific HRQoL measures in clinical practice.
Objective 2: To report neurologists’ knowledge of and current practices regarding MSspecific HRQoL measures.
Objective 3: To identify barriers and facilitators to the use of HRQoL information in the
routine care of patients with MS.
Objective 4: To investigate whether neurologists’ intention to use HRQoL information in the
routine care of patients with MS is associated with social cognitive factors (attitudes,
subjective norms and perceived behavior control).
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This study pertains to all aspects of health-related quality of life and its assessment in
patients with MS. First, in order to make a recommendation for clinical practice, Objective 1
for both Phase I and II compared two MS-specific HRQoL measures in terms of: (1) their
psychometric properties; and (2) patient and physician preferences regarding their usefulness
and practicality. Objective 2 for Phase I focused on correlates of HRQoL and its specific
domains and helps elucidate the relative contribution of visual impairment to overall
HRQoL. Finally, Objectives 2, 3 and 4 from Phase II investigated neurologists’ attitude and
practices regarding HRQoL information in MS and examine behavioral factors that have an
impact on the neurologists’ intention to use HRQoL questionnaires in the routine care of
patients with MS.

Study Significance
The current study yields important results that can be used by health care
professionals to decide which instrument to use when evaluating HRQoL in patients with MS
in routine clinical practice. Head-to-head comparisons in the same population can help
provide an evidence-based framework to guide researchers in selecting measures for variety
of purposes (Hobart, Riazi, Lamping, Fitzpatrick, & Thompson, 2004). Since the
psychometric properties of the MSIS-29, HAQUAMS, and SF-36 will be assessed using the
same cohort of patients receiving care at an outpatient clinic, the comparison will be easier to
interpret. Another important aspect of this study is the comparison of responsiveness of the
three measures, which is their ability to measure clinically important change over time. The
responsiveness of MS-related quality of life measures in general has been examined in
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context of clinical trials, after patients initiate specific treatments and are expected to
improve (Riazi et al., 2003). Most instruments perform reasonably well in such situations.
Due to the focus on use of HRQoL measures in clinical trials, it becomes difficult to
assess whether these instruments can be useful for patients who may show comparatively
smaller changes in their health status during routine care or follow-up. This study will
compare the properties of the measures in a clinical setting. As such; its conclusions may
help researchers to determine if they exhibit stability in patients showing no change and with
ongoing disease, in addition to having discriminative properties. Comparison of ease of use,
time to completion, accuracy and preference of individual patients regarding each measure,
along with the complete psychometric properties will help neurologists choose the right
measure for their setting, per their requirements.
If visual function is found to be a significant independent predictor of HRQoL in MS
patients, the study findings may have important implications for patient care. It will allow
policy makers and treating physicians to determine whether visual impairment should be
screened for periodically in MS patients using HRQoL measures, regardless of neurological
disability and other clinical characteristics of the disease. Mild visual impairment may be
overlooked during routine visits, but if accurately monitored and treated successfully, it may
have a significant impact on the HRQoL of patients.
The physician’s perception of HRQoL is important, especially because they are
primary decision makers regarding the treatment that is administered (Bezjak, Ng, Taylor,
MacDonald, & Depetrillo, 1997). Due to a multitude of chronic conditions that exist in the
society today and presence of limited healthcare resources, data from HRQoL questionnaires
can be useful in decisions whether to continue or withhold treatment or even approve new
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medications and technology (Drummond, 1987). In addition to determining the
appropriateness of MS-specific PRO measures, phase II of this project will help to determine
key factors that affect the neurologists’ intention to use HRQoL information in their clinical
setting. Since the data will be obtained from a nationwide survey of neurologists, it may also
be useful as the basis for developing large-scale evidence-based HRQoL related intervention
strategies to increase neurologists’ utilization of MS-related HRQoL information in their
clinical practice.

12

Chapter 2: Background

About Multiple Sclerosis
Multiple sclerosis (MS) is one of the most common chronic neurological diseases in
adults, affecting about one in 1000 people. There are an estimated 1.1 million MS patients
worldwide (Mitchell et al., 2005). It is an acquired primary demyelinating disease of the
central nervous system (CNS) in which myelin is the target of an autoimmune inflammatory
process (Whitaker JN & Mitchell GW, 1997). Myelin is a fatty material that insulates nerves
and allows them to transmit impulses rapidly. The speed and efficiency with which these
impulses are conducted permits smooth, rapid and coordinated movements to be performed
with little conscious effort.
The sites of the nerves where the demyelination occurs appear as hardened, sclerosed,
or scarred areas in the CNS and spinal cord. It is the presence of these sclerosed areas or
lesions at multiple sites within the CNS that gives the disease its name. These lesions have a
predilection for the optic nerves, periventricular white matter, brain stem, cerebellum and
spinal cord. The lesions track along small and medium vessels, with an influx of
inflammatory cells occurring perivascularly. The inflammation involves lymphocytes,
macrophages, and reactive astrocytes. Inflammation and demyelination leads to a disruption
in the ability of the nerves to conduct electrical impulses thus causing the many symptoms of
the disease (Jacobs & Galetta, 2004).
Clinical hallmarks of MS include: 1) a temporal profile of symptoms and neurological
deficits occurring in multiple episodes, designated as a relapse or an exacerbation, followed
by disappearance of the symptoms and restoration of normal function, called remission; and
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2) the dissemination of lesions anatomically within the CNS. In other words, lesions must be
clearly disseminated in time and space within the CNS for clinically definite diagnosis of
MS. By definition, a relapse should last for at least twenty-four hours and can not be
attributed to another cause. The severity of the relapse mainly depends on the area and the
volume of the damage caused by the demyelination (Whitaker JN et al., 1997).

Clinical Symptomatology
MS affects different people in different ways, and symptoms can vary in the same
person from day to day. The majority of patients with MS develop an increasing range of
symptoms, many of which worsen slowly, resulting in progressive and complex disability.
Symptoms of MS can be categorized into three different categories; 1) primary symptoms
that stem from actual demyelination of the CNS including spasticity, weakness, tremor,
ataxia, numbness, cognitive disabilities, bladder and bowel dysfunction, blurred and double
vision, and occasionally apraxia (total or partial loss of the ability to perform coordinated
movements or manipulate objects in the absence of motor or sensory impairment); 2)
secondary symptoms which originate because of the presence of primary demyelination such
as contractures, urinary tract infections, and obesity, and 3) tertiary symptoms which emanate
from the psychological, vocational or marital stress of a chronic disease (Schapiro RT,
Baumhefner RW, & Tourtellotte WW, 1997).
Primary neurological symptoms reflect the location of the lesion in the CNS; for
example, visual loss reflects lesions of the optic nerve; hemi-, para-, or quadri-paresis; with
or without bladder dysfunction, reflects a lesion of the spinal cord; vertigo or diplopia
(double vision), corresponds to a lesion of the brain stem; and ataxia, a lesion of the
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cerebellum (Weinshenker & Lucchinetti, 1998). As many as 50% of MS patients experience
vision loss as an initial presenting symptom, while 80% eventually end up with some degree
of visual impairment (McDonald & Barnes, 1992; Leibowitz & Alter, 1968; Sorensen,
Frederiksen, Bronnum-Hansen, & Petersen, 1999). Neuro-ophthalmologic manifestations of
MS can occur due to the impact of the disease in the afferent or the efferent visual system.
Afferent Visual System
The most common cause of vision loss in MS patients is optic neuritis (sometimes
called retrobulbar neuritis) which is an episode of demyelination in the optic nerve behind the
eyeball. Optic neuritis is frequently the initial manifestation of MS. Symptoms associated
with optic neuritis include: loss of central vision acuity, pain associated with eye movement,
abnormal color vision, visual field defects, altitudinal defects, and visual loss associated with
increased body temperature (Uthhoff’s phenomenon) (Jacobs et al., 2004). Ocular
inflammation including anterior uveitis, posterior uveitis, and periphlebitis (sheathing or
cuffing of the retinal veins) can also occur in MS patients (Jacobs et al., 2004).
Efferent Visual System
Visual symptoms as a result of the impact of MS on the efferent visual system include
diplopia (double vision), internuclear ophthalmoplegia, nuclear palsies, one-and-a-half
syndrome (caused by lesions in the pons), skew deviation and nystagmus (rapid, involuntary,
oscillatory motion of the eyeball).

Epidemiology and Prevalence
MS is approximately two times more common in females than in males and recent
data suggest that the prevalence among women is increasing (Noonan, Kathman, & White,
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2002). The disease is unusual before adolescence, rises steadily in incidence from teens to
age thirty five, and declines gradually thereafter (Sadovnick, Dyment, & Ebers, 1997; Hauser
S, 1994). Onset of the disease is slightly later in males than in females. Marked differences
in the prevalence of MS exist between different populations and ethnic groups, with it being
more common among Caucasians (particularly those of northern European ancestry)
compared to other ethnic groups (Hogancamp, Rodriguez, & Weinshenker, 1997).
MS is a disease associated with temperate climates. In both hemispheres, it occurs
with much greater frequency in higher latitudes (above 40° latitude) away from the equator
(Kurtzke JF, 1977). Migration may also be one of the risk factors for MS. This is backed by
evidence that individuals who move from a region with one risk level to a region with a
higher or lower risk, in general, adopt the risk level of their new home. This is especially
true for people moving from a low-risk to a high-risk area (Gale and Martyn, 1995; Elian
et.al, 2003; Kurtzke JF, 1977).
Conflicting data exists as to whether MS is caused or triggered by an infectious agent
(viral or bacterial) (Granieri et.al, 2001; Munger et.al, 2004; Gilden 2005; Goldacre et.al,
2004). Others have explored whether environmental factors contribute to the onset of MS, or
the probability of MS attacks (Marrie RA, 2004; Casetta and Granieri, 2000). Some studies
suggest that relapses of MS are more likely in the warmer months and less likely in the
colder months (Abella-Corral et.al, 2005; Jin et.al, 2000). Pregnancy is associated with a
decrease in the risk for MS attacks, particularly during the third trimester, while the
postpartum period sees a significant increase in the risk (Salemi et.al, 2004). In certain
populations, a genetic marker, or trait, has been found to occur more frequently in people
with MS than in those who do not have the disease (Hogancamp et.al, 1997). No specific
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gene however, has been identified that definitively confers susceptibility to MS (Dyment
et.al, 2004; Giordano et.al, 2002). It is thought that aggregation of MS in certain
geographical areas, ethnic populations, or families can be explained by common
environmental exposure, shared genetic background, or a combination of susceptibility to
both (Sotgiu et.al, 2004).

Clinical Course & Prognosis
People with MS can expect one of four clinical courses of disease, each of which can
be mild, moderate, or severe. The first, Relapsing-Remitting Multiple Sclerosis (RRMS), is
characterized by discrete clinical “attacks” or “relapses” followed by subsequent
improvement. These attacks generally evolve over days to weeks and may be followed by
complete, partial, or no recovery. Recovery may occur within weeks, months, or sometimes
may not occur for two or more years. This is the most common form of MS at the time of
initial diagnosis (NICE, 2003). The second possible course of the disease, Chronic
Progressive MS, results in gradually progressive worsening without periods of stabilization
or remission. Chronic progressive MS however, is largely an outdated term that describes
any of the following forms of MS: 1) Secondary Progressive MS; 2) Primary Progressive MS
or 3) Progressive Relapsing MS (PRMS).
Many years after onset, a majority of relapsing remitting MS patients will develop a
slow, insidiously progressive neurological deterioration (usually progressive gait
impairment) over many years, with or without clinical attacks superimposed. This is termed
as Secondary Progressive and after 10 years, about 50% of people with relapsing remitting
MS will have developed Secondary Progressive (National Institute for Clinical Excellence,
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2003b). By contrast, Progressive Relapsing MS follows a progressive course right from the
onset, punctuated by relapses. There is significant recovery immediately following relapses
similar to Relapsing Remitting MS, but the disease gradually worsens between the
occurrences of relapses. Finally, a minority of patients have Primary Progressive MS; which
is characterized by a gradual worsening right from the onset, with the complete absence of
distinct relapses or remissions. It is relatively rare and patients may show variation in rates
of progression over time, occasional plateaus, and temporary minor improvements (National
Institute for Clinical Excellence, 2003a).
The prognosis of MS is widely variable. Natural history studies prior to the use of
current immunomodulatory treatment showed that, on average, patients achieved a disability
score of six on the Expanded Disability Status Scale (EDSS) at a median of 15 years
following diagnosis (Weinshenker, 1995). This score implies the requirement of unilateral
assistance with ambulation. At the same point in time, about 10-15 % required the use of a
wheel-chair, while 20-25 % remained unrestricted in their ambulation, a condition termed
benign MS (Weinshenker BG, 1995). Other studies report that trends toward favorable
outcomes have been found in patients with optic neuritis, sensory symptoms, and younger
age at onset, which are all factors associated with Relapsing Remitting MS. On the other
hand, factors associated with Primary Progressive MS, namely motor symptoms and older
age have indicated unfavorable outcomes for the patients (Myhr et.al, 2001). Other clinical
indicators of relatively good prognosis are female gender, complete recovery from attacks,
few attacks, and long inter-attack intervals. Relatively poor prognostic factors also include
male gender, predominant cerebellar and motor involvement, incomplete resolution of
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attacks, progressive course of onset, frequent early attacks, and short inter-attack intervals
(Weinshenker et.al, 2001).

Diagnostic Criteria for Multiple Sclerosis
There is no MS-specific diagnostic test, and the intermittent nature of the disease and
high variability in presenting symptoms makes diagnosis difficult. Prior diagnostic criteria
for MS have included a combination of both clinical and para-clinical studies. The
Schumacher criteria were the first set of diagnostic criteria that were developed in 1965 to
make a clinical diagnosis of MS (Thompson et al., 2000). These criteria require two or more
episodes of neurological dysfunction at least one month apart or slow stepwise progression
for more than six months, plus objective signs of neurological dysfunction on examination
displaying dissemination in space (distinctly separate lesions). The diagnosis of MS was not
backed by any definitive laboratory tests and was essentially a clinical one.
This was followed by a revision in 1983 by Poser and colleagues (Poser et al., 1983)
in order to reflect the advances of para-clinical detection techniques such as Magnetic
Resonance Imaging (MRI) which was still in its infancy. Poser and colleagues concluded
that clinically definite MS requires two attacks and clinical evidence of two separate lesions,
or two attacks with clinical evidence of one lesion and para-clinical evidence of another
separate lesion. The revised criteria also included degrees of diagnostic certainty that were
identified by categories ranging from clinically definite diagnosis to laboratory-supported
definite MS, clinically probable MS, and laboratory-supported probable MS. None of these
criteria was appropriate for the diagnosis of Primary Progressive MS, since the basic
requirement of episodes of neurological dysfunction cannot be fulfilled.
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These criteria were used for about two decades during which the science of imaging
technology flourished. Neurologists were hampered by out-dated diagnostic paradigms due
to the lack of use of advanced technologic tools (such as MRI). Since MRI shows many
clinically silent lesions, it seemed logical to integrate MRI evidence into the diagnostic
criteria to achieve an earlier diagnosis of MS. In July 2000, the International Panel on
Diagnosis of MS was convened in London, United Kingdom to reassess the Poser criteria
and to develop new criteria (McDonald et al., 2001). The panel emphasized that para-clinical
evidence like MRI, along with analysis of cerebrospinal fluid (CSF), and visual evoked
potentials (VEP), add to clinical diagnosis and may be essential in making a definite
diagnosis when clinical presentation alone is not sufficient.
One objective of the panel was to create diagnostic criteria suitable for use by
practicing physicians and also for clinical trials. As such, the new McDonald criteria also
include a scheme for the diagnosis of the Primary Progressive type of MS. In a prospective
study of patients suffering from a clinically isolated syndrome, Dalton and colleagues
addressed the added value of the McDonald diagnostic criteria as compared to the Poser
criteria (Dalton et al., 2002). The authors supported the clinical relevance of the newer
criteria based on higher specificity, positive predictive value, and accuracy for clinically
definite MS.

Disease Management
Management of MS may be divided into categories consisting of 1) treatments that
affect the long-term course; 2) treating exacerbations; and 3) symptomatic management and
rehabilitation.
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Treatments that affect the long-term course of the disease
The goal of therapy in patients with MS is to prevent relapses and progressive
worsening of the disease (Thompson AJ, Murray TJ, McDonald WI, & Polman C, 2001).
Drug treatments can reduce future disease activity for many individuals with relapsing forms
of MS, including those with secondary progressive disease who continue to have relapses.
These agents decrease the frequency of clinical exacerbations and delay the accumulation of
physical disability. Disease progression can be treated by administering immunomodulatory
drugs namely interferon beta-1a [Avonex & Rebif], interferon beta-1b [Betaseron], and
glatiramer acetate [Copaxone] (Thompson AJ et al., 2001).
Copaxone represents an alternative to interferon beta therapy for patients with
relapsing remitting MS. Mitoxantrone is an anti-neoplastic agent that exerts potent
immunomodulatory effects, and it has been suggested that it may provide a safe treatment
alternative for patients with Relapsing Remitting MS, who experience rapid and severe
worsening of their disease despite interferon therapy (Correale, Rush, Amengual, &
Goicochea, 2005). The risk of cardio-toxicity at higher cumulative doses however, limits the
duration of treatment with this drug (Avasarala et al., 2003). All these treatments have been
approved by the United States Food & Drug Administration (USFDA) for treating patients
with MS (Galetta & Markowitz, 2005).

Treatment for exacerbations
At least 80 to 85% of people with MS have an exacerbation at some time during the
course of the disease (Polman). Exacerbations are usually treated with corticosteroids, which
may be used as "rescue" therapy, given as monthly boosters in patients who respond poorly
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to the immunomodulators (Stangel & Gold, 2005). Corticosteroids are widely used for
treatment of acute relapses because of their potent immunosuppressive and anti-inflammatory
properties (Pozzilli, Marinelli, Romano, & Bagnato, 2004).
Adrenocorticotropic hormone (ACTH) was the first agent to be helpful in recovery
from acute exacerbations. However, intravenous methylprednisolone has become the
intervention of choice in recent years, especially because it can be given as a short course
(typically 3-5 days), has a rapid onset of action, and is associated with relatively fewer sideeffects. Possible mechanisms of action of IV methylprednisolone include restoring the
integrity of the blood-brain barrier (Miller et al., 1992), eliciting an inhibitory effect on
demyelination (Richert et al., 2001) and possibly, remyelination promotion (Zivadinov, 2005;
Stangel et al., 2005). According to the Multiple Sclerosis International Federation (MSIF)
Medical Management Committee, plasmapheresis should be considered for those rare cases
that present with acute, fulminant symptomatology and do not respond to intravenous
steroids.
Symptomatic Management & Rehabilitation
Treating optic neuritis with intravenous (IV) methylprednisolone provides short-term
benefits for MS patients with visual problems. In one clinical trial, visual function returned
faster in the IV methylprednisolone group compared to oral corticosteroids and placebo,
resulting in slightly better vision in visual field testing, contrast sensitivity, and color vision
at six months. This difference however, did not last at the end of one year (Beck et al.,
1992). The use of corticosteroids and immunomodulatory agents in patients with optic
neuritis may also reduce the frequency and severity of developing clinically definite MS
(CDMS) (Arnold, 2005). Diplopia in its acute phase can be treated with an eye-patch or with
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occlusion of an eyeglass lens. Patients who experience severe diplopia accompanied by
symptoms such as vertigo or weakness can also be treated with a course of IV corticosteroids
(Jacobs et al., 2004). Medications such as gabapentin, baclofen, memantine, and clonazepam
may alleviate symptoms associated with severe nystagmus (Averbuch-Heller et al., 1997).
Identification and treatment of other symptoms besides visual dysfunction is also
considered throughout the disease course. Drugs used to relieve common MS symptoms
include: (1) muscle relaxants (baclofen, dantrolene) and benzodiazepines (diazepam,
clonazepam) to relieve spasms and stiffness; (2) anti-cholinergics, urinary tract antispasmodics (oxybutynin), and anti-diuretic hormones (vasopressin, desmopressin) for
treating urinary problems; (3) Selective Serotonin Reuptake Inhibitors (SSRIs) (citalopram,
fluoxetine, paroxetine, sertraline) and tricyclic antidepressants (imipramine, amitriptyline)
for treating MS associated depression and anxiety; (4) CNS stimulants (pemoline, modafinil)
for fatigue; (5) anti-convulsants (carbamazepine, phenytoin, acetazolamide) and tricyclic
antidepressants for neuropathic pain; and (6) laxatives (bisacodyl) for bowel irregularities
(Fox & Cohen, 2001).
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Quality of Life (QoL) Research
Historically, the term quality of life has been used in areas of politics, sociology,
anthropology and psychology (Bullinger, 2002). Pigou first mentioned it in 1920 with
regards to government support for the lower class and its impact on their lives as well as on
the national finances (Wood-Dauphinee, 1999). Social science literature also provides many
meanings of quality of life ranging from individual fulfillment and satisfaction with life – the
satisfaction of basic human needs, the ability to lead a ‘normal life’ to the quality of the
external environment (Bowling, 2001). Social indicators research which developed during
the 1960s onwards focused on the importance of measuring subjective well-being as well as
external, or objective circumstances of life such as housing, leisure activities, work, the
environment and so on. The concerns with subjective indicators led to the first large surveys
of life satisfaction, happiness, quality of life and the ‘good life’ among adults and older
people.
The development of quality of life research is characterized by three phases. The first
phase in the mid-1970s saw the rise of philosophical work regarding what quality of life is
and how to measure it (Bullinger, 2002). In 1977, ‘quality of life’ became a keyword in the
Medical Subjects Headings of the US National Library of Medicine MEDLINE Computer
Search System (Wood-Dauphinee, 1999). The second phase corresponds with a more
explicit assessment of quality of life and the corresponding development of measurement
instruments. Finally in the 1990s, the third phase evolved and was distinguished from the
other phases by the inclusion of quality of life instruments/measures in several types of
clinical studies.
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Health-Related Quality of Life (HRQoL)
Research on valued states of existence has reported that health is among the most
valued states, and among the most important areas of life and of quality of life nominated by
people (Bowling A & Windsor J, 2001). In a national opinion survey on quality of life
related to choice of where to live, Rogerson (Rogerson RJ, Findlay AM, Coombes MG, &
Morris A, 1989) found that healthcare provision ranked third in importance among the
respondents. In order to narrow its operationalization in clinical research studies, quality of
life in this regard is referred to as health-related quality of life (HRQoL).
Health-related quality of life is considered to be a multi-dimensional concept which
represents a subjective perception reported by the patients. Mirroring the World Health
Organization (WHO) definition of health, Greer (1984) has defined HRQoL as the social,
emotional and physical well-being of the patients following treatment. Kaplan on the other
hand noted that quality of life as it relates to health, was concerned with the impact of the
disease and treatment on disability and daily functioning. Bullinger et.al. (2002) found that
HRQoL focused on the impact of perceived health on the individual’s ability to live a
fulfilling life. Bowling (2001) defined HRQoL as optimum levels of mental, physical, role
(e.g. work, parent, career etc.) and social functioning, including relationships and perceptions
of health, fitness, life satisfaction and well-being. It should also include some assessment of
the patient’s level of satisfaction with the treatment, outcome, health status and with future
prospects.
The term HRQoL allows us to distinguish widely valued aspects of life which do not
fall under the health domain. Although low income, lack of freedom or a good quality
environment can adversely affect health, these problems are often distant from health or
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medical concerns (Guyatt, Feeny, & Patrick, 1993). Hence, people (clinicians) who assess
the impact of disease and treatment on lives of the patients use the term HRQoL. The focus
stays on HRQoL, although when ill or diseased, almost all aspects of life can become healthrelated for the patient (Guyatt et.al, 1993).

Advantages of Assessing HRQoL in Routine Clinical Practice
Measurement of HRQoL in routine practice can have a number of potential benefits
to both the clinician and the patient. Clinicians may often stay unaware of significant
changes in patient functioning (Nelson et al., 1987), social and even more so, psychological
problems (el Mallakh, Wright, Breen, & Lippmann, 1996; Paykel & Priest, 1992; Maguire,
Walsh, Jeacock, & Kingston, 1999). While patients may want physicians to ask them about
their problems with functioning and well being, such inquiry rarely occurs (Schor, Lerner, &
Malspeis, 1995). Quality of life instruments can aid in evaluating quality of care, assessing
acceptability of treatment, and in determining the need for physiotherapy or psychological
support (Moore, Wolfson, Alexandrov, & Lapierre, 2004). Patients and physicians may have
different priorities regarding a certain treatment course or the effect of illness on their lives
(Rothwell et al., 1997; Gulick, Cook, & Troiano, 1993), and patients are likely to assign
varying importance to different outcomes.
Evidence has shown that patients may not comply with prescribed treatments unless
they are actively included in the therapeutic process, understand their condition and its
treatment and are motivated to do so (Stanton, 1987; Morrow et al., 2004). Patient-based
measures of health present patients with clear information on a range of problems allowing
them to learn more about their condition as well as its symptoms and treatment. Such
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measures can also provide a standardized method by which physicians can gain information
on patients’ assessment of their own health, and thus may be useful as a starting point in
patient assessment and diagnosis. In these respects, HRQoL information can promote shared
decision making and may positively influence doctor-patient communication (Greenhalgh &
Meadows, 1999). Using patient-based measures of health to incorporate patients’ views in
treatment decisions will not only empower them, but can also improve satisfaction with care
and adherence to treatment (Stimson, 1974). Health-related quality of life information can
also be used to identify aspects of the disease which may otherwise go unattended as they
lack clinical relevance, but may be important in explaining disease severity or coping
problems (Higginson & Carr, 2001). Health-related quality of life measures can thus
complement, rather than replace, clinical evaluation by demonstrating the importance of
signs or symptoms to the individual patient (Moore et al., 2004).

HRQoL Assessment
Patrick and Bergner (1990) have noted that the health of the nation cannot be
determined specifically with reference to the structure and process of the health care system
and require assessment of health and quality of life outcomes. In light of the effect of social
inequities and restrictions to health care, they emphasized the use of appropriate and
inclusive measures of HRQoL. The second phase in the evolution of quality of life research
during the 1980s involved the construction and testing of instruments designed to measure
health and HRQoL.
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Generic Measures
Measures which are implicitly or explicitly geared to assess HRQoL are usually
referred to as generic measures or broader measures of health status. Generic measures are
broadly applicable across different medical treatments (Prasad, Rentz, & Revicki, 2003) or
health interventions (Pickard, Johnson, & Farris, 1999; Kauppinen, Sintonen, & Tukiainen,
1998), and across demographic (Izquierdo-Porrera et al., 2005; De Oliveira, Barbiere, Santos,
Faresin, & Fernandes, 2005) and cultural subgroups (Baker, Jacoby, Gorry, Doughty, &
Ellina, 2005). Generic measures have been used in a large number of different populations
especially subjects with chronic conditions such as rheumatoid arthritis (Kosinski, Keller,
Hatoum, Kong, & Ware, Jr., 1999), multiple sclerosis (Miller et al., 2003), and chronic
obstructive pulmonary disease (COPD) (Domingo-Salvany et al., 2002). An example of a
generic measure is the Sickness Impact Profile (SIP) which assesses the sickness-related
dysfunction in twelve different categories, producing a score for each category. Categories
may be aggregated under umbrella terms such as the physical dimension score, the
psychosocial dimension score, and an overall score (Miller et al., 2003).
Other commonly used generic health status measures are the Nottingham Health
Profile (NHP) (Teixeira-Salmela et al., 2005) and the Medical Outcomes Survey Short Form
– 12 & 36 items (SF-12 & SF-36) (Domingo-Salvany et al., 2002; Kosinski et al., 1999).
Such wide utilization makes generic quality of life instruments invaluable methods of
measurement. Since these measures permit the comparison of different populations and
different programs, they are ideal in policy analysis and decision making situations.
Continued use of generic measures allows policy makers to compare benefits of different
health interventions and facilitate resource allocation decisions. Cummulative knowledge of
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HRQoL outcomes will establish the relative burden of diseases which impact our society and
the relative success of interventions targeted towards such illnesses. An important constraint
of generic measures however, is that they are unable to identify disease-specific aspects that
are essential for the measurement of certain outcomes.
Disease-Specific Measures
Disease-specific measurement scales have the goals of being more clinically and
socially significant in relation to specific conditions and of being able to discriminate more
finely between patients’ levels of severity of a particular condition. Since a universal
questionnaire for eliciting relevant health status information for a number of conditions
would be enormous, use of disease-specific quality of life measures allow brevity. Although
it seems intuitive that these measures would be automatically more sensitive to change than
the more wide-ranging generic instruments, studies in various disease areas have found
conflicting evidence regarding such an assumption (Bessette et al., 1998; Fitzpatrick,
Ziebland, Jenkinson, Mowat, & Mowat, 1993a; Hagen, Smedstad, Uhlig, & Kvien, 1999;
Harper et al., 1997). Additionally, their narrow focus may mean that they could miss
unexpected problems, such as adverse drug reactions. It has therefore been suggested that
generic measures, such as SF-36 should act as the core of the outcome measurement, that is
to have disease-specific measures be used together with a generic measure. Several diseasespecific measures have been developed for a number of conditions including cancer, arthritis
and MS (Aaronson N, 2002).
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Quality Standards for HRQoL Measures
The choice of a quality of life measure is determined by the research question and the
application of measurement in clinical research, practice or policy analysis. HRQoL
measures may be used to discriminate among respondents at a point in time, to predict future
outcomes and/or events, and to measure changes over time (Kirshner & Guyatt, 1985). The
quality standards that a HRQoL measure should meet vary according to the objective of
measurement and the specific environment of application. Over the years, the rigors to
which quality of life measures should be developed and continually evaluated have been
investigated. Tully and Cantrill (1999) stress the importance of continuously evaluating
HRQoL instruments, even if they have been in long use in order to provide ongoing evidence
of their validity and to ensure that their language and content remains relevant to everchanging cultures. The following sections will review the measurement properties against
which HRQoL measures are judged.
Scaling Assumptions
Scaling assumptions are used to test whether the items are correctly grouped into
scales measuring a unique underlying dimension for example, physical function, and if they
can be summed without weighting or standardizing to produce a score. Scaling assumptions
are examined by determining whether items in each scale have roughly similar distributions
of item responses; display equivalence of item means and standard deviations; and possess
item internal consistency.
Acceptability
Acceptability of HRQoL measures is determined by the range and distribution of its
scores. A measure is considered acceptable if the observed scores are well distributed, and if
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mean scores are near the mid-point for each scale. Acceptability of HRQoL questionnaires is
also determined by floor and ceiling effects. Floor and ceiling effects represent the
percentages of the sample scoring the lowest and highest possible scores respectively, and
reflect the extent to which scores cluster at the bottom or the top of the score range. The
presence of floor and ceiling effects indicates that the measure may not be able to
discriminate between subjects (Mao, Hsueh, Tang, Sheu, & Hsieh, 2002). Floor and ceiling
effects over 20% are generally considered unacceptable (McHorney, Ware, Jr., Lu, &
Sherbourne, 1994).
Validity
Validity is a statement of confidence that the measure reflects the underlying concept
it is supposed to measure rather than something else. It is not a statement about the
measurement operations, but a statement about the interpretation about the instrument’s
score. Validation evidence can be divided into three types namely construct-related, contentrelated, and criterion-related (Aaronson N, 2002).
Construct validity refers to the degree to which the measure provides results the way
it should. It includes face validity which refers to what an item appears to measure based on
its manifest content. One of the simpler forms of construct validity is known-groups or
concurrent validity. This is based on the principle that certain groups of patients may be
anticipated to score in a different manner than others. An instrument is said to be valid if it is
sensitive to such differences. Investigators usually select patients in whom differences may
be anticipated within groups and as a result even small-sized studies can provide sufficient
evidence to confirm that the observed differences are unlikely to be due to chance. It is not
the p-value but the magnitude of the differences that is relevant in these situations (Fayers
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PM & Machin D, 2000). Inter-correlations are used to measure the other two types of
construct validity. When a measure correlates well with other measures of the same
construct it is said to have convergent validity, and when it correlates poorly with other
measures of some other construct it is said to have divergent validity. Advance specification
of expected differences based on specific logical relationships among relevant concepts or
constructs is necessary to establish this type of validity.
Criterion validity involves assessing an instrument against the true value, or against
some standard that is accepted as providing an indication of the true values for the
measurement and is divided into concurrent validity and predictive validity (Fayers PM et al.,
2000). Concurrent validity means agreement with the true value or “gold standard”.
Predictive validity, a type of criterion validity is the degree to which a test can predict how
well an individual will do in a future situation for e.g. future health status. It is determined
by the degree of correspondence between the assessment instrument and the specific criteria
used for future performance.
Reliability
Reliability refers to the extent to which a measure yields the same score each time it
is administered, all other things being equal. Conceptually, a test score contains a “truescore” component and an “error” component. To the extent that random error is large, a test
score will be unstable and hence unreliable. There are two basic ways to evaluate test
reliability; internal consistency reliability and reproducibility (e.g. test-retest reliability, interobserver and intra-rater reliability). Internal consistency reliability is the most frequently
used estimate of a measure’s reliability. The measure of internal consistency is the average
degree of association among the items on a test. Cronbach’s alpha, which is an index of
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internal consistency of the items, is a popular statistical test of reliability of an instrument.
Commonly accepted minimal standards for reliability coefficients are 0.70 for group
comparisons and 0.90-0.95 for individual comparisons (Aaronson N, 2002). The
interpretation of alpha is that a higher value implies that the responses are more consistent,
and the sum of the item responses yields a score for the underlying dimensions that the items
represent. A low alpha coefficient usually indicates the item does not come from the same
conceptual domain (Williams JI, 1989).
Responsiveness
Responsiveness is also referred to as sensitivity to change and is an important part of
the longitudinal validation of a HRQoL instrument. Responsiveness is the instrument’s
ability to detect change, that is, whether the measure can detect differences in outcomes, even
if those differences are small. Analyzing and interpreting changes in health status measures
can be a problem for all longitudinal observational case studies, cohort studies, clinical trials,
or health services evaluation. Changes in physiologic measures such as blood pressure can
be interpreted in terms of prognostic implications and well-established or pre-determined cutoff point. Changes in generic HRQoL measures are more difficult to interpret, although
small changes in portions of the measure for example the physical or mental scale can be
quite useful. Single score or aggregated measures can make it difficult to identify which
items or components are responsible for change. Even if changes in the scores are found to
be sensitive, the relative magnitude of the change can be difficult to ascertain for example,
how much more meaningful is a five-point difference from a three point difference (Patrick
& Deyo, 1989).
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Responsiveness of disease-specific measures may be easier to interpret, because the
items on such a measure are closely associated with the clinical measures of the disease
activity such as time to walk 8 feet and visual acuity testing in MS patients.
Self-assessed improvements by patients which are a common measure of change may be
more closely associated with a disease-specific measure compared to a generic HRQoL
measure (MacKenzie, Charlson, DiGioia, & Kelley, 1986). In situations where a battery of
HRQoL instruments is used, interpreting changes can be cumbersome due to different results
presented by the constituent measures of the battery. This is especially difficult when
multiple comparisons or statistical tests are necessary (Guyatt, Veldhuyzen Van Zanten,
Feeny, & Patrick, 1989). Responsiveness of health status measures in clinical research has
been assessed using various sensitivity-to-change coefficients including effect size (ES)
(Kazis, Anderson, & Meenan, 1989), standardized response mean (SRM), paired t value
(Liang, Fossel, & Larson, 1990; Guyatt, Walter, & Norman, 1987), Guyatt’s Responsiveness
Index (GRI) (Guyatt et al., 1987), t-value for independent change scores, receiver operating
characteristic area curve and correlation coefficients (Spearman’s ρ or Pearson’s r)
(Scrimshaw & Maher, 2001).
For a measure to have clinical usefulness it must not only have the above-mentioned
psychometric properties, but it also must be simple, quick to complete, easy to score, and
provide useful clinical data. It is imperative that all validation reports describe the conditions
under which the validation was conducted, including the demographic characteristics of the
sample, and the range of illness or symptoms experienced in the sample.
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Choice of HRQoL Measure
Choosing a quality of life measure involves two major decisions: 1) should the
measure be generic in nature or should it be disease/condition specific; and 2) whether the
measure is sensitive to and appropriate for the patients seen in the particular practice or
setting. While designing an optimal strategy for research, investigators need to assign
priority weights to measurement objectives. The preference of a generic or disease specific
measure depends not only on the psychometric properties described in the previous section,
but also the research question at hand. Project aims, methodologic concerns, and practical
considerations usually determine the relative use of generic and disease-specific measures in
an investigation. Generic measures may be particularly useful for population-based studies
used in shaping social policy decisions or in instances where allocation of resource decisions
are to be made for large numbers of people (Albrecht, 1996).
Problems may arise, however, if such scales are administered to a broad range of
persons with different diseases and chronic conditions like MS and arthritis. Since such
populations may place different emphasis on the more generic concepts of health, it may be
preferable to use standardized, generic instruments with disease-specific supplements. In the
case of quality of life assessment in routine clinical practice, the intelligent approach is to use
both generic and disease-specific quality of life measures. This will allow researchers to
compare the group of interest with national norms while still staying sensitive to the
condition in question. In summary, major factors in selecting a quality of life measure
include: the intended use of the results, method of administration, ease of use, psychometric
properties (reliability, validity and responsiveness) and the appropriateness of the scale for

35

the patients being studied and for the location in which it is used (McSweeney & Creer,
1995).

MS-Related Health and Functional Status Measures
The first quality of life study in the area of MS was published by Rudick et.al. in
1992 (Rudick et al., 1992). This was followed by an increased use of quality of life measures
based on the belief that such studies contribute knowledge essential to the health and
healthcare of MS patients that is not captured by traditional measures of disease disability. A
review by Nortvedt and Riise (Nortvedt et al., 2003) identified 33 different questionnaires
used to measure quality of life, of which ten were specifically designed for MS patients.
This list included the following MS-specific health related quality of life (HRQoL)
measures: 1) DIP: Disability and Impact Profile; 2) FAMS: Functional Assessment of
Multiple Sclerosis: 3) HAQUAMS: Hamburg Quality of Life Questionnaire in Multiple
Sclerosis: 4) LMSQoL: Leeds Multiple Sclerosis Quality of Life; 5) MSQLI: Multiple
Sclerosis Quality of Life Inventory; 6) MSIS-29: Multiple Sclerosis Impact Scale; 7)
MSQoL-54: Multiple Sclerosis Quality of Life Inventory- 54 Items; 8) QLI-MS: Quality of
Life Index- Multiple Sclerosis; 9) QOQL: Quality of Life Questionnaire for Multiple
Sclerosis and 10) RAYS: a quality of life scale for MS patients.
The most commonly used scales in MS measure impairment (objective clinical signs
and symptoms), disability (behaviors that are altered or prevented within the illness), or
HRQoL (an individual’s assessment of how a health problem and its treatment affect the
ability to perform valued activities and roles) (Balcer, 2001).
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Generic and Disease-Specific Measures
The Medical Outcomes Survey Short Form -36 (SF-36) is considered to be a gold
standard generic measure of health status and has been adapted cross-culturally in MS (Ware,
Jr. & Sherbourne, 1992; Sharrack, Hughes, Soudain, & Dunn, 1999b; Nortvedt et al., 2001;
Brunet et al., 1996; Pfennings et al., 1999b; Pfennings et al., 1999b). It is comprised of 36
items selected from a larger pool of items used by the RAND Corporation in the Medical
Outcomes Study (MOS). The SF-36 includes eight domains: 1) physical functioning; 2) role
limitations due to physical problems; 3) bodily pain; 4) general health perceptions; 5)
vitality; 6) social functioning; 7) role limitations due to emotional problems; and 8) mental
health. It also includes a single item that provides an indication of perceived change in
health. Factor analyses of the SF-36 health survey provide strong support for a two-factor
model of health, with physical health reflected primarily by measures of physical
functioning, pain and role limitations due to physical health problems, and mental health
reflected primarily by measures of emotional well-being and role limitations caused by
emotional problems. Physical and mental component summary scales for the SF-36 health
survey scales can thus be derived.
Several studies have shown that problems specific to MS patients are not completely
captured by such generic measures, thus rendering them less sensitive and less useful. The
physical scale has been known to display marked floor effects for severely disabled patients
(Nicholl et al., 2001; Nortvedt, Riise, Myhr, & Nyland, 1999) and the use of the two
summary scales seems to be problematic in MS (Nortvedt, Riise, Myhr, & Nyland, 2000;
Hobart, Freeman, Lamping, Fitzpatrick, & Thompson, 2001). Hence it is imperative that
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MS-specific measures be used to assess quality of life in such patients, either alone or in
conjunction with generic measures.
The Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) is
one such MS-specific instrument which was developed as a self-administered questionnaire
for HRQoL assessment in MS patients presenting at outpatient clinics (Gold et al., 2001).
The HAQUAMS consists of 38 items, 28 of which address the major dimensions of HRQoL
in MS, mainly fatigue and thinking, upper and lower limb mobility and mood. The ten
additional items assess sensory symptoms, bladder and bowel control, sexuality, recent health
changes, disturbed vision and a general self-rating of handicap. All subscales of this measure
showed universally high internal consistency reliability except for the mobility scores which
were less consistent over time (Gold et al., 2001). Construct validity was supported by
associations with other scales as well as objective clinical measures. The HAQUAMS also
showed no floor or ceiling effects in all of its five scales showing its applicability over a wide
range of disease status.
A follow-up to the validation study by Gold (Gold et al., 2001) found that the scores
on the self-reported form of HAQUAMS had satisfactory reliability, but showed a marked
discrepancy when compared to scores on clinical rating scales in MS patients with cognitive
dysfunction (Gold, Schulz, Monch, Schulz, & Heesen, 2003). It has been used as a HRQoL
measure in order to examine the impact of aerobic training on quality of life, among other
outcomes in MS patients (Schulz et al., 2004). The use of HAQUAMS, despite its promising
psychometric properties, has been limited only to quality of life research studies in Germany.
It is the only disease-specific measure besides the FAMS, which addresses all domains of
health related quality of life in MS and hence may be a potential candidate for use in routine

38

care of MS patients in the United States. Since it has only been validated in the German
population, the next logical step would be to test its psychometric properties in English
speaking patients in order to facilitate cross-cultural adaptation.
The Multiple Sclerosis Impact Scale (MSIS-29) is a relatively new disease-specific
questionnaire that measures the physical and psychological impact of MS from the patient’s
perspective (Hobart, Lamping, Fitzpatrick, Riazi, & Thompson, 2001). It was developed
using the standard psychometric approach which involved reducing an item pool generated
from people with MS. Its psychometric properties have been evaluated among randomly
selected, geographically stratified members of the Multiple Sclerosis Society (MSS) by
means of large independent postal surveys. It is simple, easy to administer and takes only a
few minutes to complete. Hobart (Hobart et al., 2004) found that it took two minutes and
forty-four seconds to complete in a sample of ten patients (Range= 1 minute 45 seconds to 4
minutes 26 seconds). It was developed to facilitate administration directly to patients in a
clinical or research setting or via a postal survey.
Although the MSIS-29 was found to have acceptable psychometric properties in a
random sample of the MSS, a limitation of this study was that the presence of clinically
definite MS in patients could not be confirmed. Separate studies in the following years tested
the psychometric properties of the MSIS-29 in hospital-based samples (Riazi, Hobart,
Lamping, Fitzpatrick, & Thompson, 2002; McGuigan & Hutchinson, 2004). Riazi (Riazi et
al., 2002) evaluated the psychometric properties of the MSIS-29 in three hospital-based
samples classified as those admitted for rehabilitation, those obtaining corticosteroid therapy
and a postal survey of patients with Primary Progressive MS. These properties were then
compared with data obtained from a community based sample in an earlier study (Hobart et
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al., 2001). Expected differences in mean scores were obtained between the three hospital
samples with patients in rehabilitation having the worst scores. In the rehabilitation sample,
the correlation between the MSIS-29 physical scale and the SF-36 physical functioning scale
and the Expanded Disability Status Scale (EDSS) was found to be lower that expected. The
attenuation of this correlation was believed to be due to the limited score distribution of the
SF-36 (range 0 to 65). Overall, the psychometric properties (scaling assumptions,
acceptability, reliability and validity) of the MSIS-29 scales were similar in both the
community and the hospital samples.
Another study out of Ireland compared the responsiveness of MSIS-29 in addition to
these psychometric properties (McGuigan et al., 2004). Responsiveness was evaluated by
comparing mean scores at two time points and was found to exhibit at least moderate effect
size in the static group and the changed group. These studies provide evidence of acceptable
psychometric criteria and preliminary evidence of responsiveness of the MSIS-29 in various
settings. Moreover, it has been found to be useful in assessment of the physical impact of
MS in daily life (Hoogervorst, Zwemmer, Jelles, Polman, & Uitdehaag, 2004). According to
Hobart (Hobart et al., 2004), head-to-head comparisons of the psychometric properties of the
MSIS-29 and other MS specific outcome measures will help to determine the relative
advantages of different instruments in order to facilitate evidence-based choice of measures.

Functional Status Measures
The consequences of a chronic illness such as MS on the life of the patient can be
systematically described using the World Health Organization’s International Classification
of Impairments, Disabilities and Handicaps (ICIDH) (Wood, 1980). The ICIDH is a
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classification of "disablements" and covers three dimensions: 1) body structures or functions,
i.e. impairments; 2) personal activities, i.e. disability; and 3) participation in society, i.e.
handicap. Accurate clinical assessment of disability experienced by patients with MS is of
great importance in interventions or pharmacological research and also in clinical practice to
identify problems that may be amenable to treatment (Rossier & Wade, 2002). Disability in
MS patients however, does not necessarily arise only from impairments (signs or symptoms
of MS) but can also occur due to impact on activity domains such as dexterity,
communication, work, leisure/domestic activities and personal activities of daily living.
The most commonly used measure of neurological impairment in MS clinical trials is
the EDSS (Solari, 2005). The EDSS was derived from the Disability Status Scale (DSS)
originally introduced by Kurtzke (Kurtzke, 1955) and its ratings range from 0.0 to 10.0, with
0.5 unit increments (except between 0 and 1). For a rating lower than 4.0, the EDSS score is
based on scores from eight functional systems: pyramidal, cerebellar, brainstem, sensory,
bowel and bladder, visual and mental function. Scores above 4.0 are highly dependent on the
patient’s ambulation status – primarily the ability to walk certain distances and a dependence
on assistive devices.
In spite of its dominance in MS research, the Kurtzke scale is documented to have
many weaknesses. It has been argued that the Kurtzke EDSS is not a general measure of
disability since it uses information derived from the level of impairment to allocate the first
three levels and this may be invalid given the variable link between disability and
impairment. The six higher grades concentrate on mobility which is just one aspect of
disability, while the final grade is death, which is not a disability (Rossier et al., 2002). Since
the scores above 4.0 are primarily based on ambulation status, EDSS shows reduced
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sensitivity to detect change in neurological impairment within this range (Balcer, 2001).
Studies have shown that simple timed measures of dexterity or mobility are much more
sensitive to change (Cutter et al., 1999; Goodkin, Hertsgaard, & Seminary, 1988).
The EDSS has limited reliability partly due to poor judging of distances (the main
differentiating feature between grades) by patients and doctors (Sharrack & Hughes, 1997;
Noseworthy, Vandervoort, Wong, & Ebers, 1990). The quantitative distances between
scores of the EDSS are on an ordinal or a noncontinuous scale, and as a result of this,
summary statistics such as mean and standard deviation may not be entirely appropriate for
reporting such scores (Balcer, 2001). Lastly, it takes time to complete, and requires a trained
neurologist because the functional systems analysis also needs to be completed (Rossier et
al., 2002).
Other commonly used clinical scales in MS research include The Scripps
Neurological Rating Scale (NRS) (Sipe et al., 1984), The Ambulation Index (AI) (Friedman
et al., 2005) and the Functional Independence Measure (FIM) (Granger, Cotter, Hamilton,
Fiedler, & Hens, 1990). The NRS is a reliable and valid measure of impairment and
disability but is unresponsive, while the AI which is a reliable and valid ambulation-related
disability scale is only weakly responsive. The FIM on the other hand was found to be
reliable and responsive, but is rather cumbersome to administer with a limited content
validity (Sharrack et al., 1999b).
The National Multiple Sclerosis Clinical Outcomes Assessment Task Force
developed the Multiple Sclerosis Functional Composite (MSFC) in light of the perceived
problems with existing disability measures (Fischer, Rudick, Cutter, & Reingold, 1999;
Rudick, Cutter, & Reingold, 2002). The scale has three components that yield objective and
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quantitative results 1) the Timed 25-Foot Walk; 2) the 9 Hole Peg Test (9-HPT) and 3) the 3second paced auditory serial addition test. The MSFC can be administered by trained
technicians as well as other non-physician personnel. The testing time is about 15 minutes
and required facilities to include a quiet examination room with a table or desk and a hallway
for the Timed 25-Foot Walk Test. The MSFC has also been validated against patientreported quality of life measures (Miller et al., 2000). Strong correlations were found with
the SIP and SF-36 physical dimensions while significant but slightly weaker correlation was
observed with the emotional functioning scale of the SIP.
In order to incorporate a measure focusing on disability in patients with MS, the
Guy’s Neurological Disability Scale (GNDS) was developed (Sharrack & Hughes, 1999a).
The GNDS is based on the concept that disability in MS is multi-dimensional and can be
considered in several separate categories. The authors identified twelve separate functional
domains of mutually exclusive human functions which can be commonly observed in
patients with MS namely: cognition, mood, vision, speech, swallowing, upper limb function,
lower limb function, bladder function, bowel function, sexual function, fatigue and “others”
to cover disabilities resulting from impairment of less defined systems such as pain, spasms,
vertigo, etc.. The GNDS was found to be scientifically sound, displaying good to moderate
validity, reliability and responsiveness. The GNDS can be either administered by an
interviewer or self-administered, with both formats displaying good psychometric properties
(Rossier et al., 2002). The necessary time to perform the GNDS has been documented to be
nine minutes, with an additional five minutes required for scoring (Rossier et al., 2002).
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Measures of Self-Reported Visual Function
Vision targeted patient-based activity assessments did not occur in the literature
before 1980, but the following decades have seen the development of several patient-based
visual function assessment instruments and their use in studies among patients with visual
impairments (Massof et al., 2001). The National Eye Institute - Visual Function 51-item
questionnaire (NEI-VFQ) was the first instrument developed specifically for vision-impaired
patients which included items that assess patients’ ability to cope emotionally and
psychologically with their vision loss. This was administered to patients in the Optic
Neuritis Treatment Trial (ONTT) cohort (Cole, Beck, Moke, Gal, & Long, 2000). Selfreported visual dysfunction on the 51-item NEI-VFQ as well as its short-form version Visual
Function Questionnaire – 25 items (VFQ) was found to be common among those patients
who developed clinically definite MS in the ONTT.
The VFQ consists of 25 items presented in the format of a Likert scale and patients
are asked to rate the level of difficulty of particular visual symptoms or activities such as
difficulty looking at or using a computer (Mangione et al., 2001). The following visiontargeted subscales are generated: global vision rating (1 item), difficulty with near vision
activities (3 items), difficulty with distance vision activities (3 items), limitations in social
functioning due to vision (2 items), role limitations due to vision (2 items), dependency on
others due to vision (3 items), mental health symptoms due to vision (4 items), driving
difficulties (3 items), limitations due to peripheral (1 item) and color vision (1 item), and
ocular pain (2 items). It also contains an appendix of additional items from the original
version that can be used to expand the scales up to a total of 39 items. The questionnaire can
be self-administered by paper and pencil, and also through a personal or telephone interview.
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The interviewer format takes approximately ten minutes to administer, while the selfadministered format has not been times because it is yet to be tested psychometrically.
The interviewer-administered format of the VFQ was found to have internal
consistency and validity comparable to the original 51-item version in a sample of patients
with evidence of an underlying eye disease such as diabetic retinopathy and age-related
cataracts. This format has also been used to assess and compare self-reported visual function
between MS patients and an eye-disease free reference group (Balcer et al., 2000). Mean
VFQ composite and selected sub-scale scores with the exception of color-vision, were found
to be worse in MS patients compared with the eye-disease free group.

Measures of Depression
Depression screening questionnaires are appropriate for many research efforts due to
the cost and time intensive nature of clinically diagnosing depression (Vahle, Andresen, &
Hagglund, 2000). Standardized instruments of depression measure depressive
symptomatology rather than clinical depression and are commonly used to screen people
with disabilities. The Center for Epidemiologic Studies- Depression Scale (CES-D) which
was derived from previously validated longer depression scales, is the most widely used
questionnaire for depression screening (Vahle et al., 2000; BECK, WARD, MENDELSON,
MOCK, & ERBAUGH, 1961; Raskin, Schulterbrandt, Reatig, & McKeon, 1969; BECK et
al., 1961). The instrument consists of 20 symptom items associated with depression which
are indicative of personality attributes such as self-esteem, state anxiety and trait anxiety
(Orme, Reis, & Herz, 1986). The focus of the CES-D is on current symptoms (Kohout,
Berkman, Evans, & Cornoni-Huntley, 1993), in that patients rate the frequency of each
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symptom item over the past week as a score ranging from 0 (rarely or none of the time) to 3
(most or all of the time). A low average administration time of less than seven minutes leads
to a reduction in administrative and respondent burden (Kohout et al., 1993).
The CES-D has been used among individuals with various disabling conditions
including spinal cord injury, stroke and MS (Holicky & Charlifue, 1999; Shinar et al., 1986;
Romberg, Virtanen, & Ruutiainen, 2005; Patten, Fridhandler, Beck, & Metz, 2003). The
validity and reliability of the CES-D were tested in a large sample of MS patients, general
practice patients and healthy workers (Verdier-Taillefer, Gourlet, Fuhrer, & Alperovitch,
2001). The four factors of the questionnaire explained more than 50% of the variance in
each of the sample groups. Reliability was found to be excellent with Cronbach’s α of 0.90
in patients with MS. The positive predictive value of the questionnaire was evaluated in
patients who were candidates for disease-modifying MS treatment (Pandya, Metz, & Patten,
2005). The CES-D result was impressive, with 38 (74.5%) of a total of 47 patients with a
positive test result were found to have a depressive disorder.

Psychometric Comparison of HRQoL Measures
Only three reported studies have concurrently compared the psychometric properties
of MS-specific HRQoL measures. Riazi et.al. (2003) examined and compared the full range
of psychometric properties of the MSIS-29 with the 59-item FAMS and the SF-36. The
analysis however, was limited only to the physical and psychological scales from each of
these measures in order to ensure that only similar domains were being compared. The
comparison was performed in a sample of adults with clinically definite MS who were
consecutively admitted to a hospital for rehabilitation or intravenous steroid treatment. The
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authors examined the complete set of psychometric properties including scaling assumptions,
acceptability, reliability, convergent and discriminant construct validity, and responsiveness.
Patients were asked to complete the questionnaires on admission and discharge
(rehabilitation) or on admission and six weeks later (steroids).
A substantial floor effect (20%) was detected for the SF-36 physical function scale,
but not for the physical scales of the other measures. The reliability of the mobility scale of
FAMS was lower than the acceptable level set for this study. With regards to
responsiveness, the MSIS-29 performed better compared to the SF-36 and FAMS in both the
physical and psychological scales. This evidence suggests that the MSIS-29 is more likely to
detect clinically significant changes in the impact of MS. Relative efficiency statistics
indicated that the other scales were 26% (SF-36 physical function) and 63% (FAMS
mobility) as efficient at detecting change as the MSIS-29 physical scale. Although the
MSIS-29 displayed better psychometric properties than the other measures, the authors have
acknowledged the need for continuing comparisons among MS-specific HRQoL measures.
Another study of psychometric properties of MS related health status measures,
evaluated the reliability, scale score distributions and the relationship of the measures to a set
of specifically designed criterion variables (Vickrey et al., 1997). The quality of life
measures included the SF-36 as the generic measure and the Quality of Life Questionnaire
for Multiple Sclerosis (QOLQ) and the Multiple Sclerosis Activities of Daily Living Scales
(MS-ADL scales) as the disease-specific measures. The study involved sending a mail
survey to 171 patients with definite MS who attended the Multiple Sclerosis Clinic at the
University of California at Los Angeles (UCLA). The SF-36 was supplemented with three
scales which covered dimensions felt by expert opinion and a review of literature to be
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highly relevant to individuals with MS (Vickrey, Hays, Harooni, Myers, & Ellison, 1995).
The SF-36 with supplemental scales showed marked floor and ceiling effects on the role
limitations due to physical problems and role limitations due to emotional problems scales,
respectively. The MS-ADL also showed noteworthy ceiling effects on a couple of scales,
while the QOQL showed no discernable floor or ceiling effects.
Results from relative validity analysis and the stepwise regression procedure
indicated that the disease-targeted components (cognitive function scale, mobility and selfselected physical problems scales from the QOQL and the MS-ADL social and social (help)
scales) of HRQoL in MS contributed important unique information to researchers. Although
supplementing SF-36 with certain disease-specific components was found to be useful, no
one measure was clearly and consistently superior or worse than others in terms of reliability
and construct validity. One important limitation of this study was that the authors did not
evaluate the responsiveness of these measures to change. This makes it difficult to
generalize the findings of this study to all studies of MS, particularly those which are
longitudinal in nature.
The MSQoL-54, FAMS and EuroQol (standardized outcome measure developed by
the EuroQol Group) were administered to 128 MS patients in contact with a rehabilitation
ward or a consultant in rehabilitation medicine (Nicholl et al., 2001). The purpose of this
study was to assess the relative importance of the EuroQol (EQ-5D) compared to a MSspecific and a generic quality of life questionnaire. The EQ-5D failed to perform well, owing
to the three point scale which was found to be lacking in discrimination within a highly
disabled sample. Since the visual analogue health state scale on the EQ-5D did not show
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high correlations with any other mood or disability measures, the claim that it measures
quality of life remained unsubstantiated.
The MSQoL-54 was found to have large floor effects on the physical health and role
limitations due to the physical problems subscales. The FAMS motility subscale however,
had no noticeable floor effects even though a large percentage of the study sample were
restricted to a wheelchair (66.6 %). Some patients found certain items in all three
questionnaires to be offensive due to their obvious limitations. The FAMS was found to be
the better of the three questionnaires owing to the presence of a number of subscales relevant
to MS and the lack of floor and ceiling effects. Since this study included a number of
disabled MS patients, the generalizability of the results to patients with milder symptoms is
suspect. Additionally the important property of responsiveness of these measures was left
out of this analysis.

Use of Quality of Life Information in Clinical Practice
Knowledge of usefulness of health related quality of life (HRQoL) assessment in
clinical practice such as documentation of the natural history of a disease, evaluating
treatment effectiveness and improving clinical case management has been present since the
early nineties. There have been attempts to move the formal evaluation of quality of life
assessment into the clinical setting, but it has been difficult to anticipate the impact of such
assessments in physician-behavior and patient care as well as decision making (Greenfield &
Nelson, 1992). A shift towards HRQoL assessments, in order to be accepted by clinicians
should not only benefit the patients, but also enhance the clinician’s ability to function. This
requires that the argument for use of HRQoL measures should be made on practical basis and
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not purely on theoretical grounds (Hayes, 1998). Although some evidence of practicality of
MS-related HRQoL measures is available from studies comparing their psychometric
properties, there remains a need for a study exploring a neurologist’s behavior and attitude in
relation to QOL information.
Assessments of the behavior and attitude of physicians regarding routine
measurement of HRQoL in patients with chronic conditions such as cancer (Bezjak et al.,
1997; Bezjak et al., 2001), hematopoietic stem cell transplantation (Lee et al., 2004), diabetes
(Meadows, Rogers, & Greene, 1998) and rheumatoid arthritis (Russack et.al; 2003) have
been well documented. Such studies have provided varying results regarding physician use,
knowledge and attitude regarding quality of life information in treating patients with chronic
conditions. In a survey of general practitioners (GP) and practice nurses, it was found that
almost half of the personnel were unclear as to how the health outcomes data obtained during
routine care of patients with diabetes was used. In terms of outlook towards QOL
information, the results conveyed that both GP’s and nurses showed a positive overall
attitude towards health outcome measurement (Meadows et al., 1998). Another study in a
hospital setting found that most physicians had poor knowledge of quality of life assessment
instruments and this was influenced mainly by the age of the physician and the department of
practice. Young physicians and those working in oncological departments seemed to have
more knowledge about health status measures (Belli et al., 1994).
Oncology practice has made great strides relating to research regarding quality of life
assessment in clinical care of cancer patients. Bezjak and colleagues have published a series
of research publications regarding the perspectives of oncologists regarding the use of quality
of life information in clinical practice using the MD-QOL, a self-administered questionnaire
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developed specifically for this purpose (Bezjak et al., 1997; Bezjak et al., 2001; Bezjak et al.,
1997; Bezjak, Taylor, Ng, MacDonald, & Depetrillo, 1998; Taylor, Macdonald, Bezjak, Ng,
& Depetrillo, 1996). The MD-QOL was constructed on the basis of in-depth interviews with
sixty American and Canadian oncologists and was designed to assess physician perceptions
of QOL and QOL information. Another study among rheumatologists noted that although
63% felt that patient self-report questionnaires were useful in clinical decision making, 48%
of the respondents stated that none of their patients completed HRQoL self-reports in routine
care. Only 19% of the rheumatologists had at least 50% of their patients complete self-report
health status measures. Older rheumatologists were found to be most likely to endorse
patient self-report questionnaires (Russak et al., 2003).
Quality of life information has been known to provide useful information to
researchers by adding to existing clinical knowledge. Velikova and colleagues found that a
larger proportion of patients in the intervention group (those who regularly completed
HRQoL measures) showed clinically meaningful improvement in their HRQoL. Better
HRQoL and emotional functioning was attributed to the indirect impact of patient-physician
communication. Another randomized controlled trial in epilepsy patients at a neurology
clinic found that routine use of the SF-36 provided physicians with new information in 63 per
cent of the patients in the intervention group (Wagner et al., 1997). Thus, the routine use of
health status measures enhanced patient care by prompting changes in therapy in 13% of the
patients and by facilitating communication with physicians. The HRQoL has also been
reported to be useful for informing patients of common reactions and choices made by
patients with similar diagnosis (Bezjak et al., 2001).
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It has been noted that HRQoL instruments are not commonly used in routine care of
patients with MS. In order to achieve this practice, it is important to assess the neurologists’
attitude, beliefs and barriers to the use of HRQoL information. However in order to gain a
complete understanding of the neurologists’ intention to assess HRQoL information, a
complex approach that considers several factors may be required. Social psychological
models such as the Theory of Planned Behavior (TPB) may be helpful in such situations to
better identify the key determinants of behavioral intention. The TPB proposes that an
individual’s behavior is predicted by the strength of their intention to behave in that way.
There are three variables that predict behavioral intention: attitude, subjective norms and
perceived behavioral control, which in turn can be predicted from an individual’s belief.
Attitude towards a behavior is said to be a result of the belief about the likely outcome of the
behavior (behavioral beliefs) weighted by an evaluation of the importance of the
consequence (outcome evaluation). Subjective norm is assumed to be predicted from beliefs
about the views of other important individuals or groups (normative beliefs) weighted by a
persons motivation to comply with these groups (motivation to comply).
Perceived Behavior Control (PBC) is predicted by beliefs about factors likely to
facilitate or inhibit the behavior (control beliefs) weighted by the person’s evaluation of the
power that each of these factors has to affect their behavior (power). The TPB is commonly
used to study behavioral intentions and behavior in patients but has also been found to be
relevant to healthcare providers as well (Millstein, 1996). Hu and Chau, 1999 used the TPB
to investigate technology acceptance among physicians who practiced in public tertiary
hospitals in Hong Kong and found that attitude and perceived behavior control are important
predictors of this behavior. Another study utilized the framework of the TPB to examine
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predictors of physicians’ adherence to national guidelines for management of employees with
mental health problems (Rebergen et al., 2006).
Another such model, the Transtheoretical Model of Change (Prochaska, DiClemente,
& Norcross, 1992) has been used to conceptualize the process of intentional behavior change
among health care professionals. Park and colleagues (2003) found this model to be useful in
establishing future interventions to help understand and guide physician’s behavior towards
increasing adoption of smoking cessations interventions with their patients. Similarly Price
and colleagues (2006) used the model to identify Ohio obstetricians/ gynecologists' use of
nicotine replacement therapy with pregnant smokers. The Transtheoretical Model of Change
focuses on the decision making of the individual where the stage construct is the key
organizing construct of the model. The Transtheoretical Model defines change as a process
involving progress through a series of five stages: precontemplation, contemplation,
preparation, action and maintainence and has been used in the past to improve physician
delivered counseling (Keller, Donner-Banzhoff, Kaluza, Baum, & Basler, 2000) and
adherence to cancer screening guidelines among healthcare professionals (Honda & Gorin,
2006; Hersberger, Botomino, Mancini, & Bruppacher, 2006).
Precontemplation is the stage, in which people are not intending to take action in the
foreseeable future. People in this stage are generally uninformed or under-informed about
the consequences of the behavior in question. In the contemplation stage, people are
intending to change in the next six months, while in the preparation stage they are intending
to take action in the immediate future, usually measured as the next month. Action is the
stage in which people have made specific modifications in their behavior within the past six
months and since action is observable, behavior change often has been equated with this
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stage. The final stage is that of maintenance in which people are working to maintain the
behavior change for a long time. Behavior change is rarely a discrete, single event and an
individual moves gradually from being uninterested (precontemplation stage) to considering
a change (contemplation stage) to deciding and preparing to make a change. Most people
find themselves recycling through the stages of change several times before the change
becomes truly established. The Transtheoretical model also incorporates an intervening or
outcome variable called decisional balance (the pros and cons of change). These decisional
balance measures have become critical constructs in the Transtheoretical model. The pros
and cons combine to form a decisional "balance sheet" of comparative potential gains and
losses where the balance between the pros and cons varies depending on which stage of
change the individual is in.
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Chapter 3: Methods

Conceptual Model
The focus of this study was health-related quality of life (HRQoL) in noninstitutionalized patients with multiple sclerosis (MS) and is illustrated by the conceptual
model in Figure 1. Health-related quality of life is a multi-dimensional concept which can be
measured by any one of several patient reported outcome (PRO) measures. Health-related
quality of life may be influenced by several factors, especially in a progressive disease such
as MS. One objective was to determine factors that have an independent and significant
impact on HRQoL. As such, the influence of clinical, demographic and other relevant
factors was investigated.
Measurement of HRQoL and identification of its predictors is relevant beyond the
realm of research and may be very useful if incorporated into clinical practice. Incorporation
into practice will depend upon the choice of the measure and the intention of neurologists to
use such information. Deciding on a HRQoL measure for use in routine practice can be an
arduous task and may be best addressed by facilitating evidence-based choice. This was
accomplished by comparing currently relevant measures on various psychometric properties
as well as preferences of MS patients and neurologists regarding these measures. Preferences
regarding their relevance, usefulness, wording, and length were assessed.
Simplifying such decisions may not be sufficient to promote acceptance of HRQoL
among neurologists. It is necessary to understand what other factors may be associated with
the willingness of neurologists to utilize HRQoL information. These were investigated by

55

Factors affecting HRQoL
Clinical Factors:
Disability, Depression, and Visual Impairment

Health-Related Quality of Life
in Multiple Sclerosis

Demographic Factors:
Age, Gender, Marital and Employment Status
Other Factors:
Duration of disease, Comorbid Conditions

Stage of Change (TTM)

Application of HRQoL in clinical
practice

Attitudes (TPB)

Subjective Norms (TPB)

Choosing a suitable patient
reported outcome questionnaire in
the routine care of MS patients

Psychometric Properties: Acceptability,
Scaling Assumptions, Reliability, Validity
and Responsiveness
Patient Preferences: Length, wording,
Relevance to Daily Functioning

Intention of the neurologists to
assess HRQoL information in
patients with MS

Physician Preferences: Usefulness,
Wording, Length

= PHASE I
= PHASE II

Figure 1: Conceptual Model
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Behavior Control (TPB)

Demographic Factors:
Age, Gender

Other Factors:
Experience, Patient Load,
Participation in MS-Related
Clinical Trial, Place of Practice

using a framework of the Theory of Planned Behavior (TPB) and the Transtheoretical Model
of Change (health behavior theories).
Phase I involved collection of primary data from a sample of non-institutionalized
MS patients. Data from Phase I was used to measure HRQoL, identify factors affecting
HRQoL, compare the HRQoL measures on their psychometric properties, and assess patient
preferences. A mail survey of neurologists was performed in Phase II. This data facilitated
investigation of: neurologist preferences regarding the HRQoL measures used in Phase I;
intention of neurologists to use HRQoL information in practice; and factors that have a
significant influence on this behavioral intention.

Phase I
Research Design
The study design was longitudinal involving a convenience sample of patients with
multiple sclerosis (MS) at a large university hospital. The study involved completion of a
battery of patient-reported outcome (PRO) measures and quantitative tests of motor function
by the patients at the time of enrollment (Baseline, Time 1). Those patients who successfully
completed baseline assessments were asked to complete selected self-report questionnaires
via mail three to six months later (Time 2). A monetary reimbursement was given to all
participants following successful completion of questionnaires and/or tests at each time point.
The timeline for this study was March 2006 to October 2006.
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Study Population
Patients were included in this study if they were diagnosed as having clinically
definite MS and were treated for MS by at least one of the staff neurologists prior to baseline
data collection. Clinically definite MS was confirmed by neurologists using the McDonald’s
diagnostic criteria (discussed in the background section). Following identification of this
population, patients were excluded for any of the following reasons: 1) patients who had an
exacerbation (relapse) in the four weeks prior to enrollment; 2) those less than 18 years of
age; 3) those who were not literate in English; 4) those who were pregnant; and 5) those who
were not willing, or were unable to complete a series of questionnaires owing to cognitive or
functional limitations. These exclusion criteria were adapted from previous MS literature
(Patti et al., 2003). One hundred and sixteen patients meeting these criteria were identified
from the records of the outpatient neurology clinic at Ruby Memorial Hospital in
Morgantown, West Virginia. The sample consisted of those MS patients who were seen
regularly at the clinic, including those having a recent diagnosis of MS being seen for a
second opinion, as well as patients referred for consultation about management of MS.
Approval for the study was obtained from the West Virginia University Institutional Review
Board (WV-IRB).
Two weeks prior to their scheduled appointment patients were mailed a letter printed
on university letterhead, endorsed by their attending neurologist (Appendix A). The letter
provided a short description of the study and encouraged patients to participate. It also asked
them to account for some additional time during their upcoming visit, if they were interested
in taking part in the study. Physician endorsement was utilized in order to improve chances
of patient participation. Following their arrival at the outpatient clinic at Ruby Memorial
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Hospital, the attending staff neurologist reminded the patient about the study and introduced
them to the principal investigator (PI). The PI then described the study to the patient and
invited them to participate. Informed consent statements were read to patients who were
willing to participate and patient signature was obtained before any questionnaires or tests
were administered.

Instrument Selection
Selection of Measures for Psychometric Comparison
Selection of a HRQoL instrument generally depends upon the specific context in
which the instrument is going to be used (Holcik and Koupilova, 1999). Since the focus of
this study was HRQoL assessment in routine clinical practice, brevity of the instrument was
one of the main inclusion criteria. Questionnaires that were too long would be tiresome to
complete and might decrease the number of subjects willing to participate. The candidate
quality of life measures were also required to be self-administered, valid, available in
English, and previously applied in a sample of patients with MS. Based on these criteria, the
SF-36 was selected as the generic measure while HAQUAMS and MSIS-29 were selected as
the MS-specific quality of life measures. The HAQUAMS is one of the few MS-specific
measures that addresses most relevant domains of HRQoL. The MSIS-29 has been shown to
have good psychometric properties in comparison to commonly used measures such as the
Multiple Sclerosis Quality of Life – 54 Items (MSQ0L-54) and the Functional Assessment in
Multiple Sclerosis (FAMS). Finally, in absence of a gold standard HRQoL measure in MS,
the SF-36 was chosen as a generic comparator for this study.
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Reasons for Exclusion of Other HRQoL Measures
FAMS although commonly used has been shown to have lower reliability on its
motility scale compared to the MSIS-29 (Riazi et al., 2003). Additionally, eleven items of
HAQUAMS were derived from it, as such FAMS was not chosen as a comparator in this
psychometric comparison. The MSQoL-54 was excluded due to poor psychometric evidence
and the respondent burden (patients have to complete 54 items) that it poses. The MSQoL54 was developed as a disease-specific quality of life measure for MS and consists of the 36
items of the SF-36 and an additional eighteen condition-specific items. However, in
comparison with the SF-36, the MSQoL-54 was found to have no better psychometric
properties than the former and hence excluded. It was found to display marked floor and
ceiling effects and poor responsiveness and in addition, its sexual function and satisfaction
scales had a high proportion of missing data. Additionally, the MSQoL-54 overall quality of
life scale showed only moderate correlations (r= 0.34 to 0.45) with four measures of varying
constructs (Expanded Disability Status Scale, Functional Independence Measure, London
Handicap Scale, General Health Questionnaire) implying that it does not address a single
underlying construct (Freeman, Hobart, & Thompson, 2001). From among the other HRQoL
measures specific to MS, the Multiple Sclerosis Quality of Life Inventory (MSQLI) was not
included due to its length (takes approximately forty-five minutes to complete) and RAYS
Quality of Life Scale in Multiple Sclerosis due to absence of validity and reliability studies in
more than one setting.
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Selection of a Outcome Measure for Objectives 2 and 3
Total and sub-scale HAQUAMS scores were used as quality of life outcome variables
(dependent variable) for Objectives 2 and 3. The HAQUAMS was chosen for this purpose
over SF-36 and MSIS-29 because; not only is it MS-specific but it also addresses aspects of
patients other that just physical and psychological functioning. Although commonly used,
the SF-36 is still considered as a generic measure of quality of life, while MSIS-29 is
reported to be a measure of physical and psychological impact of MS and not of overall
quality of life
Data Collection
The protocol for phase I involved the completion of a battery of PRO measures, and
quantitative tests of motor function by all patients who consented to participate in the study.
Data was collected in a private area at the neurology clinic at Ruby Memorial Hospital. First,
the PI administered the Guys Neurological Disability Scale (GNDS) (see Appendix B), and
the Visual Function Questionnaire (VFQ) (see Appendix C) to the patients. Each patient was
then asked to complete the Centers for Epidemiological Studies- Depression Scale (CES-D)
(see Appendix D). The CES-D assesses depressive symptoms and is not a clinical measure
of depression. The terms depressive symptoms and depression will be used interchangeably
for the purpose of this study. An additional questionnaire (see Appendix E) gathered
information regarding age, gender, race, employment status, marital status, number of
comorbid conditions, and duration of the disease.
Comorbidity data were collected by asking the respondent specifically if they were
ever diagnosed or treated for the presence of any of a number of disease conditions (see
Appendix F). For the final analysis, comorbidities for each patient were calculated as a
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simple count of twelve common chronic diseases. These diseases included: arthritis,
diabetes, asthma, chronic obstructive pulmonary disease, high blood pressure, high
cholesterol, back problems, stomach ulcers, sexually transmitted disease, cancer, thyroid
problems and any category of heart disease. Duration of disease was expressed as the time
since diagnosis with MS. Patti and colleagues (2004b) have suggested that most patients
with MS remember the exact year they were diagnosed. However, it is more difficult to
know exactly when the onset of the disease occurred. The instructions for each questionnaire
were reviewed with the patients and the PI sat in a nearby area and was available to clarify
any questions that the patients had while completing the questionnaires.
Following the completion of the questionnaires, the patients were asked to complete
two quantitative tests of motor function from the Multiple Sclerosis Functional Composite
(MSFC): the Timed 25-Foot Walk Test and the 9-Hole Peg Test (9-HPT). The MSFC is a
three-part, standardized, quantitative, assessment instrument for use in clinical studies,
particularly clinical trials of MS. The instructions for each quantitative test of motor function
were given exactly as they appeared in the MSFC manual. The Timed 25-Foot Walk is a
quantitative mobility and leg function performance test in which the patient was directed to
one end of a clearly marked 25-foot course and was instructed to walk the marked distance
quickly, but safely. The time was calculated from the initiation of the instruction to start till
the patient reached the 25-foot mark. This task was immediately administered again by
having the patient walk back the same distance. This test allowed the use of assistive devices
if necessary and the score was the average of the two completed trials. Total administration
time of the test varied from one to five minutes depending on the ability of the patient.
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Both, the dominant and the non-dominant hands of the patient were tested twice using
the 9-HPT (a total of four trials). The patient was asked to sit at a table with a small, shallow
container holding nine pegs and a wood or plastic block with nine empty holes in it. The
patient was then asked to pick up the pegs, one at a time as quickly as possible and put them
into the nine holes and once all the pegs were in place, the patient was to remove them one at
a time as quickly as possible and replace them in the shallow container. The time to
complete this activity from start to finish was recorded. The score on the 9-HPT was
calculated as the average score (time of completion) of the four trials. Administration time
for this test was usually less than ten minutes, and varied depending on the ability of the
patient. During the administration of these tests (Timed 25-Foot Walk & 9-HPT), only the PI
and the patient were present in the testing room and all potential external distractions were
kept to a minimum.
Following these assessments, the patients were given a booklet (see Appendix G)
which contained three health-related quality of life (HRQoL) questionnaires along with a
business reply envelope. These questionnaires were randomly ordered in each booklet and
consisted of: (1) the Medical Outcomes Survey Short Form- 36 items (SF-36); (2) the
Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS); and (3) the
Multiple Sclerosis Impact Scale (MSIS-29). Additionally, information regarding
approximate time of completion and opinion regarding ease of use and relevance of content
for each of the questionnaires in the booklet was also collected. Questions assessing these
additional properties were included at the end of each HRQoL questionnaire. Patients were
asked whether they considered each questionnaire to be long, complex or difficult to
complete. The responses of these questions were on a scale of 1 to 3 (where 1=not at all,
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2=somewhat and 3=very much so). Questions relating to patient preference and assessment
of practicality have been adapted from pervious research for the purpose of this study
(Cooley et al., 2005; Bouchet, Guillemin, Paul-Dauphin, & Briancon, 2000). The patients
were asked to complete this booklet at home and return it in the mail within one week.
Three to six months following the initial assessment (Time 2), all patients who
successfully completed all questionnaires and tasks at the time of the first assessment, were
mailed a second booklet containing the same set of three quality of life questionnaires, again
randomly ordered. The patients were asked to send the booklet back by mail in the
accompanying business reply envelope within one week of receiving it. This was done in
order to examine the responsiveness of the three measures (SF-36, HAQUAMS and MSIS29).

Instrument Scoring
Medical Outcomes Survey Short Form (SF-36)
The SF-36 consists of eight sub-scales: physical functioning, role-physical, bodily
pain, general health, vitality, social functioning, role-emotional and mental health. These
sub-scales are scored such that a higher score indicates a better health state, for example,
functioning scales are scored so that a high score indicates better functioning and the pain
scale is scored so that a high score indicates freedom from pain. Scoring for each sub-scale
in the SF-36 was performed in the following steps
(1) Data Entry: Data was entered as coded in the questionnaire.
(2) Recoding for ten items that require recoding: Item recoding is the process of deriving the
item values that will be used to calculate scale scores. Recoding involves changing out-of-
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range values to missing, reverse coding of items and substituting person-specific estimates
for missing items.
(3) Dealing with missing data: It is recommended that a scale score be calculated if the
respondents answer at least half of the items in a multi-item scale (or half plus one in the case
of scales with an odd number of items)
(4) Computing a raw score: This score is a simple algebraic sum of responses for all items in
a particular sub-scale
(5) Transformation of scale scores: The raw scales are transformed to a 0-100 scale in order
to convert the lowest and highest possible scores to 0 and 100 respectively. Scores between
these values represent the percentage of the total possible score achieved. This was
calculated using the following formula:
Transformed Scale = (Actual raw score- lowest possible raw score) x 100
Possible raw score range
Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS)
The final English version of the HAQUAMS consists of 38 items which are used as
the basis for computation of five subscale scores reflecting major dimensions of HRQoL in
MS: fatigue/thinking (four items), lower limb mobility (five items), upper limb motility (five
items), social function (six items) and mood (eight items). Most items are scored from one to
five where “1 = not at all” and “2 = very much”. A total of eight items (item numbers 15, 23,
25, 26, 34, 35, 36 and 37) are positively worded for example, “I am satisfied with my sex
life” or “I get support from my family”. Sub-scale raw scores were computed by first
recoding the positively worded questions, so that high scores indicate a low quality of life in
all questions. Mean scores were then computed for all subscales and mean substitutions were
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allowed for missing items. Subscales were not calculated if more than 20% of the items were
missing (Gold et al., 2001).
Multiple Sclerosis Impact Scale (MSIS-29)
The MSIS-29 was used to calculate two scores; physical impact score and
psychological impact score (Hobart et al., 2004). The physical impact score was calculated
by summing item numbers 1 through 20. This score was transformed to a score on a scale of
0-100 using the following formula:
100 x (observed score – 20)
100 – 20
As in case of the physical impact score, the psychological impact score was calculated by
summing items 21 through 29, and then transformed to a score on a scale of 0-100 using the
following formula:
100 x (observed score – 9)
45 – 9
Guy’s Neurological Disability Scale (GNDS)
The GNDS is divided into twelve separate categories each with an interview and
scoring section. Each sub scale was scored from 0 to 5, representing disability grades
ranging from “0 = normal status” to “5 = total loss of function: maximal help required”. An
overall score of the patients total disability was obtained by summing up all different subscores giving a sum score ranging between 0 (no disability) and 60 (maximum possible
disability) (Sharrack et al., 1999a).
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Visual Function Questionnaire (VFQ)
The VFQ was scored in a two step process. First, the original numeric values from
the survey were re-coded following scoring rules outlined in Table 1. A higher score
represents better functioning. Each item was converted to a 0-100 scale so that the lowest
and highest possible scores were set at 0 and 100 points. This format allows scores to
represent to the achieved percentage of the total possible score. In other words a score of 50
represents 50% of the highest possible score. Following this procedure, items within each
sub-scale were averaged together to create 12 sub-scale scores. Items contributing to each
specific sub-scale are presented in Appendix H. In the case of missing data, the items were
not taken into account when calculating scale scores. A sub-scale score was generated only
when at least one item was answered within that sub-scale. The VFQ sub-scale scores were
generated based on the average of all items in the sub-scale that the respondent answers.
Centers for Epidemiological Studies Depression Scale (CES-D)
The Centers for Epidemiological Studies – Depression scale can be scored in three
steps. First, sixteen items in this instrument are assigned one value in the following manner
for each response category; rarely or none of the time (less than one day) = 0; some or a little
of the time (1-2 days) = 1; occasionally or a more moderate amount of time (3-4 days) = 2 or
more or all of the time (5-7 days) = 3. For four items, namely questions 4, 8, 12 and 16, this
scoring is reversed. Once the value is assigned for each item, a total is computed by adding
the values for each of the twenty items. The resulting score usually ranges between zero and
sixty. The total is not computed if more than four answers are missing. Higher scores on the
CES-D indicate higher levels of distress (depressive symptomatology and not clinical
depression).
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Analysis for Phase I: Objective 1
For Phase I, Objective 1, the following five psychometric properties were examined
and compared for the SF-36, HAQUAMS and MSIS-29: scaling assumptions; acceptability;
validity; reliability; and responsiveness.
Scaling Assumptions, Acceptability and Patient Preferences
Item internal consistency was examined by calculating the Pearson’s r between each
item and total scale score. An item correlation with its domain (total scale score) of at least
0.30 was considered a valid indicator of scaling success (Riazi et al., 2003). Descriptive
analyses were performed for floor and ceiling effects (percentage of respondents having the
lowest and highest possible scores respectively), time of completion and patient opinion
regarding ease of use and relevance of content of the PRO measures. Floor and ceiling
effects less than 20% were considered as a criterion of acceptability in this study (McHorney
et al., 1994).
Validity
Construct validity (convergent and divergent validity) was tested using multitraitmultimethod (MTMM) analysis (CAMPBELL & FISKE, 1959; Langfitt, 1995; Campbell DT
& Fisk DW, 1959). The MTMM is simply a matrix or table of correlations arranged to
facilitate the interpretation of the assessment of construct validity. The MTMM makes it
possible to examine both convergent and divergent validity of various scales simultaneously
using one matrix. The general principle of this technique is that two or more methods, for
example different instruments can each be used to assess the same traits such as quality of
life aspects, items or subscales (Fayers PM et al., 2000).
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In the present study, scales assessing both, similar and different dimensions were
chosen from each measure based on scale names. The physical and psychological sub-scales
from each of the HRQoL measures were used: SF-36 physical functioning, MSIS-29 physical
impact scale and the HAQUAMS upper and lower mobility subscales. Convergent validity
was examined as the average of the correlations among pairs of scales measuring the same
concept. Divergent validity was tested by comparing validity coefficients between scales
measuring different dimensions. An example of divergent validity is to compare the mental
health scale (SF-36) with the lower limb scale (HAQUAMS). It would be expected that
comparisons of similar domains will display higher intercorrelations, while comparisons of
differing domains will exhibit lower intercorrelations. Convergent validity was also
established by observing the intercorrelations between the mobility subscales of SF-36,
HAQUAMS and MSIS-29 with the scores of the patients on the quantitative tests of motor
function from the multiple sclerosis functional composite (Timed 25-Foot Walk and the 9hole Peg Test).
Concurrent validity was compared for all measures by examining differences in
HRQoL scores across level of disability and level of ambulation. Disability, for the purpose
of this study was defined using patient self-report on the GNDS which is a new clinical
disability scale for patients with MS. Disability grades on the GNDS were classified as
having no disability (score of 1 to 12), mild disability (score of 13 to 24), moderate disability
(score of 25 to 36), severe disability (score of 37 to 48) and total loss of function (score of 49
to 60) (Sharrack et al., 1999a). Similarly, responses of the participants on question 7 of the
GNDS allowed us to categorize each of the participants in one of three groups based on
ambulation status: (1) able to walk independently (corresponding to a score of 0 to 2 on
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question 7 of GNDS); (2) requiring either a unilateral or bilateral support to walk
(corresponding to a score of 3 or 4 on question 7 of GNDS); or (3) confined to a wheelchair
(corresponding to a score of 5 on question 7 of GNDS).
Relative validity (relative efficiency) analysis was also performed. This analysis
provides an estimate of the sensitivity of the different PRO measures to important clinical
differences measured on external criteria such as level of disability. It was expected that
patients reporting a lower grade of disability on the GNDS would report better HRQoL
compared to the other patients. Analysis was performed using analysis of variance
(ANOVA), which compared the scale scores between all three HRQoL measures for the
different disability grades and one way ANOVA F-ratios were computed for each scale.
These F-ratios were then compared as a basis for evaluating the relative sensitivity (validity)
of individual scales to the known group differences. The relative validity was reported as the
ratio of the F-ratio of each scale to the F-ratio of a designated reference scale, usually the
scale with the smallest F-ratio. Standard parametric methods may be used to analyze quality
of life data, as recent evidence has shown that non-parametric testing methods produce
results similar to those presented by standard parametric tests (Walters & Campbell, 2004).
Additionally, post hoc comparisons were performed to identify which ambulation groups
differ significantly from each other. Duncan's multiple-range test which is a specialist
multiple comparison test that maintains a low overall type I error was utilized. A
significance level of p = 0.05 was used for this analysis.
Reliability
Cronbach’s alpha (α) coefficients were calculated for the total and subscale scores of
the included measures to estimate the internal consistency reliability. Evidence of
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satisfactory internal consistency reliability was set at the criterion of α > 0.70 (Nunnnally JC,
1978; Bennett et al., 2003; Meyer-Rosberg et al., 2001). Cronbach’s α coefficient of 0.80 or
greater was used as a more rigorous indicator of satisfactory internal consistency reliability
of the instruments.
Responsiveness
All psychometric properties specified above, except for responsiveness, were
assessed using cross-sectional data obtained at baseline (Time 1). Responsiveness of the
three measures was assessed using self-report data at two time points i.e. at baseline (Time 1)
and at three to six months following the initial assessment (Time 2). Change scores were
calculated as the difference between baseline (Time 1) and Time 2 scores for each domain of
the three questionnaires. Responsiveness was assessed using the following statistics: ES and
SRM (Kazis et al., 1989; Liang et al., 1990). At Time 2, each patient was asked to respond
to a transition question adapted from a study in rheumatoid arthritis (Fitzpatrick, Ziebland,
Jenkinson, Mowat, & Mowat, 1993b): “Thinking of any overall effects MS may have on you;
how would you describe yourself compared with the last time you completed these
questionnaires: Do you feel that you are much better, slightly better, the same, slightly worse
or much worse?” The ES is a standardized measure of change obtained by dividing the
average change between the initial and follow-up measurement by the standard deviation of
the initial measurement. The SRM is also a standardized measure of change which is
calculated by dividing the average change between initial and follow-up measurements by
the standard deviation of the change scores. These measures are commonly used in study
designs in which health status measures are administered at two points in time (Stratford,
Binkley, & Riddle, 1996), and hence are appropriate for this objective. ES has also been

71

used as a responsiveness measure in an earlier comparison of MS related quality of life
measures (Riazi et al., 2003). Usually an ES of approximately 0.20 is considered to be a
small change, one of 0.50 indicates a moderate change, and those of 0.80 or above reflect a
large change (Cohen J, 1977).
Sub-scales for each of the PRO measures were examined in terms of ES and SRM,
among a sub-sample of patients stratified into one of the following two groups on the basis of
their response to the transition question: (1) Worse: those patients who reported worsening in
their health status (those who reported slightly worse or much worse in response to the
transition question); (2) Better: those who considered themselves to have stayed the same
(those who reported much better or slightly better or the same). Investigators have often used
such indices because such questions have been shown to be useful bench-marks against
which to compare change scores on health status instruments (Guyatt et al., 1987;
MacKenzie et al., 1986).

Analysis for Phase I: Objectives 2 and 3
Objective 2 for Phase I was to identify predictors of HRQoL in patients with MS and
to determine the relative contribution of visual impairment on HRQoL in addition to
depressive symptomatology, level of disability and other clinical factors. This was achieved
by constructing a hierarchical regression model. Hierarchical regression models involve
entry of one predictor variable or a block of variables at a time, based on some a priori
criteria. Each step is a separate regression model and the resulting model is similar to the
model which is obtained by adding all variables simultaneously. An additional advantage of
such models over the multiple linear regression approach is that a change in R2 is computed
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at each step. This allows researchers to test whether a significant amount of additional
variance is accounted for by the variable or variables entered at that step.
In this model, the dependent variable was the HRQoL score on the HAQUAMS, and
the independent variables were: (1) visual impairment as measured by the visual function
questionnaire (VFQ); (2) as measured by the Guy’s Neurological Disability Scale (GNDS);
(3) age; (4) gender; (5) marital status; (6) race; (7) employment status; (8) depression; and (9)
duration of the disease. Bivariate analyses were performed to examine the extent to which
the individual variables were associated with overall HRQoL. Pearson’s correlations were
computed to examine the intercorrelations between the predictor variables and the HRQoL
scores. The degree of association between nominal and interval variables were assessed by
using the eta squared statistic. Eta squared is a measure of strength of relationship based on
sums of squares computed in analysis of variance and can be interpreted as the percent of
variance in the dependent variable explained linearly or nonlinearly by the independent
variable. The significance of the level of correlation in this case was determined by the Ftest analysis of variance.
If a given variable had an association with the significance level of p ≤ 0.10, that
variable was included in the multiple regression analysis. The exceptions to this rule were
disability as measured by the GNDS and depression score on the CES-D, based on their
significant associations with quality of life as evidenced by past research. The selected
independent variables were then entered into the model in blocks, with all variables within a
block entered in a single step
The change in R2 showed the amount of unique variance explained by every new
variable or block added to the model. Because one focus of this objective was the relation
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between the HRQoL and visual impairment, the score on the VFQ was added last in the
model. The change in R2 for visual impairment (VFQ score) represented the unique variance
explained by visual impairment when all other factors were accounted for.
Separate multiple linear regression analyses were performed to determine factors that
have a significant impact on the various domains of HRQoL for Phase I, Objective 3. The
domains of quality of life were identified by the HAQUAMS: fatigue, upper mobility, lower
mobility, mood and social function. The selection process of the independent variables for
each of the five regression models was similar to that for Phase 1, Objective 2.

Phase II
Research Design
Phase II of this project was a cross-sectional survey of neurologists with descriptive
and analytic components. Data from one section of the survey was used in conjunction with
Phase I which compared properties of three HRQoL measures in patients with MS.

Study Population
Surveys were mailed to neurologists currently working in the United States. The list
of neurologists was supplied by SK&A Information Services Inc., a private mailing list firm
located in Irvine, California. This firm researches, formats and maintains contact and
profiling information for over 2 million healthcare providers, including 600,000 physicians.
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Sample Size Calculation
Sample size was calculated using the following formula:
SS = Z2 x (p) x (1-p)
C2
Where,
Z = Z value
p = population proportion, expressed as a decimal
c = confidence interval, expressed as a decimal
The sample size for the study using a 95% confidence level (Z = 1.96 for a 95%
confidence level) and a 5% confidence interval (c = 0.05) was estimated. The population
proportion (p) is the percentage of people in the population who will provide a given
response to a survey question. Since there was no population proportion for the sample, a
conservative estimate of 50% (p = 0.5) was used. Substituting these values for Z, p and c in
the above formula, the sample size was estimated to be 384. A response rate of about 25%
was assumed. This was a conservative estimate as compared to the mean response rate of
54%, typically seen in published surveys of physicians (Asch, Jedrziewski, & Christakis,
1997).

Survey Questionnaire Development & Validation
The survey instrument used was a five page questionnaire consisting of six sections
(see Appendix J). Information was collected on neurologists’: opinion regarding two
HRQoL questionnaires which were used in Phase I of this study, attitudes, subjective norms
and perceived behavior control regarding HRQoL assessment in patients with MS; intention
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to assess HRQoL information in patients with MS; perceived barriers and facilitators to
HRQoL assessment; current behavior regarding HRQoL assessment and inclination to use
HRQoL information in clinical practice; knowledge regarding specified HRQoL
questionnaires; and socio-demographic information (age-group, gender, practice site, years in
practice, participation in MS clinical trials, and patient load per week).
The members of the research committee which included one neurologist and four
health outcomes researchers, were approached to asses the clarity, readability and the
appropriateness of the instrument. This was done in order to improve the face and content
validity, assess the relevance of the questions and clarity of the instructions and ease and time
to completion. These results were then used to make further improvements in the
questionnaire.

Study Procedures
Approvals for all Phase II survey related material was obtained from the WVU
Institutional Review Board in July 2006. Three thousand mailing labels were purchased
from SK & A, and a simple random sample of 2,400 neurologists was produced using
Microsoft Excel’s random number generator function. The decision to include 2,400
neurologists in the final sample was taken in order to meet the sample size requirement of
384, assuming a 25% response rate.
The questionnaires mailed to the neurologists were printed on colored paper and
accompanied by a personalized cover letter on WVU letterhead (Appendix I), describing the
study and encouraging them to complete the survey. Neurologists were asked to return it
anonymously in an accompanying pre-addressed postage paid envelope. Four weeks
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following the contact, a second mailing consisting of the survey instrument, cover letter and a
pre-addressed postage paid envelope was sent to all non-responding neurologists.
At the end of eight weeks following the initial mailing, all respondents were broken
down into three groups: Non-respondents: those who did not return the survey; Returned but
not applicable: this group included those who indicated that they were not involved in the
routine care of patients with MS or when the survey was returned as undeliverable by the
postal service; and Returned responses: this group included those who returned the survey
(either partially or entirely filled out). At the end of data collection, the response rate was
calculated by dividing the total number of respondents in the returned responses group by the
total number of eligible respondents (2400 – respondents in the returned but not applicable
group).

Study Variables
Operationalization of the variables for the descriptive and analytic components of the
study is listed below:
The variables for the descriptive study are as follows:
Neurologists’ opinion regarding the usefulness, length and the wording of two MSspecific HRQoL measures were assessed using three questions on a 7-point Likert scale
(Page 1 of the questionnaire). A list of potential barriers and facilitators to the utilization of
HRQoL information were adapted from previous research (Bezjak et al., 2001). Six items
formed the barriers scale while the facilitators scale consisted of the remaining four items.
Each statement was rated on a 7-point Likert scale reflecting the degree to which each item is
perceived to be a barrier or facilitator to HRQoL assessment where ‘1 = Strongly Disagree’
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to ‘7 = Strongly Agree’. Barrier items addressed issues such as difficulty in scoring HRQoL
questionnaires and irrelevance of such information to neurologists. (Barrier and facilitator
items can be found on Page 4 of the questionnaire)
Current behavior regarding HRQoL assessment in patients with MS and
categorization of the neurologists based on their knowledge and inclination to use HRQoL
information (Page 4 of the questionnaire). Neurologists’ knowledge of and experience with
using specified HRQoL measures used in MS were also assessed. These questionnaires were
identified from the literature as being the most commonly used in MS research. The list
consisted of generic as well as MS-specific quality of life measures (Page 5 of the
questionnaire)
Socio-demographic characteristics (Page 5 of the questionnaire): Gender, age group,
primary practice site, number of MS patients seen per week, participation in MS-related
clinical trial, year of board certification and number of years in practice. The independent
and dependent variables for the study of the neurologist’s intention to use HRQoL
information in patients with MS were operationalized as follows:
Dependent Variable
Intention to use HRQoL information: Behavioral intention was measured by a single
question on a seven point Likert scale where ‘1 = strongly disagree’ and ‘7 = strongly agree’.
(last item on page 3 of the questionnaire).
Independent Variables
An elicitation study was conducted among eight neurologists at the neurology clinic
at West Virginia University to assess attitude, subjective norms and perceived behavior
control.
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Attitude
Indirect measures of attitude were used by conducting separate interviews with
several neurologists and neurology residents at the West Virginia University Neurology
Clinic. The interviewees were asked about their beliefs regarding the consequences of
assessing HRQoL information using validated formal questionnaires in routine practice.
Using the results of the elicitation interviews seven attitudes were identified that are common
among neurologists about the consequences of assessing HRQoL information in patients with
MS during routine practice. Neurologists were asked to make judgments regarding each of
these consequences (outcomes): an assessment of how strongly they agreed that an
consequence would occur if they assessed HRQoL information in patients with MS; and an
assessment of how desirable or undesirable each outcome is in their opinion (outcome
evaluation). Questions regarding outcomes were constructed on a seven point Likert scale
where ‘1= strongly disagree’ and ‘7= strongly agree’. Outcome evaluations were measured
on a scale of -3 to +3 where ‘-3= extremely undesirable’ and ‘+3 = extremely desirable’.
Product scores for each of the seven consequences were computed by multiplying the
neurologists’ probability rating regarding the outcome by the outcome evaluation score.
These scores were then summed to create the attitude score. (Items 2 through 8 on pages 2
and 3)
Subjective Norms
Two salient referents were identified from the elicitation interviews. One was the
American Academy of Neurology (AAN), which is a medical specialty society for
neurologists and the other was colleagues or other neurologists. Neurologists were asked to
assess the position of these referents with respect to HRQoL assessment in MS patients and
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how motivated they were to adhere to those positions. Both judgments were scored on
seven-point bipolar scales. The scales ranged from ‘1 = strongly disagree’ to ‘7 = strongly
agree’ for the position assessments and from ‘1 = not at all’ to ‘7 = very much’ for the
motivation assessments (Items 9 and 10 on page 3). The score for social norms was
computed by summing across the neurologists’ position rating and the motivation measure.
Perceived Behavior Control
Neurologists were asked whether the decision to assess HRQoL information from
patients with MS was beyond their control. Responses were scored on a seven-point Likert
scale where ‘1 = strongly disagree’ to ‘7 = strongly agree’. They also assessed whether it
was difficult or easy to assess HRQoL information in their patients with MS on a seven-point
scale where ‘1= extremely difficult’ and ‘7= extremely easy’. The two scores were averaged
to give the perceived behavior control score.

Analysis for Phase II
To determine whether there was any difference in the opinion of neurologists
regarding the HAQUAMS and MSIS-29, the Wilcoxon signed rank test was utilized.
Statistically significant differences were identified at p < 0.05. The Wilcoxon signed rank
test also referred to as the Wilcoxon matched pair test, is a non-parametric technique used to
test the median difference in paired data. This test was utilized due to the non-normality of
the responses to these items. Wilcoxon signed rank test is the non-parametric counterpart of
the paired t test. The assumption of normality is avoided in the Wilcoxon signed rank test,
because the test is based on rank order of the differences rather than the actual value of
differences.
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Frequency distributions for categorical data and means and standard deviations for
continuous variables were calculated using descriptive analyses to present an overall picture
of barriers and facilitators of HRQoL information use, knowledge and current behavior
regarding HRQoL assessment in patients with MS.
Multiple linear regression analysis was used to determine the predictors of behavioral
intention. Linear regression is a statistical technique for measuring the strength of a linear
relationship between a dependent variable (Y) and one or more independent variables (X1,
X2, X3 … Xn). The dependent variable is the one being affected (intention to use HRQoL
information) and the independent variables are the causes of that effect. The independent
variables included in the model were: attitude; subjective norms; perceived behavioral
control; primary practice site; years in practice as a neurologist; age; participation in a MS
trial and number of patients seen per week.

Regression Diagnostics
All regression models were inspected for assumptions of normality using the ShapiroWilk W test. One assumption of linear regression analysis that assures that the t-tests are
valid is that residuals are normally distributed. The p value of the Shapiro-Wilk test statistic
is based on the assumption that the distribution is normal. Assumption of normality was
rejected if p ≤ 0.05 for the Shapiro-Wilk (W) statistic. The White test which is a formal test
for the presence of heteroscedasticity was performed to establish homogeneity of the
variance of residuals. Significance of the test statistic (p ≤ 0.05) for the White test indicated
that the variance is not homogenous. Variance inflation factor (VIF) values were used for
each predictor to detect possible multicollinearity among predictors in the model.
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Multicollinearity is when variables are highly correlated and multicollinearity statistics
expose the redundancy of variables and the need to remove variables from the analysis.
Increased multicollinearity leads to difficulty in partitioning out the individual effects of
independent variables. The VIF measures how much multicollinearity has increased the
variance of a slope estimate. The VIF ranges from 1 to infinity, where a high VIF value (>1)
indicates that the variable may be affected by multicollinearity. The VIF value less than 4.0
is a common rule of thumb for acceptable multicollinearity in a regression model (Fisher JC
& Mason RL, 1981).

Power Considerations
Concurrent validity of PRO measures
A priori power analysis are conducted in order to ascertain sample size required to
perform the analyses necessary at a level of power desired prior to the start of the study. In
order to perform sample size calculations, researchers need to decide upon an alpha level; the
desired power, and the effect size. Alpha is the probability of making a Type I error that is
rejecting the null hypothesis when it is true. Effect size is a name given to a family of indices
that measure the magnitude of a treatment effect and unlike significance tests; these indices
are independent of sample size. Cohen (Cohen J, 1988) established a measure of effect size
termed Cohen’s d, which is the number of standard deviations separating two group means.
Although there is no universally accepted criteria for determining whether a given d is large
enough, researchers often use Cohen’s recommendations of small (d= 0.2), medium (d= 0.5)
and large (d= 0.8) effect sizes. A conservative effect size (d=0.3) along with a target power
of 0.8 and alpha level of 0.05 was selected for comparing patients classified into groups by
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disability levels as well as ambulation levels. Using these criteria produced the sample size
estimate of 111 subjects for Phase I, Objective 1.

Regression analyses for Phases I and II
The anticipated effect size index for regression is denoted by f2, where f2 reflects the
proportion of variance accounted for by some source in the population (PVs) relative to the
residual variance proportion (PVe), such that f2= PVs/PVe. For Phase I, the hypothesis being
tested was that the correlation of the visual impairment and other independent variables with
the overall quality of life score in the population to which the results are to be generalized is
zero. For a set of predictors explaining 20% of the variance in the dependent variable, f2is
0.25, and with nine predictors, a sample size of 72 subjects was necessary to achieve a power
of 0.8 and 89 subjects to achieve a power of 0.9 for Phase I, Objective 3 of this study.
For Phase II, Objective 4, the hypothesis being tested was that the correlation
between the independent variables (attitude, subjective norms, perceived behavior control
and demographic variables) and the intention to assess HRQoL information is zero for the
population to which the results are to be generalized. For a set of predictors explaining 20
percent of the variance in the dependent variable, f2 is 0.25, and with eight predictors, a
sample size of 66 subjects was necessary to achieve a power of 0.8 and 84 subjects to achieve
a power of 0.9.
All power analyses were performed by using G*Power, a general power analysis
program (Erdfelder, 1996). The G*Power program uses the number of predictors in the
analysis and expected effect size to calculate sample requirements. It should be recognized
however, that several rules of thumb exist to guide sample size selection in studies examining
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relationships between variables of interest. For testing individual predictors and assuming a
medium-sized relationship, a conservative estimate of sample size is N > 50 + 8 m (N=
sample size, m is the number of independent variables) (Green SB, 1991). Although Green’s
formula is comprehensive, there are a few other guidelines that may be considered. For
regression equations using six or more predictors, Harris (1985) recommends an absolute
minimum of ten participants per predictor variable. Still others have suggested a minimum
total sample of 400 (Cohen & Cohen, 1984) while some have declared a minimum of forty
subjects per predictor (Tabachnick BG & Fidell LS, 1996a). Generally speaking, such rules
are only approximations and the number of observations required may change based on two
important factors, the effect size (large or small) and the correlations among predictors (e.g.
multicollinearity).
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Chapter 4: Results

Phase I
Sample Characteristics
One hundred and thirty-six patients with MS agreed to participate in this study and
completed the self-report measures and the quantitative tests of motor function in the clinic.
Of these, 116 patients returned the completed HRQoL questionnaires in the mail. Table 1
shows the characteristics of the patients who completed both the in clinic assessments and the
HRQoL questionnaires. The mean age for this group was 44.8 years (range = 19 to 79 years)
with over 70% of them being women. Sixty-two participants failed to complete the
questionnaires at follow-up, leaving only 54 patients who completed the questionnaires at
both time points (Time 1 and Time 2).
Almost all of the participants were White (97.4%), while the remaining 2.6% were
African-American. Fifty-six percent of the participants were currently married and 33.6%
were currently working for pay; either full-time or part-time. Of those who were
unemployed, 75% mentioned that multiple sclerosis (MS) was the main reason for
unemployment. The mean duration of having MS was 8.8 years (range = 0 to 41).
Approximately 43% of the sample reported having no comorbidites, while 12.3% of the
patients said that they had at least three comorbid conditions from the checklist described in
the methods section. Based on the scores on question 7 (regarding lower limb problems) in
the Guys Neurological Disability Scale (GNDS), almost 16% of the participants were
restricted to a wheelchair, 27.6% used some type of aid for walking while 56% could walk
independently.
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Table 1: Characteristics of the sample
Variable
Sample Size
Gender
Female

N (%)
116 (100.0)
82 (70.7)

Age (in years)
Mean (SD)
Range

44.8 (13.8)
19-79

Race
White

113 (97.4)

Marital Status
Married

65 (56.0)

Employment
Unemployed due to MS
Unemployed
Employed

57 (49.1)
19 (16.4)
39 (33.6)

Ambulation
Walks unaided
Walks with aid
Uses wheelchair

65 (56.0)
32 (27.6)
19 (16.4)

Duration of MS since
diagnosis (years)
Mean (SD)
Range

8.8 (8.5)
0-41

Comorbid conditions
0
1
2
3 or more

46 (43.4)
32 (30.2)
15 (14.2)
13 (12.3)

SD= Standard Deviation
MS= Multiple Sclerosis
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Comparison of Health-Related Quality of Life Questionnaires
Acceptability
Mean scale scores and percentage of scores at the floor and ceiling are shown in
Table 2. Scales for all HRQoL questionnaires had relatively small floor and ceiling effects
except for the SF-36 role-physical function (59.5%) and role-emotional (39.7%) scales. The
floor effects for the Hamburg Quality of Life Questionnaire in Multiple Sclerosis
(HAQUAMS) upper mobility (14.7%) and social function (12.9%) scales were slightly high,
but were still below the maximum value of 20% set as a criterion for this study.
The HAQUAMS upper mobility scale however, did not display any ceiling effects
(0.0%). Ceiling effects for scales measuring similar domains were 0.9% for the Multiple
Sclerosis Impact Scale (MSIS-29) physical impact scale, 5.2% for the SF-36 physical
function scale and 6.9% for HAQUAMS lower mobility. The HAQUAMS lower mobility
scale had the smallest floor effect (1.7%), followed by the MSIS-29 physical impact scale
(3.5%), SF-36 physical function scale (8.6%) and the HAQUAMS upper mobility scale
(14.7%).
With regards to the psychological domain, floor and ceiling effects for the
HAQUAMS mood scale fell in between those of SF-36 and MSIS-29. SF-36 displayed the

least floor effects on the mental health scale (0.0%), while this percentage was 0.8 for the
HAQUAMS mood scale and 2.6 for the MSIS-29 psychological impact scale. Only 0.9 % of

the respondents had a maximum score on the MSIS-29 psychological impact scale compared
to 1.7% on the HAQUAMS mood and 2.6% on the SF-36 mental health scale.
There were marked differences in the acceptability for the HAQUAMS and SF-36
social function scales. The HAQUAMS social scale had much higher floor effects than the
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Table 2: Acceptability for HRQoL Measures (n=116)
Scale

No. of
Items

Mean

SD

Percent Scoring Percent Scoring
Minimum
Maximum

SF-36
Physical Function
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role-Emotional
Mental Health

10
4
2
5
4
2
3
5

41.0
23.3
56.3
45.3
39.9
57.5
45.7
62.8

31.1
35.0
27.7
23.1
21.0
25.9
44.1
22.1

8.6
59.5
1.7
0.9
2.6
3.5
39.7
0.0

5.2
12.1
14.7
0.0
0.0
12.1
35.3
2.6

0.87
0.87
0.87
0.87
0.87
0.86
0.88
0.87

HAQUAMS
Fatigue
Lower Mobility
Upper Mobility
Social Function
Mood

4
5
5
6
8

11.8
14.1
10.6
13.0
21.6

4.1
6.1
5.0
5.5
7.9

1.7
1.7
14.7
12.9
0.8

3.5
6.9
0.0
0.8
1.7

0.82
0.80
0.79
0.84
0.79

MSIS-29
Physical
Psychological

20
9

42.8
42.0

26.1
24.7

3.5
2.6

0.9
0.9

0.84
0.84

No. = Number
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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Cronbach’s
Alpha

SF-36 social functioning (12.9% vs. 3.5%) but significantly lower ceiling effects (0.8% vs.
12.1%). When comparing the HAQUAMS fatigue and SF-36 vitality scales a pattern opposite
to the one for the social functioning domain was observed. The HAQUAMS fatigue scale had
lower floor effects (1.7% vs. 2.6%) but higher ceiling effects (3.5% vs. 0.0%) compared to
the SF-36 vitality scale.
Reliability
Cronbach’s alpha for the scales and summary scales are also shown in Table 2. A
majority of the scales exceeded the internal consistency reliability criteria of 0.80 set for this
study. Only the upper mobility and the mood sub-scales for the HAQUAMS did not meet
these recommendations, however the alpha values were 0.79 for both scales, which is still
high enough to be considered acceptable. With regards to scales measuring physical and
psychological domains, the SF-36 scales had the highest values of Cronbach’s alpha
followed by the MSIS-29 and HAQUAMS. The SF-36 vitality scale and social functioning
scales had a slightly higher internal consistency reliability coefficients compared to their
HAQUAMS counterparts: 0.87 vs. 0.82 for the HAQUAMS fatigue scale and 0.86 vs. 0.84 for

the HAQUAMS social scale.
Scaling Assumptions
For all sub-scales, frequency distributions for the items were almost the same; items
within each scale had similar means scores and standard deviations (see Table 3). The
percentage of missing data was highest for the HAQUAMS lower (18.1%) and upper (3.5%)
mobility scales. The percentage of missing responses for all the remaining scales ranged
from 0.0 to 2.6%. Scales measuring the physical dimension of HRQoL displayed better
item-total correlations for the HAQUAMS (Range = 0.67-0.87) compared to the SF-36
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Table 3: Scaling Assumptions for HRQOL Measures (Total N=116)
Scale

Item Mean
Scores

Item SD

% Missing

Item Total
Correlation

SF-36
Physical Function
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role-Emotional
Mental Health

1.3-2.5
1.2-1.3
3.6-4.0
2.4-3.0
2.9-3.4
3.2-3.4
1.4-1.5
3.4-4.7

0.6-0.8
0.4-0.5
1.4
1.0-1.4
1.3-1.4
1.2
0.5
1.4-1.5

0.0-0.9
0.0
0.0-0.9
0.9-2.6
0.0-0.9
0.0-2.6
0.0
0.0-0.9

0.59-0.86
0.63-0.75
0.89
0.44-0.75
0.64-0.75
0.55
0.74-0.86
0.53-0.78

HAQUAMS
Fatigue
Lower Mobility
Upper Mobility
Social Function
Mood

2.4-3.3
2.5-4.0
1.6-2.8
2.0-2.5
2.2-4.0

1.2-1.3
1.4-1.5
1.0-1.4
1.3-1.4
1.1-1.4

0.0-0.9
0.9-18.1
0.0-3.5
0.0-2.6
0.9-2.6

0.60-0.72
0.68-0.87
0.67-0.82
0.38-0.74
0.59-0.78

MSIS-29
Physical
Psychological

2.0-3.3
2.5-2.8

1.2-1.5
1.2-1.4

0.9-2.6
0.9

0.58-0.82
0.13-0.80

SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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physical function (Range = 0.59-0.86) and MSIS-29 physical impact scale (Range = 0.580.82). Similar observations were made for the psychological scales: item-total correlations
for the HAQUAMS mood scale ranged from 0.59 to 0.78 and from 0.53 to 0.78 for the SF-36
mental health scale. Item 21 (In the past two weeks, how much have you been bothered by
feeling unwell) of the MSIS-29 psychological impact scale had a very low correlation with
the total scale score (0.13).
The HAQUAMS fatigue scale had item-total correlations (Range = 0.60 to 0.72)
similar to that of the SF-36 social function scale (Range = 0.64 to 0.75). With respect to the
social functioning dimension, item 25 of the HAQUAMS social scale (I get support from
friends and neighbors) had an item-total correlation of 0.38, while the highest correlation
within this scale was 0.74 for item 29 (I feel separated). The average item-total correlation
for the two items of the SF-36 social function scale (items 6 and 10) was 0.55. Overall, the
item-total correlations for all scales except for item 21 of the MSIS-29 exceeded the target
criterion of 0.30.
Construct Validity
This study attempted to provide evidence that the HAQUAMS and MSIS-29 scales
measure the underlying constructs of physical and emotional impairments that they are
known to represent. Table 4 depicts the matrix comparing the physical and mental scales for
SF-36, HAQUAMS and MSIS-29. All scale correlations within and across the measures
were statistically significant at the p ≤ 0.05 level. Evidence of convergent validity was
drawn from examination of the coefficients in the monotrait-multimethod triangles, enclosed
by the solid lines. For example, the coefficient of -0.69 corresponding to row 2 and column 1
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Table 4: Construct Validity of SF-36, HAQUAMS and MSIS-29 Physical and
Psychological Scales
Instrument/Scale

1

2

3

1) SF-36 Physical Function
2) HAQUAMS Upper Mobility
3) HAQUAMS Lower Mobility
4) MSIS-29 Physical Impact Scale

-0.69
-0.82
-0.79

0.76

0.82

5) SF-36 Mental Health
6) HAQUAMS Mood
7) MSIS-29 Psychological Impact Scale

0.31
-0.54
-0.50

-0.29
0.58
0.54

-0.33
0.58
0.54

4

5

6

-0.41
0.71
0.70

-0.51
-0.68

0.62

Note: N=116
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
Monotrait-Multimethod correlations are underlined: Correlations between two scales of two different
questionnaires measuring similar constructs
Multitrait-Monomethod correlations are in bold: Correlations between two scales of the same questionnaire
measuring different constructs
Multitrait-Multimethod correlations are italicized: Correlations between two scales of two different
questionnaires measuring different constructs
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7

of Table 4 indicates the correlation between two scales measuring a similar trait or construct
(physical function and upper mobility) using multi or different methods (SF-36 and
HAQUAMS). The construct validity for the physical sub-scales for all three questionnaires
was found to be consistent with the predictions. The upper mobility scale of HAQUAMS
correlated more highly with the SF-36 physical function scale (r = -0.82) compared to the
physical impact scale of the MSIS-29 (r= -0.79). The negative correlation coefficients were
expected because a higher overall score indicates better quality of life on the SF-36 but
poorer quality of life on both, the HAQUAMS and MSIS-29. The correlation between the
physical scales (Range= 0.69-0.82) was higher than the correlations among the physical and
the psychological scales (Range= 0.31-0.71). However, this was not the case with the
psychological scales. The correlation among the mood subscales was substantial (Range=
0.51-0.68) but not as high as observed for the physical domain scales.
To demonstrate divergent validity the multitrait-multimethod and the multitraitmonomethod correlation coefficients must be lower than the monotrait-multimethod
correlation coefficients. In other words, the correlation coefficient between two scales of the
same or different questionnaires, measuring different underlying constructs must be lower
than the correlation between two scales from different questionnaires measuring the same
underlying construct. For example, the correlation coefficient between the MSIS-29 physical
and psychological impact scales (0.71 in Table 4) and between the MSIS-29 physical and SF36 mental health scale (-0.41 in Table 4) must be higher that the correlation coefficient
between the MSIS-29 physical impact and SF-36 physical function scales (-0.79 in Table 4).
In Table 4, multitrait-monomethod correlations are bolded, while multitrait-multimethod
correlations are italicized and are represented in the rectangle enclosed by the broken lines.
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As would be expected, most of the scales that are supposed to measure different underlying
constructs are weakly to moderately correlated, independent from the method that is used
(range = 0.29 to 0.58). The only exception to this is the HAQUAMS mood scale, whose
correlation of 0.70 with the MSIS physical impact scale (see row 6/column 4) is higher than
its correlation with the SF-36 mental health (0.51) and MSIS-29 psychological impact scales
(0.62).
Criterion Validity
Objective Tests of Motor Function and Depression Scale
Convergent validity of the physical scales of all three questionnaires with respect to
the quantitative tests of motor function such as Timed 25-Foot Walk Test and 9-Hole Peg
Test (9-HPT), ranged from 0.28 to 0.39 (see Table 5). The SF-36 physical function scale had
the highest correlation with 9-HPT (-0.42) followed by the MSIS physical impact scale
(0.41). It was expected that the HAQUAMS upper mobility scale would correlate strongly
with the 9-HPT scores, however, this correlation was found to be lower compared to that of
the other scales (0.33). The HAQUAMS lower mobility scale on the other hand, correlated
as expected with the scores on 25-Foot Walk Test. This correlation coefficient was matched
by the SF-36 physical function scale (-0.39) and was higher that the correlation between
MSIS-29 physical impact scale and 25-Foot Walk Test (0.28). Evidence for divergent
validity of scales measuring physical dimensions was provided by their correlations with
scores on the depression scale (Range = 0.30 to 0.44). The psychological scales for all three
questionnaires exhibited strong correlations with the Centers for Epidemiological Studies –
Depression Scale (CES-D) (refer to Table 5). The correlation was strongest for the MSIS-29
psychological impact scale (0.71) and lowest for the HAQUAMS mood scale (0.62).
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Table 5: Concurrent Validity of SF-36, HAQUAMS and MSIS-29 Physical and
Psychological Scales against External Criteria
Instrument/Scale

CES-D

9-HPT

1) SF-36 Physical Function
2) HAQUAMS Upper Mobility
3) HAQUAMS Lower Mobility
4) MSIS-29 Physical Impact Scale

-0.38†
0.32†
0.30†
0.44†

-0.42†
0.33†
0.33†
0.41†

-0.39†
0.29†
0.39†
0.28†

5) SF-36 Mental Health
6) HAQUAMS Mood
7) MSIS-29 Psychological Impact
Scale

-0.68†
0.62†
0.71†

-0.27†
0.48†
0.34†

-0.02
0.11
0.07

†

25-Foot Walk

Significant at p < 0.01
CES-D: Centers for Epidemiological Studies- Depression scale
9-HPT: 9 Hole Peg Test & 25-Foot Walk Test: Objective clinical tests of motor function
Note: Negative correlations between external criteria variables (CES-D, Timed 25-Foot Walk Test and 9-HPT)
and SF-36 are due to differences in scoring. Higher scores indicate better quality of life on the SF-36 but higher
level of depressive symptomatology and poorer physical function
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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Correlations for scales measuring the psychological dimension of HRQoL were low to
moderate with measures of motor function (Range = 0.02 to 0.48). Negative correlations
between SF-36 and CES-D as well as the quantitative tests of motor function were due to the
inverse relationship between them as a result of scoring methods. Higher scores on the SF36 indicate better quality of life but poor physical function according to CES-D and the tests
of motor function.

Degree of Disability
Mean scores on the HRQoL measures for the sub-groups classified by disability of
the disease using GNDS are shown in the Table 6. Since the overall sample was less severe,
the participants were classified in to three groups: No Disability (N=40); Mild Disability
(N=54) and Moderate Disability (N=22). For the scales on all questionnaires, ordering mean
scores tended to follow the hypothesized order of better HRQoL scores in the group having
no disability, with progressively lower scores in the groups reporting mild and moderate
disability.
There were significant group differences on scores for all scales (p ≤ 0.01). The
physical impact scale of the MSIS-29 and the physical function scale of the SF-36 had the
highest relative validities of all scales, 7.5 and 5.8, respectively. The relative validity
coefficients for the HAQUAMS were 4.9 for the upper mobility scale and 4.8 for the lower
mobility scale. However, the overall QoL score for the HAQUAMS had the highest relative
validity coefficient (= 8.2) of all scales, indicating that it most sensitive to discriminate
between groups of MS patients based on disability. The mental health scale of the SF-36 was
the least sensitive to group differences in disability scores. Overall, all scales of the
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Table 6: Relationship between HRQoL Scores and Disability (Concurrent Validity)
Level of Disability
None
(N=40)

Mild
(N=54)

Moderate
(N=22)

F-Ratioa

Relative
Validityb

SF-36
Physical Function
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role-Emotional
Mental Health

65.9c
46.9c
71.0c
57.5c
50.3c
69.1c
60.0c
69.7c

32.2d
14.4d
53.1d
43.7d
37.9d
57.9c
45.7c
62.7c

17.5e
2.3d
37.4e
26.8e
26.1e
35.8e
19.7e
50.7e

33.0
19.6
13.6
16.0
11.7
14.5
6.5
5.7

5.8
3.4
2.4
2.8
2.1
2.5
1.1
1.0

HAQUAMS
Fatigue
Lower Mobility
Upper Mobility
Social Function
Mood
Total QoL

9.4c
9.6c
7.5c
10.3c
17.1c
10.7c

12.0d
15.5d
10.8d
13.4d
22.0d
14.6d

15.5e
18.6e
15.6e
17.5e
28.8e
19.2e

22.7
27.5
27.9
15.0
21.2
46.5

4.0
4.8
4.9
2.6
3.7
8.2

MSIS-29
Physical
Psychological

21.0c
27.7c

48.2d
43.9d

67.4e
68.8e

42.6
21.6

7.5
3.8

Scale

All F ratios were significant at p ≤ 0.01
a
One way ANOVA of the HRQoL scales and the MS levels of disability classified using the Guys Neurological
Disability Scale (GNDS)
b
Reference scale for calculating relative validities is the Mental Health subscale (SF-36)
c,d,e
Means within a row with different superscripts differ significantly (p ≤ 0.05, Duncan’s Multiple Range Test)
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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HAQUAMS were quite sensitive to group differences, with four scales having relative
validity coefficients of 4.0 or greater, compared to the reference scale (SF-36 mental health
scale). As can be observed from the post hoc comparison, all scales of HAQUAMS and
MSIS-29 successfully discriminated each of the three disability groups (none, mild and
moderate. From the SF-36, only the physical function, bodily pain, general health and
vitality scale has significantly different scores for each of the three groups.

Current Ambulation Status
The ability of the HRQoL measures to discriminate between patients with MS,
classified on the level of ambulation are reported in Table 7. Sixty-five patients reported that
they were able to walk unaided, 32 patients indicated that they needed either unilateral or
bilateral support to walk, and 19 patients indicated that they were confined to a wheelchair
both indoors and outdoors. For the scales on all questionnaires, ordering mean scores tended
to follow the hypothesized order of better HRQoL scores in the group which could walk
unaided, with progressively lower scores in the groups requiring some support to help with
ambulation.
The results of the ANOVA indicated that the scores on the scales measuring physical
domain of all three questionnaires differed significantly between the three ambulation
groups: the SF-36 physical function scale (F= 60.3, p < 0.01); the HAQUAMS upper
mobility (F= 40.0, p < 0.01) and lower mobility (F= 71.6, p < 0.01) scales; and the MSIS
physical impact scale (F= 52.9, p < 0.01).
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Table 7: Relationship between HRQoL Scores and Level of Ambulation (Concurrent
Validity)
Level of Ambulation
Walk
(N=65)

Walk Aid
(N=32)

Wheelchair
(N=19)

F-Ratioa

Relative
Validityb

SF-36
Physical Function
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role-Emotional
Mental Health

60.2c
33.9c
64.7c
54.1c
44.9c
66.9c
50.8c
66.2c

23.0d
11.8d
46.2d
38.4d
34.1d
52.3d
44.8c
59.0c

6.1e
8.6d
45.1d
26.7e
33.9d
34.2e
29.8c
57.9c

60.3†
7.6†
7.8†
15.2†
4.4*
16.0†
1.7
1.7

35.5
4.5
4.6
8.9
2.6
9.4
1.0
1.0

HAQUAMS
Fatigue
Lower Mobility
Upper Mobility
Social Function
Mood
Total QoL

10.7c
10.4c
8.0c
12.1c
18.3c
11.8c

12.6c, e
16.6d
12.3d
13.6c, e
24.9d
16.0d

14.0e
22.3e
16.4e
15.8e
27.2d
19.1 e

5.9†
71.6†
40.0†
3.5*
16.6†
37.6†

3.5
42.1
23.5
2.1
9.8
22.1

MSIS-29
Physical
Psychological

27.5c
34.5c

54.1d
49.4d

74.3e
61.7d

52.9†
9.6†

31.1
5.6

Scale

†

Significant at p ≤ 0.01
Significant at p ≤ 0.05
a
One way ANOVA of the HRQoL scales and the level of ambulation classified using responses on question 7
of the Guys Neurological Disability Scale (GNDS)
b
Reference scale for calculating relative validities is the Mental Health subscale (SF-36)
c,d,e
Means within a row with different superscripts differ significantly (p ≤ 0.05, Duncan’s Multiple Range Test)
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
*
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There was no significant differences between the three groups based on scores of the
SF-36 mental health scale (F= 1.7, p = 0.18). However, the HAQUAMS mood scale (F=
16.6, p < 0.01) and MSIS-29 psychological impact scale (F= 9.6, p < 0.01) scores differed
significantly. There was a significant difference in the scores of the HAQUAMS social scale
(F= 3.5, p < 0.05), but this was not as significant as the difference observed for the SF-36
social function scale (F= 16.0, p < 0.01).
As would be expected, the sensitivity of the HRQoL scales to these known group
differences was much higher for the scales assessing physical function (the SF-36 physical
function, MSIS-29 physical impact scale and HAQUAMS upper & lower mobility scales)
than for psychological scales (the SF-36 mental health, MSIS-29 psychological impact scale
and HAQUAMS mood scales). The lower mobility scale of the HAQUAMS had the highest
relative validity (Relative validity coefficient= 42.1) followed by the physical function scale
of the SF-36 (Relative validity coefficient= 35.5) and finally the MSIS-29 physical impact
scale (Relative validity coefficient= 31.1). The sensitivity of the overall QoL score of
HAQUAMS was also quite high, as evidenced by a relative validity coefficient of 22.1.
Duncan’s multiple range analysis illustrated that scales assessing physical domain for
all three questionnaires displayed significant differences in their scores for each of the three
ambulation groups. Other scales that displayed significant differences were: the general
health and social function scales of the SF-36 and the overall QoL score of the HAQUAMS.
Responsiveness
Effect sizes (ES) and standardized response means (SRM) have been reported for two
sub-groups classified based on the response to the global transition question. Effect size was
calculated as the mean change score (difference between Time 1 and Time 2) divided by the

100

standard deviation of the Time 1 scores. Standardized response mean was calculated as the
mean change score divided by the standard deviation of the change score. Fifty-four of the
116 participants successfully completed the assessment at Time 2 and were included in the
calculation of the responsiveness indices.
Responsiveness indices (ES and SRM) for those patients whose global perception of
change was either “slightly worse” or “much worse” (N=20) compared to baseline (worse
sub-group) are shown in Table 8. In the worse sub-group, only the general health scale from
the SF-36 was found to have the appropriate direction for the change score and at least a
small change in scores (ES= 0.29; SRM=0.55). Appropriate direction of the change score
refers to a change score value with a negative sign for HAQUAMS and MSIS-29 scales and a
positive sign for the SF-36 scales. This difference in the expected sign or direction for these
measures exists because; a higher score indicates better quality of life on the SF-36 but
poorer quality of life or functioning on the HAQUAMS and MSIS-29. Hence, patients in the
worse sub-group are expected to have lower scores compared to baseline on the SF-36 scales
(indicating decreased functioning in the various SF-36 domains), but higher scores compared
to baseline on the HAQUAMS and MSIS-29 (indicating decreased functioning in the various
domains for these measures). Other scales of the SF-36 with appropriate sign for the change
score were: the bodily pain scale (+5.0); the vitality scale (+1.8); and the social functioning
scale (+0.6). Of these, only the bodily pain scale had slightly higher responsiveness indices
(ES= 0.19; SRM= 0.22). Four of the six scales of the HAQUAMS had negative change
scores, that is, change scores with the appropriate sign. These included fatigue (-0.4), lower
mobility (-0.8), social function (-0.7) and overall quality of life scales (-0.3).
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Table 8: Responsiveness of the HRQoL measures for Those Who Reported Their
Overall Condition Having Worsened Over the Last Three-Six Months
Time 1
Mean (SD)

Time 2
Mean (SD)

Change
Mean (SD)

Effect Size†

SRM¶

SF-36
Physical Function
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role-Emotional
Mental Health

17.3 (17.7)
5.0 (10.3)
49.1 (26.0)
35.3 (19.6)
30.3 (18.8)
49.4 (14.3)
30.0 (34.0)
57.2 (23.3)

19.7 (20.9)
7.9 (23.7)
44.1 (26.7)
29.6 (17.8)
28.5 (18.5)
48.8 (34.0)
33.3 (43.0)
57.4 (18.4)

-2.1 (10.5)
-2.6 (26.2)
5.0 (22.5)
5.7 (10.4)
1.8 (16.7)
0.6 (25.2)
-3.5 (42.9)
-0.2 (12.1)

0.12
0.25
0.19
0.29
0.10
0.04
0.10
0.01

0.20
0.10
0.22
0.55
0.11
0.02
0.08
0.02

HAQUAMS
Fatigue
Lower Mobility
Upper Mobility
Social Function
Mood
Total QOL

13.4 (3.6)
18.1 (4.7)
15.1 (4.3)
14.7 (6.5)
25.9 (6.3)
17.44 (3.7)

13.8 (3.0)
18.9 (4.9)
15.0 (4.8)
15.4 (5.7)
25.8 (6.6)
17.8 (4.0)

-0.4 (2.6)
-0.8 (1.9)
0.2 (2.6)
-0.7 (3.9)
0.2 (5.9)
-0.3 (2.1)

0.11
0.17
0.05
0.11
0.03
0.08

0.15
0.42
0.08
0.18
0.03
0.14

MSIS-29
Physical
Psychological

60.7 (19.7)
49.4 (19.9)

57.5 (18.3)
50.7 (20.4)

3.2 (15.4)
-1.3 (10.8)

0.16
0.07

0.21
0.12

Instrument/Subscale

†
¶

Mean change score divided by standard deviation of Time 1 scores
Standardized response mean= mean change scores divided by standard deviation of change scores
Note: Change scores that had a sign (direction) that was expected for that group have been bolded. Total
N=20
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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For the MSIS-29, the psychological impact scale displayed a negative change score (-1.3).
Of these scales, the HAQUAMS lower mobility scale with a SRM of 0.42, was much more
responsive than all other scales (ES or SRM < 0.20).
Responsiveness for the thirty-four patients who responded as having gotten better
compared to baseline has also been reported (see Table 9). None of the scales in the better
sub-group had both: an appropriate direction for the change scores (i.e. change score with a
positive sign) and a responsiveness index of at least 0.20. Appropriate direction for the
change score refers to a change score value with a positive sign for HAQUAMS and MSIS29 and a negative sign for the SF-36. This is because; a higher score indicates better quality
of life on the SF-36 but poorer quality of life or functioning on the HAQUAMS and MSIS29.
The scales for the PRO measures in the better sub-group are expected reflect an
improvement relative to their scores at baseline. Based on this information, one would
expect either the same or a lower score on the scales for the HAQUAMS and MSIS-29 at
Time 2 compared to baseline. On the other hand, the same or a higher score would be
expected on all scales of the SF-36 at follow-up to indicate some improvement in the HRQoL
and its domains. Only the MSIS-29 displayed a change score with the appropriate sign
(positive) for the better group for both its scales (physical and psychological impact scales).
The mean change in the psychological impact scale was +3.0 with an effect size of 0.12 and
SRM of 0.21, while the responsiveness for the physical impact scale was minimal (ES and
SRM < 0.5). Change scores with appropriate signs were also observed for: the HAQUAMS
fatigue and upper mobility scales (+0.1 and +0.3 respectively), and the SF-36 role-physical (4.5), social function (-0.2) and physical function scales (-1.3).
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Table 9: Responsiveness of the HRQoL Measures for Those Who Reported Their
Overall Condition Having Gotten Better Over the Three-Six Month Time Period
Time 1
Mean (SD)

Time 2
Mean (SD)

Change
Mean (SD)

Effect Size†

SRM¶

SF-36
Physical Function
Role-Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role-Emotional
Mental Health

47.8 (30.5)
28.3 (37.1)
61.0 (29.3)
49.7 (23.8)
46.1 (20.5)
66.9 (21.2)
61.2 (44.1)
69.1 (22.3)

49.1 (29.4)
32.8 (38.4)
60.1 (26.4)
49.1 (23.5)
42.2 (22.1)
67.1 (26.3)
59.8 (44.0)
68.4 (23.7)

-1.3 (11.9)
-4.5 (34.7)
0.9 (21.4)
0.6 (19.6)
3.9 (17.9)
-0.2 (18.5)
1.4 (41.4)
0.7 (19.5)

0.04
0.14
0.01
0.14
0.24
0.09
0.02
0.01

0.11
0.15
0.01
0.17
0.30
0.10
0.02
0.02

HAQUAMS
Fatigue
Lower Mobility
Upper Mobility
Social Function
Mood
Total QoL

11.2 (4.1)
11.9 (5.1)
9.4 (3.9)
12.1 (5.1)
19.0 (7.5)
12.1 (4.2)

12.6 (3.9)
12.1 (5.3)
9.1 (3.5)
12.3 (5.4)
19.4 (8.3)
13.1 (4.0)

0.1 (2.1)
-0.2 (2.8)
0.3 (2.9)
-0.2 (3.7)
-0.4 (5.6)
-1.0 (2.0)

0.03
0.08
0.05
0.06
0.17
0.10

0.05
0.14
0.07
0.08
0.26
0.2

MSIS-29
Physical
Psychological

32.9 (22.1)
36.8 (25.1)

33.1 (19.4)
32.7 (26.0)

0.6 (14.2)
3.0 (14.2)

0.03
0.12

0.04
0.21

Instrument/Subscale

†
¶

Mean change score divided by standard deviation of Time 1 scores
Standardized response mean= mean change scores divided by standard deviation of change scores
Note: Change scores that had a sign (direction of change) that was expected for that group have been bolded.
Total N=34
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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Responsiveness indices for all these scales were below 0.20.
Time for completion and patient opinion
The average time for completion of the SF-36 and HAQUAMS were 9.9 minutes and
9.5 minutes respectively (see Table 10). The MSIS-29 took the least amount of time to
complete: 6.9 minutes. With respect to the length of the HRQoL questionnaires, 7% of the
sample thought that the number of questions in HAQUAMS was “too many” compared to
8.9% for MSIS-29, and 11.7% for the SF-36. Overall, 88.7% of the patients thought that the
length of HAQUAMS was just right; more than that for MSIS-29 (82.0%) and SF-36
(82.3%). A higher percentage of participants (90.4%) thought that the wording of the MSIS29 was “mostly easy to understand”, while this number was slightly lower for HAQUAMS
(87.0%), and much lower for SF-36 (78.1%). A small proportion of participants reported that
the wording was “mostly difficult to understand” for HAQUAMS (1.7%) and SF-36 (5.3%)
but none for MSIS-29 (0.0%). The percentage of participants that thought that the content of
the questionnaires was relevant to most of the problems faced in their day-to-day activities
were 86.1% for MSIS-29, 81.7% for HAQUAMS, and 72.8% for the SF-36.
Although the mean time of completion was highest for HAQUAMS, a higher
percentage of respondents indicated that the number of questions were just right (about 89%).
This may imply that although HAQUAMS takes a slightly longer time to complete, its
content is more relevant to patients with MS.
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Table 10: Completion Time and Patient Opinion Regarding the HRQoL Measures
Variables

SF-36

HAQUAMS

MSIS-29

Time of completion in
minutes: mean (SD)
Number of Questions¶
Too many (%)
Too few (%)
Just Right (%)
Wording¶
Mostly easy (%)
Mostly difficult (%)
No Opinion (%)
Relevance of content¶
Mostly Yes (%)
Mostly No (%)
Not Sure (%)

9.9 (7.7)

9.5 (7.9)

6.9 (7.7)

11.7
6.3
82.0

7.0
4.4
88.7

8.9
8.9
82.3

78.1
5.3
16.7

87.0
1.7
11.3

90.4
9.6

72.8
9.7
17.5

81.7
4.4
14.0

86.1
5.2
8.7

¶

Numbers corresponding with each option indicate the percentage of participants
SF-36= Medical Outcomes Survey Short Form – 36 Items
HAQUAMS= Hamburg Quality of Life Questionnaire in MS
MSIS-29= Multiple Sclerosis Impact Scale
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Preliminary Analysis
Table 11 shows interrelationships between the investigated independent variables and
the quality of life domains (as measured by the HAQUAMS). Interrelationships between
interval variables were reported as Pearson’s correlation coefficients while eta values were
calculated to illustrate associations between nominal and interval variables. The significance
level of each correlation was determined by the F test of the analysis of variance (ANOVA).
Disability, depression, visual impairment and employment status displayed significant (p <
0.01) correlations with all HRQoL domains such as overall quality of life, fatigue, upper and
lower mobility, mood and social function.
As would be expected, disability was most strongly correlated with overall quality of
life score (0.77), while gender, race and marital status had the weakest correlation with
overall quality of life (0.01 to 0.03). Similarly, significant correlations were observed
between overall quality of life score and visual impairment (-0.68, p < 0.01), depression
(0.56, p < 0.01), employment status (0.47, p < 0.01), number of co-morbid conditions (0.27,
p < 0.01), duration of disease (0.19, p < 0.05) and age (0.25, p < 0.01). The correlation
between overall HRQoL measured by the HAQUAMS and visual impairment measured by
the visual function questionnaire (VFQ) was negative, owing to differences in scoring. A
higher score on the HAQUAMS indicates better quality of life but poorer visual function on
the VFQ.
Where disability, visual impairment and employment status had a moderate to strong
correlations with the mobility scales, other variables such as depression, age, duration of the
disease and comorbid conditions also displayed significant (p < 0.01) but relatively weaker
associations with these scales. Among these variables, depression had the highest correlation
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Table 11: Bivariate Relationships (Correlations) Between Interval Predictor Variables
and HRQoL Domains

Disability¶
Depression¶
Visual Impairment¶
Age¶
Duration of Disease¶
Comorbid Conditions¶
Gender‡
Race‡
Marital Status‡
Employment‡

Total QoL

Fatigue

Upper

Lower

Mood

Social

0.77†
0.56†
-0.68†
0.25†
0.19*
0.27†
0.02
0.03
0.01
0.47†

0.63†
0.46†
-0.51†
0.16#
0.12
0.18#
0.20*
0.05
0.04
0.40†

0.65†
0.29†
-0.53†
0.28†
0.22*
0.23*
0.11
0.09
0.08
0.43†

0.62†
0.27†
-0.53†
0.35†
0.30†
0.19*
0.03
0.01
0.09
0.46†

0.60†
0.60†
-0.59†
0.12
0.08
0.18#
0.08
0.04
0.07
0.34†

0.52†
0.55†
-0.54†
0.12
0.04
0.26†
0.04
0.12
0.06
0.27†

#

Significant at p < 0.10
Significant at p < 0.05
†
Significant at p < 0.01
¶
The association between two interval variables was estimated with Pearson’s correlation coefficient
‡
The association between nominal and interval variables was estimated with the association measure Eta.
The significance level of the correlation was determined by the F-test on the analysis of variance (ANOVA)
QoL= Quality of life
*
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with the HAQUAMS upper mobility score (0.29, p < 0.01), whereas age had the highest
correlation with the HAQUAMS lower mobility score (0.35, p < 0.01). Number of comorbid
conditions was found to be significantly correlated with the fatigue (0.18, p < 0.10), mood
(0.18, p < 0.10) and social functioning (0.35, p < 0.01) dimensions of HRQoL. None of the
demographic variables showed any significant correlations with any of the quality of life
dimensions. Gender had a significant but weak correlation with the fatigue scale (0.20, p ≤
0.05) but not with the other dimensions. The remaining demographic variables (marital
status and race) were not significantly correlated (p > 0.05) with any of the quality of life
domains including overall quality of life score.

Predictors of Overall Quality of life
The results of the hierarchical regression analysis, which identified demographic and
disease-related factors that were most strongly associated with overall HRQoL, are presented
in Table 12. Disability, depression, visual function and age were significantly associated
with poor HRQoL in relation to multiple sclerosis. Disability accounted for the greatest
increment of variance for HRQoL; with approximately 59% of the model being explained by
this variable. Higher scores on the GNDS (higher disability) were associated with higher
scores on the HAQUAMS (poorer quality of life). The results indicated that increase in
disability can lead to a significant decrease in HRQoL in patients with multiple sclerosis (β=
0.37, p ≤ 0.05).
In the second step [ΔR2 0.04, F (2,113) = 97.12], whether depression explained any
variance in HRQoL was examined. The results showed that depression (β= 0.10, p < 0.05)
was also a significant predictor of quality of life. In the third step [ΔR2 0.03, F=53.48],
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Table 12: Hierarchical Regression Analysis to predict quality of life by disability,
depression, demographic variables, duration of MS, other co-morbidities and visual
impairment. (n=116)
Step 1

Step 2

Step 3

Step 4

Step 6

Step 5

VIF±

Block 1
Disability

0.37†

0.31†

0.27†

0.29†

0.29†

0.23†

2.26

Block 2
Depression

-

0.10†

0.10†

0.10†

0.10†

0.08†

1.46

Block 3
Age
Employment Status

-

-

0.03
-0.99

0.04*
-1.00

0.04
-1.01

0.05*
-0.66

1.77
1.35

Block 4
Comorbidity

-

-

-

-0.29

-0.29

-0.21

1.43

Block 5
Duration¶

-

-

-

-

-0.01

-0.01

1.49

Block 6
Visual Impairment

-

-

-

-

-0.07†

1.92

0.59
160.44

0.63
0.04
97.12

0.65
0.02
51.55

0.66
0.01
42.36

R2
Δ R2
F
*

0.66
0.00
34.99

0.70
0.04
35.19

Significant at p < 0.05
Significant at p < 0.01
Δ R2 = R2 change from previous step
±
Variance Inflation Factor
¶
Duration of disease measured in Years
Dependent Variable: Quality of Life measured as overall quality of life score on the HAQUAMS
Independent Variables: Disability measured using Guys Neurological Disability Scale (GNDS); Visual
Impairment measured using Visual Function Questionnaire (VFQ); Depression measured using Centers of
Epidemiological Studies- Depression Scale
†
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it was explored whether patient demographics would explain any changes in HRQoL scores.
Neither age nor employment was significantly associated with HRQoL scores. This was
followed by steps 4 and 5, whereby number of comorbid conditions and duration of disease
were added to the model. These variables were not significantly associated with HRQoL
scores comorbidity (β= -0.29, p = 0.10); duration (β= -0.01, p = 0.88) and both steps
collectively explained only 1% of the variance in the dependent variable. The last variable
that was added to the model was visual impairment (scores on the VFQ). Participants with a
high level of visual impairment (lower scores on the VFQ) reported significantly lower
HRQoL (higher scores on the HAQUAMS) (β= -0.07, p < 0.05). Visual impairment
explained an additional 4% variance in the HRQoL scores independent of disability and
depression [ΔR2 0.04, F (7,108) = 35.19]. As presented in Table 11, predictors at all but one
step explained significantly more variance in the total HRQoL scores and the final model
explained 70% of the total variance in HRQoL. The variance inflation factors of all predictor
variables ranged from 1.35 to 2.26 and were less than the conventional cutoff of 4.0
indicating absence of any significant multicollinearity in the model.

Predictors of other Quality of Life Dimensions
Results of the separate multiple linear regression analyses to examine predictors for
each of the HRQoL dimensions are given in Table 13. The regression model of each
dimension had a different set of predictor variables. Independent variables for each model
were selected based on the strength of their correlation with that particular HRQoL
dimension (refer to Table 11). The depression variable was left out of the regression model
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Table 13: Separate Multiple Linear Regression Analyses for Each of the Five Quality of Life Domains (HAQUAMS SubScales)
Independent Variables
Disability
Depression
Visual Impairment
Employment
Comorbid Conditions
Age
Duration of Disease
Gender
*
†

Fatigue
β
SE
0.20†
0.06*
-0.03
-0.64
-0.31
0.02
-1.64*

0.05
0.03
0.02
0.68
0.21
0.02
0.63

Upper Mobility
β
SE
0.26†
-0.04
-0.06*
-1.36
-0.18
0.05
-0.01
-

0.05
0.04
0.03
0.83
0.25
0.03
0.05
-

Lower Mobility
β
SE
0.27†
-0.04
-0.08*
-2.28*
-0.54
0.10*
0.04
-

0.07
0.04
0.03
1.0
0.31
0.04
0.06
-

Mood
β
SE
0.31†
-0.15†
-0.45
-0.15
-

0.09
0.04
1.38
0.40
-

Social Function
β
SE
0.12
0.16†
-0.08*
0.61
0.32
-

0.06
0.04
0.03
0.99
0.28
-

Significant at p < 0.05
Significant at p < 0.01
Missing values for beta coefficients and standard error indicate that the independent variable was not included in that particular model. Total N= 116.
β = Beta Coefficient
SE= Standard Error
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for mood (measured by HAQUAMS), since both these scales measure the same underlying
concept. Only variables that were significantly correlated with the dependent variable at an
alpha level of 0.10 or less were included in the models.
Disability was the main determinant of fatigue (β= 0.20) followed by gender (β= 1.64) and depression (β= 0.06). With respect to gender, males with MS seem to have less
fatigue compared to females. Visual impairment was not found to be a significant predictor
of fatigue. However, it had a small but significant impact on mobility (β= -0.06 for upper
mobility and β= -0.08 for lower mobility). The negative sign for the correlation was
expected because a higher score indicates better visual functioning on the VFQ, but lower
functioning on the HRQoL scales. Employment status (β= -2.28) and age (β= 0.10) were
also found to be significant predictors of lower mobility. The negative β coefficient for the
employment status indicates that those who are employed have lower scores on the
HAQUAMS lower mobility scale, that is, they are more likely to have better mobility than
those who are not employed. Similarly, it is possible that an increase in age will lead to
lower scores on the HRQoL domains (β= 0.10). Number of comorbid conditions and
duration of disease were not significantly related to mobility in patients with multiple
sclerosis.
In addition to visual impairment (β= -0.08), only depression was found to
significantly predict social function (β= 0.16). The main determinants of mood were
disability (0.31) and visual impairment (β= -0.15). The β coefficients indicate one point
increase in disability leads to a 0.31 point increase in the depression score. Similarly, a one
point increase in VFQ scores leads to a 0.15 point decrease in the depression scale score.
The negative correlation coefficient between VFQ and CES-D is due to the differences in
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scoring. A higher score on the VFQ indicates better visual function but increased depression
symptoms as measured by the CES-D. All models were significant at p < 0.05.

Regression Diagnostics for Phase I: Objectives 2 and 3
Variance inflation factors of independent variables were less than 2.5 for all Phase I
regression models implying absence of any significant multicollinearity. Tests for normality
of residuals (Shapiro-Wilk Test) and homogeneity of variance (White Test) were not
significant at p ≤ 0.05 (see Table 14), indicating that these assumptions were also met for all
models.
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Table 14: Tests of Normality and Homogeneity of Variances of Residuals for All
Regression Models
Dependent Variable

W

p value

Chi-Sq

p value

Total Quality of Life
Fatigue
Upper Mobility
Lower Mobility
Mood
Social Function

0.98
0.99
0.98
0.98
0.99
0.98

0.15
0.30
0.06
0.35
0.27
0.24

39.47
48.50
37.26
37.64
13.25
19.14

0.24
0.41
0.82
0.77
0.43
0.45

W= Shapiro-Wilk Statistic for testing normality of the residuals
Chi-Sq= White test for homogeneity of variance of the residuals
Significance determined at p ≤ 0.05
All dependent variables were measured using the Hamburg Quality of Life Questionnaire in Multiple Sclerosis
(HAQUAMS)
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Phase II
Response Rates and Physician Characteristics
The mailing list from SK & A consisted of 6500 neurologists within the United
States. Of these, a randomly selected sample of 2400 neurologists was mailed the final
survey. The response rate was 4.6% after those who were ineligible or unreachable (i.e.
those who had left the practice, had retired, or were not involved in the routine care of
patients with MS) were deducted from the 2400 approached, as these were not true refusals
(See Figure 2).
One hundred and seven questionnaires were completed and returned by neurologists
involved in the routine care of patients with MS. Table 15 depicts the key characteristics of
these respondents. Males comprised 84% of the sample. Eighty-one percent of the
neurologists had been practicing for at least ten years. There were a higher proportion of
neurologists between the ages of 51 and 60 years (40.2%) compared to any other age group,
and a majority of them were practicing in office based settings (83.2%). Only 15% of the
respondents had participated in a MS-related clinical trial with a HRQoL component once in
the past. There was an observable difference in the perceived usefulness of HRQoL
information use among neurologists. The overall consensus was that HRQoL information
can be advantageous (Mean: 5.3; SD: 1.0 on the facilitator scale) and that there were fewer
drawbacks associated with using this information in the routine care of patients with MS
(Mean: 2.9; SD: 1.0 on the barriers scale). Cronbach’s alpha for the statements comprising
the barrier (0.76) and facilitator (0.74) scales exceeded the minimum requirement of 0.70
indicating good internal consistency reliability.
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Figure 2: Flow Chart Displaying Response to the Neurologist Survey

Total number of neurologists in mailing list
6500

4 Weeks

First mailing
2400 Neurologists

Second mailing
1800 Neurologists

80 Usable
51 Returned but Unusable
22 Unreachable

26 Usable
37 Returned but Unusable
10 Unreachable

106 Usable
88 Returned but Unusable
32 Unreachable
Response Rate:
106
2400 – (88+32)
= 4.6%
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Table 15: Characteristics of the Responding Neurologists (Total N=107)
Variable

†

N (%)

Gender
Male
Female

90 (84.1)
17 (15.9)

Age Group
31 to 40 years
41 to 50 years
51 to 60 years
61 or older

16 (15.0)
23 (21.5)
43 (40.2)
25 (23.4)

Primary site of practice
Hospital
University Hospital
Solo, Office Based
Group, Office Based

3 (2.8)
15 (14.0)
38 (35.5)
51 (47.7)

Participation in MS Clinical Trial
Yes
No

16 (15.0)
91 (85.1)

Number of years as neurologist
5 years or fewer
6 to 10 years
10 years or more

13 (12.2)
13 (12.2)
81 (75.7)

Stage of Change†
Stage 0
Stage 1
Stage 2
Stage 3
Stages 4 & 5

24 (22.6)
45 (42.5)
20 (18.9)
11 (10.4)
6 (5.7)

Facilitator Scale Score
Mean (SD)

5.3 (1.0)

Barrier Scale Score
Mean (SD)

2.9 (1.0)

No. of patients seen per week
Median (Range)

4 (1-150)

Stage 0= unaware of any HRQoL questionnaires; Stage 1= aware of HRQoL questionnaires, but never
thought about using them; Stage 2= thinking of using HRQoL questionnaires within the next 6 months;
Stage 3= thinking of using HRQoL questionnaires within the next month; Stage 4= have been using
HRQoL questionnaires for less than six months; Stage 5= been using HRQoL questionnaires for more
than six months
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The number of patients with MS seen per week by the neurologists ranged from 1 to 150
(Median= 4).

Classification Based on the Transtheoretical Model
The staging of HRQoL related behavior based on the Transtheoretical Model has also
been reported (refer to Table 15). About 65% of the neurologists were either unaware of
HRQoL questionnaires and their use, or had not thought about using formal standardized
questionnaires in routine practice (Stages 0 and 1). Approximately 19% of the respondents
were planning on using standardized HRQoL questionnaires in routine practice within the
next six months (Stage 2) while about 10% of the respondents reported that they were
planning on using such questionnaires within the next month (Stage 3). Only 6% indicated
that they were currently using such questionnaires in the routine care of patients with MS
(Stages 4 and 5).
Subgroup analyses of pre-contemplators (Stages 0 and 1) and contemplators (Stages 2
and 3) revealed significant differences between the two groups in terms of perceived barriers
and facilitators to HRQoL assessment in patients with MS (see Table 16). As would be
expected, the contemplator group such as those who were planning to use HRQoL
information within at least the next six months, had higher scores on the facilitator scale
[Mean (SD): 5.7 (1.0) vs. 5.2 (1.0), p < 0.05] and lower score on the barrier scale [Mean
(SD): 2.5 (0.9) vs. 3.1 (1.0), p < 0.01] compared with that of the pre-contemplator group i.e.
those who were unaware or had not thought of using HRQoL information.
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Table 16: Differences Between Pre-Contemplators and Contemplators

*
†

Variable

Pre-Contemplators
Mean (SD)

Contemplators
Mean (SD)

p*

Importance of HRQoL information†

5.1 (1.5)

5.9 (1.1)

<0.01

Facilitator Scale Score

5.2 (1.0)

5.7 (1.0)

0.03

Barrier Scale Score

3.1 (1.0)

2.5 (0.9)

<0.01

Independent sample t-tests
Mean score on the following question from the neurologist survey: How important is it to collect HRQoL
information in the routine care of patients with multiple sclerosis?
Note: Data excludes those who are currently using HRQoL information in routine practice. Total N=101.
Pre-Contemplators included respondents classified under stages 0 & 1. Contemplators included
respondents classified under Stages 2 & 3.
SD= Standard Deviation
HRQoL= Health Related Quality of Life
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In other words, unlike the pre-contemplator group, contemplators perceived greater
usefulness of HRQoL information and fewer disadvantages and/or problems associated with
HRQoL assessment in the routine care of patients with MS. In terms of their degree of
agreement with the following question: “How important is it to collect HRQoL information
in the routine care of patients with multiple sclerosis?” the contemplator group (mean= 5.9;
SD= 1.1) had significantly (p < 0.05) higher perceived importance of HRQoL assessment in
MS compared to the pre-contemplator group (mean=5.1; SD= 1.5).

Comparison of HAQUAMS and MSIS-29
With respect to HAQUAMS and MSIS-29, the opinion of neurologists regarding: 1)
the questionnaires’ ability to provide any additional useful information compared to what is
normally available; and 2) their ease of use from the perspective of the patients with MS,
were compared using the Wilcoxon Sign Ranked test (see Table 17). There was a significant
difference between the scores on the questions assessing additional usefulness (p < 0.05), as
well in the perception of the length of the questionnaire (p < 0.01) from the patient’s
perspective for both questionnaires.
According to the neurologists, the HAQUAMS does a better job of providing
additional useful information compared to what is available from conventional physical
exams and clinical testing methods than does the MSIS-29 (Median: 6.0 vs. 5.0). However,
the HAQUAMS was reported to be longer to complete as compared to the MSIS-29. There
was no difference in the opinion of the neurologists regarding the way in which the questions
for the two HRQoL measures were worded, as evidenced by the same median score (2.0) on
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Table 17: Median Scores of Neurologists’ Opinion About HAQUAMS and MSIS-29
Regarding their Usefulness and Ease of Use in Patients with MS
Opinion Questions

HAQUAMS†

MSIS-29†

p*

Additional useful information
Length
Wording

6.0
5.0
2.0

5.0
4.0
2.0

0.02
<0.01
0.10

†
*

Median values for each opinion question
p values for Wilcoxon Signed Rank Test
HAQUAMS= Hamburg Quality of Life Questionnaire in Multiple Sclerosis
MSIS-29= Multiple Sclerosis Impact Scale
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that particular item. The median score of 2.0 indicated that in the neurologists’ opinion, both
questionnaires comprised of questions which were relatively easy to understand.

Knowledge and Use of Specific HRQoL Questionnaires
Overall, utilization of any of the commonly used HRQoL questionnaires in MS
research listed in this survey was very low among responding neurologists (see Table 18).
Only six percent reported having used the Functional Assessment of Multiple Sclerosis
(FAMS) questionnaire in the past. Minimal use of the Medical Outcomes Survey Short
Form, Multiple Sclerosis Quality of Life-54, and the Multiple Sclerosis Quality of Life
Inventory was also reported (Range= 3.1% to 4.1%). With respect to knowledge about
existing HRQoL measures however, a much larger proportion of the neurologists reported
that they had heard of the HRQoL questionnaires included in this survey. More than 40% of
the respondents had heard of the Multiple Sclerosis Quality of Life – 54 as well as the
Multiple Sclerosis Quality of Inventory. Awareness about the other questionnaires ranged
from 25% to 37% among the responding neurologists with 12% reporting knowledge of other
questionnaires not referenced in the survey.
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Table 18: Numbers and Percentages of Neurologists that Reported Having Used or
Heard of MS-related HRQoL Questionnaires
Questionnaire
Medical Outcomes Survey Short Form (SF-36)
Multiple Sclerosis Quality of Life 54 (MSQoL-54)
Functional Assessment of Multiple Sclerosis (FAMS)
Multiple Sclerosis Quality of Life Inventory (MSQLI)
Multiple Sclerosis Impact Scale (MSIS-29)
Hamburg Quality of Life Questionnaire in MS
(HAQUAMS)
Sickness Impact Profile (SIP)
Other
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Used
N (%)

Heard of
N (%)

3 (3.1)
4 (4.1)
6 (6.1)
4 (4.1)
1 (1.0)
1 (1.0)

34 (34.7)
43 (43.9)
33 (33.7)
41 (41.9)
31 (31.6)
37 (37.8)

1 (1.0)
1 (1.0)

25 (25.5)
12 (12.2)

Predictors of the Neurologists’ Intention to Use HRQoL Information
The results of the multiple linear regression model used to examine predictors of the
neurologists intention to use HRQoL information are presented in Table 19. The primary
independent variables included in this model were: attitude (measured by items 2 to 8 on the
neurologist survey, see Appendix J); subjective norms (where referents were the American
Academy of Neurology and Fellow Neurologists), and perceived behavioral control
(measured by items 9 and 10 on the neurologist survey. See Appendix J). Other independent
variables were gender (male vs. female), age-group, primary place of practice (hospital vs.
office based), years in practice as a neurologist, number of MS patients seen per week and
participation in a MS related clinical trial (yes vs. no).
Attitude was found to be a significant predictor of behavioral intention (β = 0.03, p <
0.01), where a positive attitude was associated with an increased intention to use HRQoL
information. Number of years in practice as a neurologist (β = -0.46, p = 0.03) was
significantly but inversely associated with the intention to use HRQoL information in the
routine care of patients with MS. This means that neurologists who had been practicing for
10 years or more were less likely to show any intention of assessing HRQoL in patients with
MS compared to those who had been practicing for fewer than 10 years. Subjective norms
were also significantly associated with intention to assess HRQoL information (β = 0.01, p =
0.05). This indicates that positive social pressure (from referents such as the American
Academy of Neurology and Fellow Neurologists) is associated with an increased likelihood
of HRQoL assessment in the routine care of patients with MS. Among other variables, agegroup had a slight tendency towards predicting behavioral intention (β = 0.26, p = 0.06).
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Table 19: Factors Associated with the Intention to Use HRQoL Information in Routine
Practice
Independent Variable
Attitude
Years practice as neurologist
Subjective Norms
Age group
Gender
Place of practice
Behavioral control
Number of patients per week
Involved in MS-related trial

β Estimate Std. Error
0.03
-0.43
0.01
0.26
-0.14
0.43
0.14
0.01
0.22

0.003
0.21
0.01
0.14
0.28
0.30
0.10
0.01
0.32

p

VIF

<0.01
0.03
0.05
0.06
0.63
0.16
0.20
0.42
0.49

1.14
2.23
1.15
2.04
1.15
1.42
1.09
1.35
1.50

Note: Data from the original sample (N=106).
Independent variables: Attitude, subjective norms, behavioral control, gender, years of practice as neurologist,
primary place of practice (hospital vs. office), age, number of MS patients seen per week and involvement in a
MS clinical trial.
Dependent variable: Neurologists’ intention to use HRQoL information.
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None of the other independent variables in the model were found to be significant. The
overall model was found to be significant (F = 16.19, p < 0.01) and explained almost 61% of
the variation in the dependent variable (behavioral intention). The variance inflation factors
for all independent variables were well within the acceptable limit of 4.0 (VIF < 2.5 for all
variables), indicating absence of any significant multicollinearity within the model.

Regression Diagnostics for Phase II: Objective 4
The residuals for behavioral intention, which was the dependent variable, departed
radically from normal distribution (Shapiro-Wilk W = 0.96, p = 0.0016). To deal with this
problem, studentized residuals, which are a type of standardized residual, were examined to
identify outliers. If a single observation is substantially different from all other observations
(an outlier), it can make a large difference in the results the regression analysis. One
observation with a studentized residual greater than -4.0 was dropped from the dataset in the
interest of validity of the coefficients of the regression model.
The regression model was then rerun using data for 106 respondents (Refer to Table
19). None of the variance inflation factors exceeded 2.5, indicating that multicollinearity was
not a problem with the data. Variance inflation factor was 2.23 for the variable years in
practice as a neurologist and 2.04 for age group. Both these variables were retained in the
final model since these values did not exceed the value of 4.0, which is a generally accepted
limit for multicollinearity (Fisher JC et al., 1981). The residuals for the final model met the
criteria of normality (Shapiro-Wilk W = 0.98, p = 0.12) as well as homogeneity of variance
(Chi Sq = 40.29, p = 0.86)
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Chapter 5: Discussion and Conclusions

The overall goal of this study was to investigate several research questions relevant to
the area of health-related quality of life (HRQoL) in patients with multiple sclerosis (MS).
Currently, there are several patient reported outcome (PRO) measures intended for use in
patients with MS. However, there is no general consensus as to which measure is most
suitable or appropriate to assess HRQoL in MS, especially in the routine clinical practice
setting. One aim of the current study was to compare the psychometric properties, as well as
neurologists’ and patients’ opinions regarding two PRO measures: the Hamburg Quality of
Life Questionnaire in Multiple Sclerosis (HAQUAMS) and the Multiple Sclerosis Impact
Scale (MSIS-29), with the intention of enabling evidence-based selection of PRO measures
for use in the routine care of patients with MS.
Information obtained from such head-to-head comparisons can guide neurologists’
choice of a PRO suitable for use in their routine clinical practice. An exhaustive comparison
of the PRO measures which have been shown to be relevant to MS and have displayed
desirable psychometric properties as evidenced by prior published studies (Gold et al., 2001;
Hobart et al., 2001; Riazi et al., 2002) was performed. In the absence of a “gold standard”
PRO measure in MS research, the Medical Outcomes Survey Short Form – 36 items (SF-36),
which is a commonly used generic measure of MS-related HRQoL was used in this
comparison.
In addition to addressing issues relating to HRQoL assessment, several research
studies have been conducted whose main focus was to identify and examine the influence of
several factors on the quality of life of patients with MS (Benedict et al., 2005; Amato et al.,
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2001; Lobentanz et al., 2004; Wang et al., 2000). Disability and depression have been
identified as primary determinants of HRQoL in patients with MS. Problems with visual
functioning are also very common in MS. Visual impairment and its impact on HRQoL in
MS had not been thoroughly studied, due to the absence of validated vision-related PRO
measures in this population. However, research in this area has recently gained some
attention in the last few years, following the validation of the Visual Function Questionnaire
(VFQ) in a sample of patients with MS (Ma et al., 2002b; Balcer et al., 2000). Another aim
of the current study was proposed in order to substantiate findings regarding the predictors of
HRQoL and also investigate the influence of additional relevant variables such as visual
impairment and chronic comorbid conditions such as heart disease, diabetes and arthritis,
which had not been studied in the past.
Although commonly used in research and clinical trials, the utilization of HRQoL
information in clinical practice has been limited. For the provision of optimum care to
patients with MS, HRQoL assessment needs to transcend the realm of research into routine
clinical practice. In order to do this however, it is necessary to identify current utilization,
and areas that need to be targeted to facilitate the acceptance of HRQoL information by
neurologists. Hence, a nationwide survey of neurologists was performed to provide
empirical evidence of current practices regarding use of HRQoL information in patients with
MS. In order to identify factors that have an influence on the intention to use such
information in clinical practice, a framework of two health behavior theories was used. The
Trans-Theoretical Model was used to categorize neurologists based on their stage of change
regarding HRQoL information use. Additionally, the Theory of Planned Behavior was used
in order to identify predictors of HRQoL intention (behavioral intention) in this population.
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Phase I: Objective 1
Head-to-head Comparison of PRO Measures
Comparison of the PRO questionnaires (MSIS-29 and HAQUAMS) was performed
on their psychometric properties and the opinions of patients and neurologists regarding their
usefulness and ease of use. The first step for the psychometric comparison was to evaluate
summated ratings scales, for example, HAQUAMS upper and lower mobility scales. This
was done by determining the extent of missing data at the item level. A summated rating
score cannot be estimated with the same degree of confidence if there is a large amount of
missing data for a particular item. Missing responses might indicate problems with the
wording of the response choices for those items. It also might indicate that respondents did
not understand how to complete or provide the most suitable answer for that part of the
questionnaire.
It can be observed from the findings of this study that one item on the lower mobility
scale of the HAQUAMS had unusually high percentage of missing data. This item asked the
respondents to estimate the distance that they could walk in metric units (meters). It was not
surprising to encounter missing data for this question as respondents in the United States
(US) may not be accustomed to using this system of measurement. The English language
version of HAQUAMS was made available for the purpose of this study and hence no
changes were made to maintain its validity. Correcting this issue however, may require
replacement of the response choices with commonly used units of measuring length such as
feet, yards or miles followed by a small scale validation study for use in patients in the US.
Item means and standard deviations were also examined for the two PRO measures.
Item means are required to be approximately equivalent within a scale under traditional
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Likert scaling criteria and were found to meet this criterion for both MSIS-29 and
HAQUAMS. Item standard deviations should also be roughly equivalent; the rule of thumb
being a standard deviation of around 1.0 for scales with five-choice response such as the
HAQUAMS and MSIS-29 (Ware, Jr. & Gandek, 1998). The variances of the items within
the scales for two PRO measures did not vary greatly and hence are consistent with this
criterion. Further standardization of the items is probably not necessary as there is little to be
gained by making such adjustments (Ware JE, Harris WJ, Gandek B, Rogers BW, & Reese
PR, 1997)
Ideally, item-total correlations should be fairly high for items with their own
corrected scale score. Items for all scales except for item 21 of the MSIS-29 (psychological
impact scale: 0.12) were found to be stronger than the pre-determined correlation of 0.30. A
low item-total correlation means the item is little correlated with the overall scale and the
researcher should consider dropping it. Hence, the inclusion of item 21 of the MSIS-29 in
calculating the psychological impact score needs to be re-assessed. Item-total correlations
greater than 0.30 for all scales of HAQUAMS provide greater confidence that they are
precisely measuring the underlying singular concept, thereby permitting comparison between
two or more distinct groups of patients with MS.
Among scales measuring similar domains (physical and mental domains for each of
the three measures), the HAQUAMS upper mobility scale displayed a somewhat high floor
effect compared to the other physical function scales, although these were still well within
the acceptable range of 20% (van der Putten, Hobart, Freeman, & Thompson, 1999). Floor
effects displayed by this scale may represent its limited ability to discriminate between noninstitutionalized samples of adults with MS based on self-reported upper physical
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functioning. Floor and ceiling effects can also have an influence on responsiveness of the
measures. The scale range for any measure must extend beyond the range of function
(absence of floor or ceiling effects) of the patients for whom it will be used, or it will be
incapable to demonstrating further improvement or deterioration between two or more time
points. On the whole, HAQUAMS and MSIS-29 did not show any significant floor and
ceiling effects. This may be partially due to the nature of the response sets to the questions,
which are not limited to dichotomous answers. High floor and ceiling effects are observed
for questions 4 and 5 of the SF-36, partly due to presence of ‘yes/no’ response options.
Pearson’s r was calculated for physical and psychological domain scale scores of
each instrument, and then correlations between them were analyzed using a multitraitmultimethod matrix. This well accepted method of evaluating convergence and divergence
requires that at least two traits or constructs each be assessed by at least two disparate
methods. Although the intercorrelations observed for the HAQUAMS mood scale with its
upper and mobility scales were similar to what was reported by Gold and colleagues (2001),
patterns of construct validity with respect to other PRO measures and quantitative tests of
motor functions were inconsistent with their predictions. Divergent validity for the
HAQUAMS mood scale would be supported if its correlation with MSIS-29 psychological
and SF-36 mental health was higher than its correlation with MSIS-29 physical and SF-36
physical function. However, compared with the MSIS-29 psychological impact scale, the
HAQUAMS mood scale had relatively a weaker relationship with the SF-36 mental health as
well as with scores on the CES-D. Moreover, its associations with scores on the 9-Hole Peg
Test and the Timed-25 Foot Walk Test (quantitative tests of motor function) were higher than
that for the MSIS-29 psychological scale.
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Interestingly, the correlation coefficient (0.71) between the HAQUAMS mood scale
and the MSIS-29 physical impact scale (scales from two different instruments measuring
different constructs) was almost the same as the correlation (0.70) between the physical and
psychological impact scales of the MSIS-29 (two scales from the same instrument measuring
different constructs). The intercorrelation between the MSIS-29 scales observed in this study
(0.70) was much higher than what was reported previously (0.438) by McGuigan and
colleagues (2004). One explanation may be that the shared features of the method of
assessment could lead to the high correlation coefficient amongst MSIS-29 physical and
psychological impact scales. However, the relatively large correlation coefficient between
the HAQUAMS mood and MSIS-29 physical impact scales does not conform with the
expectation that the multitrait-multimethod correlation should be lower compared to
monotrait-multimethod correlations. These observations suggest relatively poor divergent
validity of the mood scale of HAQAUMS, and to some extent the physical impact scale of
the MSIS-29.
To gain a better understanding of where this anomaly arises, correlation coefficients
between the HAQUAMS mood and MSIS-29 physical impact scales were calculated
separately for the demographic variables. With respect to gender, this analysis revealed a
higher correlation in males (0.81) compared with the females (0.66) implying an overlap in
the mood and physical domains of these specific scales among community dwelling males
with multiple sclerosis. Although the correlation was weaker among females, it was still at
the upper extreme of acceptable limits (0.66 compared with the initial value of 0.71). With
respect to other demographic variables, the correlation coefficients between the HAQUAMS
mood and MSIS-29 physical impact scales were still quite high: 0.77 for those who were not
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married; 0.69 for participants who were employed, and 0.67 for participants who were
currently married. A comparatively low correlation between these scales was only seen for
those who reported that they were currently unemployed (0.57). Poor construct validity may
limit the legitimacy of the inferences that can be made regarding the underlying theoretical
constructs for the HAQUAMS mood and MSIS-29 physical impact scales.
In summarizing this section on construct validity, it is important to consider the basic
tenet of the multitrait-multimethod matrix that, “the pattern of relationships is more
important than the absolute magnitude of the correlation coefficients”. The correlations
between the scores of the HAQUAMS mobility and MSIS-29 physical scales were
significant and relatively large suggesting well-established convergence (monotraitmultimethod triangle for physical domain scales). These coefficients were also larger than
most of the coefficient scores within the same instrument (multitrait-monomethod triangles)
which provided evidence of divergence. Although the MSIS-29 physical impact scale had
high correlation with the other mood scales, the overall pattern of correlations was consistent
with the expectations of the multitrait-multimethod matrix. All of its correlations with the
physical domains scales (0.76 and 0.82 with HAQUAMS mobility; -0.79 with SF-36
physical function scales) were consistently higher than multitrait-multimethod (-0.41 and
0.71) and multitrait-monomethod correlations (0.70) (pattern over magnitude). Negative
correlations with SF-36 were due to differences in scoring for the two measures. A high
score indicates better quality of life on the SF-36, but poor quality of life on the HAQUAMS.
The HAQUAMS mood on the other hand, failed to correlate as expected with other
scales, thus violating the assumptions of the multitrait-multimethod matrix. The monotraitmultimethod correlations for this scale were not consistently higher than the multitrait-
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monomethod or multitrait-multimethod triangles. This problem could either be a snag in the
construct underlying one or all of these instruments, faults in the scales themselves or a
combination of both. However, its abnormally high correlation with both self-report and
clinical measures of physical domain implies that the problem lies with the HAQUAMS
mood scale. The MSIS-29 appears to meet all the assumptions of the multitrait-multimethod
matrix whereas the construct mismatch of the HAQUAMS mood scale implies poor construct
validity and may need further evaluation in a U.S. population.
Concurrent and well as relative validity was examined for all measures included in
this study against two external criteria variables: level of disability and ambulation. Relative
validity analysis identifies those scales that contribute important distinctive information to
each criterion variable. Based on the results of the relative validity analysis, the MSIS-29
physical impact scale was most strongly related to level of disability followed by the physical
function scale of the SF-36 and the upper and lower mobility scales of HAQUAMS. Similar
patterns were observed for the psychological domain scales with the MSIS-29 psychological
impact scale performing slightly better that the HAQUAMS mood and SF-36 mental health
scales. The overall HRQoL score on the HAQUAMS however, had the strongest relative
validity to discriminate between levels of disability in this sample of patients with MS.
HAQUAMS lower mobility scale had a much stronger relative validity coefficient with
respect to the level of ambulation (second criterion variable), compared with the MSIS-29
physical impact and SF-36 physical function scales. Furthermore, relatively lower but still
significant associations were also observed for the lower mobility and total quality of life
score of the HAQUAMS. Thus relative validity analysis elucidates the superior sensitivity of
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the mobility and overall quality of life score of the HAQUAMS to important clinical
differences in level of disability and ambulation status in patients with multiple sclerosis.
A retrospective method was used to detect clinically important change over time by
comparing change scores (baseline score minus follow up score) with an external criterion of
change such as a transition question (Juniper, Guyatt, Willan, & Griffith, 1994). The change
scores for all sub-scales of the three PRO measures were compared in this study. As would
be expected in a non-institutionalized sample not undergoing an intervention or treatment
(e.g. steroids), the responsiveness showed minimal effect sizes and standardized response
means for both HAQUAMS and MSIS-29. One reason for this may be the fact that change is
caused by natural progression over time rather than by treatment effect following a treatment
(Norman, Stratford, & Regehr, 1997). Changes due to natural progression are generally
expected to be very small and may be difficult to discern compared to immediate changes
due to effect of say, a treatment. The responsiveness indices (effect size and standardized
response mean) for scales of both measures that are important from the stand point of routine
care such as overall quality of life scale of the HAQUAMS; physical and psychological
impact scales of the MSIS-29, had insignificant effect sizes (less than 0.20). The results of
the responsiveness indices however, need to be considered with care due to the small sample
size used in this study.
Although past head-to-head comparisons of HRQoL measures have incorporated the
standard criteria (data quality, scaling assumptions, validity, reliability and responsiveness),
the present study also elicited patient and neurologist opinions regarding the usefulness of
HAQUAMS and MSIS-29. Overall, the MSIS-29 was preferred by the patients in terms of
ease of understanding, time for completion and relevance of content. These observations are
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only generalizable the patients with MS included in this study and hence lack external
validity. According to the results of the survey, neurologists believe that the HAQUAMS
provides useful information, in addition to what can be obtained from conventional tests in
MS, to a greater extent than the MSIS-29.

Recommending a PRO Measure for Use in Clinical Practice
In summary, this objective of the study extensively compared two PRO measures in
MS. Each measure has attractive features which would lend itself to clinical practice as well
as clinical trial settings. The results of this study support the evidence of the psychometric
soundness of MSIS-29 as a measure of impact of MS on patients (Riazi et al., 2003;
McGuigan et al., 2004; Hobart, Riazi, Lamping, Fitzpatrick, & Thompson, 2005). In
addition it was found to be relevant from the patients standpoint, easy to score and concise.
From this perspective, it would be practical to be incorporate this in the routine care of
patients with MS.
However, MSIS-29 fails to address other aspects of the disease that may be relevant
to patients with MS. In addition to having all the desirable properties of MSIS-29,
HAQUAMS also emphasizes domains of fatigue and social complications that form part of
the total burden experienced by patients with MS. Relative to the social function and vitality
scales of the SF-36, the HAQUAMS social and fatigue scales displayed comparable criterion
validity for level of disability. Both scales were also moderately correlated with their SF-36
counterparts (social scales: -0.43; fatigue and vitality: -0.58) indicating that they measured
similar constructs. The negative correlation was observed because a higher score on the SF36 indicates better quality of life but a poorer quality of life on the HAQUAMS and MSIS-
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29. On an average, the HAQUAMS took less than ten minutes to complete and could be
easily administered by members of a multidisciplinary team or junior medical staff. It could
also be self-administered by the patients themselves in the waiting room, prior to be seen by
the neurologist.
Based on these analyses no one measure emerged clearly or consistently better or
worse than the other in terms of psychometric properties or neurologists’ and patients’
opinion. Hence, a recommendation of one particular PRO measure for use in MS-related
clinical practice cannot be substantiated. This study conveys that HAQUAMS and MSIS-29
can both be effectively used in clinical practice, but seems unlikely that one measure will
satisfy all the requirements deemed necessary by specific neurologists or practices. The
choice of a quality of life measure ultimately rests on the clinician and may be indirectly
related to their perception of the usefulness and intention to use such information in the
routine care of MS patients.

Phase I: Objectives 2 and 3
Predictors of HRQoL in MS
As described earlier, assessment of HRQoL information is especially relevant to MS,
which is linked with a broad spectrum of physical and social impairments. Several studies
have found a significant influence of certain clinical variables on HRQoL in patients with
MS. A substantial body of evidence has shown that impairment and disability has an
independent but modest contribution to HRQoL in patients with MS. Other predictors that
have been shown to have an influence on HRQoL are: course of MS, depression and fatigue.
In the present study many of these variables were controlled for and for the first time an
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attempt was made to investigate the influence of visual impairment and concomitant
comorbid conditions (both self-reported).
Considering the research question posed (which factors have a unique contribution to
HRQoL in patients with MS?), inspection of regression coefficients indicated that disability
was the strongest significant and independent factor associated with HRQoL. The
importance of disability in patients with MS is in agreement with other findings (Miller &
Dishon, 2006; Benedict et al., 2005). Besides disability, we also found that depressed mood
and increasing age were related to lower HRQoL. Finally, the results of this study
demonstrated that visual impairment explained a significant amount of the variance in overall
HRQoL and almost every HRQoL domain except for fatigue.
Interestingly, comorbid chronic conditions did not have a significant negative impact
on overall HRQoL in patients with MS. Simple counts of comorbid conditions based on
patient self-report were used to calculate comorbidity. Simple counts of comorbidities have
been commonly used in HRQoL literature (Wensing, Vingerhoets, & Grol, 2001; Michelson,
Bolund, & Brandberg, 2000; Cheng et al., 2003). The commonly used Charlson index of
comorbidity was not considered for this study because of evidence of its inability to
comprehensively explain variations in physical or mental aspects of HRQoL (Fortin et al.,
2005a). Also, quality of life outcomes have been shown to correlate most strongly with selfreported comorbid conditions weighted by severity, followed by number of conditions by
chart review and finally well-known comorbidity measured such as the Charlson
Comorbidity Index (Bayliss, Ellis, & Steiner, 2005).
After accounting for the other predictors, visual impairment explained an additional
4% of the variance in overall HRQoL in the proposed model. The results of this study are
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notable due to the fact that we measured disability using the Guys Neurological Disability
Scale instead of the commonly used Expanded Disability Status Scale (EDSS). In contrast to
the EDSS, the GNDS is capable of embracing a whole range of disabilities which can be
encountered in the course of MS (Sharrack et al., 1999a). Thus, controlling for a wide range
of other potential predictors provides us with a true representation of the impact that visual
impairment can have on HRQoL in MS. The validity of these results is further strengthened
by the fact that the visual function questionnaire (VFQ) has been established as a sensitive
and useful tool in assessing visual function in patients with MS (Noble, Forooghian, Sproule,
Westall, & O'Connor, 2006; Balcer et al., 2000; Ma et al., 2002a).
Seperate studies have suggested that HRQoL in MS is significantly affected by
impairment and disability measured by the Expanded Disability Status Scale (Janardhan et
al., 2000), cognitive impairment (Cutajar et al., 2000) and fatigue (Merkelbach, Sittinger, &
Koenig, 2002b). Depression has been also shown to have a strong association with HRQoL
in MS, independent of clinical course and disability (Provinciali, Ceravolo, Bartolini,
Logullo, & Danni, 1999; Bakshi et al., 2000; Wang et al., 2000). The results of this study
corroborated the prior evidence as disability (as measured by the GNDS) and depressive
symptoms (as measured by the CES-D) both, had a strong and significant influence on
HRQoL. Since patient and physician perceptions regarding these influential aspects of the
disease (disability, depression, etc) differ, the results of the current study re-emphasize the
need to recognize and evaluate them using PRO measures in routine care.
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Importance of Visual Impairment to HRQoL in MS
The findings of this study regarding the role of visual impairment can have important
implications in the routine care of patients with MS. Asymptomatic patients with MS, those
who have no history of optic neuritis, subjective signs of visual impairment and normal
visual acuity; may still have visual field defects that may not be detectable with conventional
tests of visual acuity. Vidovic and colleagues (2005) reported that almost 58% of the
symptom-free patients with MS had visual field defects, a finding similar to what was
recorded by others in the past (Patterson & Heron, 1980). It has been suggested that these
visual field defects, located in the peripheral areas of the field of vision, may evolve slowly
and go unnoticed by patients with MS. Given the prevalence of visual impairment and the
influence that it has on overall HRQoL, it may be necessary to routinely screen patients with
MS using standard ophthalmic examination procedures or self-administered questionnaires
such as the VFQ and others. A recent study has also published preliminary evidence of the
ability of a supplementary questionnaire which increases its capacity of the VFQ to capture
self-reported visual dysfunction in patients with MS (Raphael et al., 2006).

Phase II: Objective 1, 2, 3 and 4
Utilization of HRQoL Information in Routine Practice
Research paves the way for evidence-based selection of an appropriate measure of
HRQoL, and identification of important variables that have a significant influence on
HRQoL in patients with MS. However, in order to make effective use of such information, it
is necessary that it is translated by practicing neurologists into the routine care of patients
with MS. MS literature does not provide any evidence regarding the extent of the current use

141

of HRQoL questionnaires in routine clinical practice. Physicians in general, do not favor
HRQoL assessment and this may be true for neurologists who are involved in the routine
care of patients with MS.
Based on the Theory of Planned Behavior a hypothesis for exploration was
developed: that neurologist’s intention to use HRQoL information in patients with MS would
be most influenced by their attitudes towards such information, their social norms and their
perceived control over this behavior among other things. As hypothesized, neurologists’
attitude towards HRQoL information in MS, strongly predicted their intention to use this
information in routine practice. This suggests that interventions that strengthen or promote
positive attitude towards HRQoL information may be effective in changing current practices.
However, the mean score on the attitude scale [Mean (SD) = 61.7 (35.5); Range= -147 to
+147] reflected a weak to moderate positive attitude in favor of assessing HRQoL in MS.
Hence, programs that are created with the aim to promote acceptance of HRQoL assessment
in practice, may not show significant improvements in neurologists’ attitude. Such programs
will need to have a rigorous study design and an evaluation strategy to detect changes in
attitudes.
In accordance with the theory, normative beliefs - reflecting the neurologists’ general
perception of utilization of HRQoL information by their colleagues in MS and the stance of
the American Academy of Neurology (AAN) - also predicted intention to use this
information in practice. Although normative beliefs were strongly predictive of behavioral
intention, the mean score on the subjective norm scale was very low [Mean (SD): 4.16 (1.3);
Range= -42 to +42). In other words, the referents chosen for this study (AAN and other
neurologists), seem to exert an influence on the behavioral intention of neurologists, but
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these normative beliefs need to be strengthened. This indicates that support for HRQoL
assessment in MS by professional organizations such as the AAN in the future, may increase
use of such information among practicing neurologists. It is also possible that neurologists,
who start incorporating HRQoL assessment in routine care of their patients with MS, may
influence their colleagues follow suit. Perceived behavior control, that is, neurologists’
perception of how much the behavior (HRQoL assessment) is under their control was not
found to have a significant influence on intention.
Although neurologists expressed an interest in the topic and thought that HRQoL
information was trustworthy, this aspect of the patients’ perspective was far from being
incorporated into everyday practice. Those who obtained quality of life information, did so
in a relatively unstructured way as part of their clinical interview and only a minimal number
of neurologists reported using HRQoL questionnaires routinely. Based on their responses
and comments in the survey it appears that this could be because they are very busy and lack
resources as well reimbursement for the extra time required to administer and score HRQoL
questionnaires. Similar organizational problems including time, staff, resource constraints,
as well as lack of reimbursement for services provided have been identified as major hurdles
for physicians in provision of preventive care services in clinical practice (Carter, Belcher, &
Inui, 1981).
This study also examined the relationship of the barriers and facilitators for HRQoL
assessment to self-reported intention to assess such information in practice. In order to
investigate this relationship, the barriers and facilitators scales were used as a proxy for
decisional balance constructs. The decisional balance that a person feels may be thought of
as a balance between the pros and the cons (barriers and facilitators in this study) associated
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with the particular target behavior, which in this case is HRQoL assessment in clinical
practice. According to those in the precontemplation stage may weigh in more heavily on the
side of the cons toward a particular behavior. As individuals become conscious of the desire
for change (contemplation stage), the decisional balance becomes less unipolar.
This study exhibited the expected decisional balance pattern in the sample of
surveyed neurologists. Neurologists in the precontemplation group had a significantly higher
score on the barrier scale and a significantly lower score on the facilitator scale compared to
the contemplators. Thus, this study provides some evidence that changes in intention to
assess HRQoL information may follow stages of change, which reflect a decisional balance
between the barriers and facilitators of making such a change. Future research may be
required to validate the proxy measure of decisional balance (barriers and facilitators scale).
Improvements in this model may provide researchers with a framework that can be helpful in
evaluating long term programs aimed at improving HRQoL acceptance by neurologists.

Improving HRQoL Acceptance among Neurologists
Based on these findings, certain important points come to light. Firstly, training
efforts need to be targeted towards neurologists to facilitate assessment (administering and
scoring of HRQoL questionnaires) as well as evaluating quality of life outcomes in patients
with MS. Dealing with the issue of payment for the additional time required to assess
HRQoL information can be problematic, since HRQoL assessment is not standardized in
routine practice. One possible way to overcome this problem may be to establish a relative
value-based payment system based upon Current Procedural Terminology (CPT) codes
which has also been recently applied to the provision of medication therapy management
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services by pharmacists (The Lewin Group, 2005). Although, one should keep in mind that
such payment structures can only be brought into existence following the backing of relevant
authorities (such as the American Academy of Neurology) and further legislative mandates
for the incorporation of such information in the routine care of patients with MS.
Contrary to what has been documented regarding other specialists (Bezjak et al.,
1998), a majority of the neurologists conveyed that they did not have problems in
understanding how to use HRQoL information in the routine care of patients with MS, and
did not think that scoring HRQoL questionnaires was difficult. Other explanations for the
lack of utilization of HRQoL information in clinical practice may be that most of the
neurologists, while considering the topic of HRQoL as very relevant and beneficial, seem
unacquainted with available HRQoL instruments. Additionally, only a few of them actually
had experience using HRQoL or any other PRO questionnaires. Lack of familiarity and
comfort with HRQoL measurement may be one factor that hinders their use in daily practice.
Doctors are trained to obtain subjective information through clinical interviews.
Using standardized HRQoL questionnaires to assist with treatment and monitoring is neither
a standard component of medical training nor a familiar part of routine practice (Skevington,
Day, Chisholm, & Trueman, 2005). Neurologists probably rely on their own clinical
judgments, and are more acquainted with interpretation of a wide variety of clinical tests on a
daily basis e.g. MRI scans. Hence, lack of use of HRQoL information may not be due to
issues with the HRQoL questionnaires themselves, but may represent the hesitancy of
neurologists to use unfamiliar techniques over the perceived assurance of familiar techniques.
This may explain the finding that the intention to use HRQoL information was negatively
associated with the number of years the respondent had been practicing as a neurologist.
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Neurologists, who have been practicing for ten years or more, are less likely to show the
behavioral intention compared to someone who had been practicing for fewer than ten years.
It may be that neurologists who have been practicing for a long time may tend to adhere too
strongly to their specific routine or beliefs and be less likely to be open to using relatively
newer methods such as HRQoL questionnaires.
One suggestion that has been recommended to address this, is the incorporation and
use of HRQoL measures during medical training leading to repeated exposure to these
methods (Russak et al., 2003). Repeated use of health status and HRQoL questionnaires
causes clinicians begin to instinctively make sense of the ranges over which scores can be
expected and the meanings associated with the deviations from these values (Pincus &
Wolfe, 2000; Wolfe & Pincus, 1991). Clinicians may also begin to comprehend the changes
in scores reported across two or more visits using the patients as their own referents or
controls. Initial (graduate) training in the use of HRQoL questionnaires would be able to
provide the familiarity that may be necessary to facilitate their acceptance by neurologists
and physicians in general.
This study provided evidence of the ease of administration (face-to-face and by mail)
and scoring of recently developed questionnaires assessing functioning and HRQoL of
patients with MS in an outpatient clinic. In a clinic setting, such questionnaires can be
administered by health care professionals other than neurologists such as nurses, interns or
even research assistants. Alternatively, the HRQoL and health status information may be
collected by mail. The data collected can then be stored in a database on the clinic premises.
Having access to such a database may allow neurologists to continually monitor their patients
with MS without the need for frequent clinic visits, thus conserving time and resources.
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Such questionnaires may also improve communication with patients and allow neurologists
to understand aspects of the disease which are more relevant from the patient’s perspective.

Limitations
Overall, Phase I (Objectives 1, 2 and 3) of this study was adequately powered and the
sample size of 116 fell within the target range for all proposed analyses (testing concurrent
validity and regression analyses to determine predictors of HRQoL and its domains). This
sample size also met the recommendations of most statistical “rules of thumb” discussed
earlier. However, the generalizability of the results will be somewhat limited because the
sample was a convenience sample and included only regional patients with MS (mostly from
West Virginia but also included some residents of Pennsylvania, Maryland and Ohio).
Item-scale and scale-domain structure of the questionnaires could have been tested to
investigate some deviations observed in their psychometric properties such as, the high
correlation coefficient between MSIS-29 physical impact and HAQUAMS mood scales as
and the low item-total correlation for item 21 of MSIS-29. Testing the structure of the
HRQoL questionnaires however, would require the utilization of statistical tests such as
confirmatory factor analysis. A good general rule of thumb for factor analysis is a sample
size of at least 300 (Tabachnick BG & Fidell LS, 1996b). The sample size of 116 in this
study precluded the use of such techniques.
The course of MS for each patient, for example, whether the type of MS was
Secondary Progressive, Primary Progressive, Relapsing Remitting, or Primary Relapsing,
could not be identified due to unavailability of this information from many of the patient
medical records. Course of MS has been shown to be a significant predictor of MS-related
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HRQoL in the past and would have been a relevant variable to include in this study. Hence,
the results of the regression analyses to identify predictors of HRQoL and its domains in this
study may be subjected to omitted-variable bias.
Another limitation of this study was that time since last relapse was not assessed for
patients who were included in the final sample. Exclusion of this variable may have
implications for our findings. First, since the effects of a relapse can last for months or even
a year, it is possible that some patients in our sample may not have completely recovered
from a relapse that they had more than four weeks (inclusion criterion) prior to the first
assessment. This may have affected their responses to the HRQoL questionnaires at the time
of administration, as they were not at their true baseline state at that time. Second,
differences may exist even between those who have completely recovered from a relapse.
For example, someone who has completely recovered from a relapse three months ago may
perceive their health status or quality of life differently than someone who completely
recovered from a relapse more than two years ago.
Simple counts of comorbid conditions were used to calculate the comorbidity variable
for the regression models (Phase 1, Objectives 2 and 3). One disadvantage of this approach
was the reliance on a simple count of comorbid chronic conditions from a limited list of
diseases, regardless of their severity. Also, the number and type of medical conditions may
differ from those used elsewhere and limit the comparison of these results with other relevant
studies. Future research that intends to adjust for comorbidity in relation to quality of life
outcomes in MS can consider using other recommended multi-morbidity indices such as the
Cumulative Illness Rating Scale (CIRS) and the Functional Comorbidity Index (FCI) (Fortin
et al., 2006; Fortin et al., 2005b).
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Responsiveness of the HRQoL measures was calculated using scores at baseline
(Time 1) and follow-up (Time 2). In order to accurately calculate responsiveness, the time
difference between the baseline and follow-up assessment is very important. This study was
initially designed to determine responsiveness of the measures in the sample after three
months. Hence, the follow-up assessment for each patient should have been made exactly
three months following initial administration. However, due to difficulties encountered in
scheduling patient visits exactly three months following baseline assessment, follow-up
assessments were made during a three to six month time period following the baseline
administration for each patient.
Only 54 of the 116 participants completed the assessments at Time 2 and the
calculation of responsiveness was limited only to these participants. One reason for a low
number of participants at follow-up was the short timeline for the study (March 1 to October
31, 2006). Since time to follow-up was decided to be at least three months following initial
administration, the first follow-up assessment in the study period occurred after May 31,
2006. Similarly, follow-assessments were not done for anyone whose first administration
was on or following August 1, 2006, because these assessments fell beyond the study period.
Hence, follow-up data was collected only for those patients who had their first administration
on or before July 31, 2006
A sample of 278 would be required in order to calculate responsiveness with a
conservative effect size of 0.3 and a power level of 0.8. With respect to this estimation, the
sample size for responsiveness analysis in this study was very small. The interpretation of
the responsiveness should therefore be made with attention to the issues encountered with
data collection and the small sample size. The responsiveness indices displayed no
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significant change in the HRQoL of the patients with MS, irrespective of the direction (or
sign) of the change score. However, the follow-up time was six months at the most and this
may not have been sufficient to capture changes in non-institutionalized patients with MS.
Longer follow-up periods ranging from 12 to 24 months would have been better able to
capture such changes. A longer timeline can provide data that would not only allow for easy
interpretation of responsiveness but also increase the overall sample size of the study.
Since this study relied exclusively on patient reported questionnaires, its conclusions
may be affected by self-report or reporting bias. Self-report bias is inherent to the area of
quality of life and involves an exaggeration or diminution of symptoms/functioning by the
patients. Another type of reporting bias is called recall bias. Recall bias occurs when the
way the respondent answers a question is affected not just by the correct answer, but also by
the respondent's memory. Such a bias may have affected data regarding the year of diagnosis
of MS (patient self-report). This is a limitation since the actual year of clinical diagnosis
may have been different from what was reported by the patient. However, because of
unavailability of such information in the patient medical records, the actual year of diagnosis
could not be confirmed. It should be noted that prior to the first assessment, neurologists
approached patients with MS and requested their participation in the study. Hence, it is
possible that patient reports may have been influenced by their belief of how the treating
neurologist may perceive their responses to the questionnaires in the study (similar to social
desirability bias).
The findings of Phase II of this study are fairly generalizable since the respondents to
the survey were a national sample of neurologists practicing in outpatient settings. One
threat to the validity and generalizability of the results was a lower than usual response rate
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(4.6%). This low response rate may have occurred due to absence of incentives provided to
the neurologists. Monetary and non-monetary incentives can increase response rates among
physicians and usually more impact when delivered with the initial questionnaire than when
promised upon its return (Hopkins KD & Gullickson AR, 1992; Everett SA, Price JH, Bedell
AW, & Telljohan Sk, 1997). Using lotteries has also been demonstrated as a cost-effective
method to increase response rates among physicians in larger surveys (Baron, De Wals, &
Milord, 2001). Lotteries involve a promise of an incentive (e.g. an opportunity to win a cash
prize) in order to stimulate a better response rate.
A larger proportion of the sample (65%) reported that they were in the precontemplation stage (either unaware or not planning on using HRQoL information in
practice). These respondents also indicated that it was less important to assess HRQoL
information in patients with MS compared to contemplators. Based on these findings it may
be that many neurologists may not assign sufficient importance to HRQoL assessment to
warrant even completion of the HRQoL-related survey such as the one in this study. This
could be a common trend amongst neurologists and another reason for lack of response.
In any case achieving a high response rate on physician surveys has been known to be
a challenging task and physician response rates as low as 11% have been documented (Asch
et al., 1997; Cummings, Savitz, & Konrad, 2001). The low response rate of this study may
be incidental either to the length of survey (five pages plus two HRQoL questionnaires each)
or to the target population i.e. neurologists. Differences may exist in the response rates of
medical specialists (e.g. neurologists) compared to that of primary care physicians, and any
such potential variations may still need further exploration. Response rates among
neurologists may be improved by sending pre-screening cards asking whether they would be
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willing to participate in an upcoming mail survey. The final survey instrument would then be
sent only to those who respond positively to the pre-screening mailing in order to improve
response rate.
The results of this study may also be susceptible to non-response bias (differences
between responders and non-responders that may have an impact on the generalizability of
the results). As a continuation of this study, follow-up letters will be mailed in order to
collect non-response data from the neurologists in the sample. Another way to assess nonresponse bias could be to perform a telephone survey and determine whether there were any
significant differences between those who returned the completed questionnaires and those
who did not on variables such as age-group, gender, practice characteristics etc. This method
would involve making a clinical appointment with the neurologist over the phone to collect
this data and reimbursing them for their time. Such a non-response analysis can be
performed in future surveys of neurologists. Other studies have assessed non-response bias,
by comparing demographics of physicians based on their time of response. Late responders,
that is, those that did not respond to the first mailing, were considered as proxies for nonresponders. A review of these studies showed that minor differences were observed in
medical practice variables (e.g. number of years in practice), while income, area and type of
practice, gender and age on did not differ significantly among physicians (Kellerman &
Herold, 2001).
Since information regarding HRQoL assessment is self-reported, results of this study
may also be susceptible to social desirability bias. In some circumstances, respondents may
be tempted to give the socially desirable response rather than describe what they actually
think, believe, or do. This bias may have affected responses to questions that asked about the
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intention to assess HRQoL information in clinical practice or the usefulness of such
information in the routine care of patients with MS.

Considerations for Future Research
This study was the first of its kind to incorporate all psychometric properties as well
as neurologist and patients’ opinion regarding two currently relevant PRO measures in MS
(MSIS-29 and HAQUAMS). Neither of the measures was found to be psychometrically
superior to the other. However, it is clear that these measures are more suitable for use in
MS compared to generic measures of HRQoL such as SF-36. The sample size for this study,
although adequate to measure the psychometric properties of the measures, was modest. It is
possible that stronger evidence of reliability, validity and item-level scaling success might
have been found with a larger sample size and increased power. This study is one of the few
that compared responsiveness for the PRO measures in a sample of non-institutionalized
patients with MS. Although the analysis was not sufficiently powered to detect the changes
in such patients, this study provides preliminary evidence of responsiveness of HAQUAMS
and MSIS-29 and also insights into methodological problems that can be encountered when
collecting data from non-institutionalized MS patients. Hence, further comparisons of these
PRO measures should preferably be conducted as multi-site studies with a large and diverse
(patients with varying levels of severity) population of patients with MS, in order to improve
generalizability of the findings.
Incorporating HRQoL assessment in routine practice an as aid to clinical decisionmaking in MS patients is a logical follow up to the evidence that has been provided by this
study using MS-related PRO measures. As can be observed from these findings, PRO

153

measures can not only be succinct, easy to score and administer but can also shed light on
factors that are most relevant to non-institutionalized patients with MS for example, visual
impairment. Pilot studies utilizing PRO measures (VFQ, GNDS) should be undertaken in the
future to monitor critical factors affecting HRQoL (HAQUAMS) in patients with MS in
routine clinical practice and this evidence should be corroborated with objective clinical tests
(visual acuity, quantitative tests of motor function). In addition to known determinants of
HRQoL the impact of other variables such as type of treatment should also be investigated.
This is important because newer medications such as Tysabri (Natalizumab), a recombinant
monoclonal antibody, may improve HRQoL in patients with MS not only due to patientfriendly dosing regimens (once a week administration) but also due to a different mechanism
of action than that of conventional drugs (Interferons).
A shift of emphasis needs to take place with increased focus on practical applications
of HRQoL questionnaires and their inclusion in clinical decision-making and policy
decisions. Very few neurologists if any are utilizing even the most basic and standard
instruments such as the SF-36. A larger push from professional organizations such as the
American Academy of Neurology and the National Multiple Sclerosis Society is necessary to
ensure that HRQoL questionnaires play a significant albeit an auxiliary role in the routine
care of patients with MS.
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Appendix A: Patient Invitation Letter

October, 2005
Patient Name
Dear ___________________:
The Departments of Neurology and the School of Pharmacy at West Virginia University,
have come together to conduct a research study in the area of multiple sclerosis. You may be
aware of the various symptoms of this condition which can have an impact on your quality of
life. The objective of this study is to determine where the focus of care needs to be directed to
enable us to ensure that you are receiving the best care possible for your multiple sclerosis and
also identify ways to allow the neurologist to understand the issues which are most important
from your perspective. I would like to encourage you to participate in this study during your
next visit scheduled on the ________________. Your participation will entail completion of a
set of questionnaires and two non-invasive clinical tests. This study may provide useful
information which will serve as a guide for your attending neurologist. Your input will be a
source of tremendous help in providing general information which will be used by neurologists
to help others who have your same health concerns.
The information that you provide, when participating in the study, will be kept as
confidential as legally possible and results will be presented only in an aggregate format.
You do not have to answer every question in the questionnaire and participation in the
study is completely voluntary. You may choose not to participate at any time; however, after
you have provided the information, it will become anonymous and you will be unable to
withdraw your data since there will be no way to identify individual information. If you choose
not to participate, this will not jeopardize in any way your relationship with me or with the WVU
neurology clinic.
Please allow about forty-five minutes during your upcoming visit to participate in this
study. You may answer the questions during the wait period before your consultation and
complete the rest later. The study coordinators thank you in advance for your time and your
contribution to a greater understanding of the health concerns of patients with multiple sclerosis.
If you have any questions or need more information, please contact Vivek Pawar MS at (304)
685 7812 or Dr. Lesley-Ann Miller at (304) 293 0228.
Sincerely,

_____________________, MD
Department of ______________________
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Appendix B: Guys Neurological Disability Scale
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Appendix C: Visual Function Questionnaire
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Appendix D: Centers for Epidemiological Studies – Depression Scale
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Appendix E: Additional Questions

The following section will ask some questions you and your multiple sclerosis.
Please check or fill in the appropriate responses. Thank You!
1) What is your gender?
Male
Female
2) What is your age? ______ Years
3) What is your current marital status?
Single, Never Married
Married
Separated
Divorced
Widowed
A member of an unmarried couple
4) Which of the following would you say best describes your race?
White
African-American
Hispanic
Other
5) What is your current employment status?
Employed
Unemployed
Unemployed due to multiple sclerosis
6) Please provide the year in which you were diagnosed with Multiple
Sclerosis: _______
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Appendix F: Comorbidities

Please check if you have had or been treated for the following conditions in
the past. If you have had a diagnosis or treatment for a condition not noted in
the table, please describe under “Other conditions not noted in the table”. If
you have not had any diagnosis or treatments in the past, please check the box
at the bottom of the page.
_____ Abnormal mammogram

_____ Ear/nose/throat trouble

_____ Kidney problem

_____ Abnormal PAP smear

_____ Eating disorder

_____ Learning disabilities

_____ Alcohol/other substance use

_____ Eye problems

_____ Measles/Mumps/Rubella

_____ Anemia

_____ Gout

_____ Mental health condition

_____ Arthritis/joint disease

_____ Diabetes

_____ Insomnia

_____ Asthma

_____ Head injury

_____ Mononucleosis

_____ Back problems

_____ Headaches

_____ Neck injury

_____ Bleeding trait

_____ Hearing loss

_____ Seizures

_____ Broken bones

_____ Heart disease

_____ Heart murmur

_____ Sinusitis

_____ Chicken pox

_____ Hepatitis

_____ Skin diseases

_____ Chronic cough

_____ High blood pressure

_____ Thyroid problem

_____ Congenital defect

_____ High cholesterol

_____ Dizziness or fainting spells

_____ Joint injuries

_____ Cancer Æ Type ___________________________________
_____ Sexually transmitted disease Æ Type ___________________________________
_____ Ulcer / stomach or digestive problems
_____ Other ________________________________________________________________________
___________________________________________________________________________________

I have not had any diagnosis or treatment in the past for any of the conditions noted above or
any other conditions
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Appendix G: HRQoL Booklet
SECTION 1
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The following questions are regarding the section (Section 1) that you just completed.
1. Approximately how long did it take for you to complete this section? _____ minutes
2. What is your opinion regarding the number of questions in this section?
The questions were too many
The questions were too few
The number of questions was just right
3. What is your opinion regarding the way the questions in this section were written?
The questions were mostly easy to understand
The questions were mostly difficult to understand
No opinion
4. Do you feel that this section helped you express your opinion regarding most problems
that you face in your day-to-day activities?
Mostly Yes
Mostly No
SECTION
2
Not Sure
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SECTION 2
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The following questions are regarding the section (Section 2) that you just completed.
1. Approximately how long did it take for you to complete this section? _____ minutes
2. What is your opinion regarding the number of questions in this section?
The questions were too many
The questions were too few
The number of questions was just right
3. What is your opinion regarding the way the questions in this section were written?
The questions were mostly easy to understand
The questions were mostly difficult to understand
No opinion
4. Do you feel that this section helped you express your opinion regarding most problems
that you face in your day-to-day activities?
Mostly Yes
Mostly No
Not Sure
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SECTION 3
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The following questions are regarding the section (Section 3) that you just completed.
1. Approximately how long did it take for you to complete this section? _____ minutes
2. What is your opinion regarding the number of questions in this section?
The questions were too many
The questions were too few
The number of questions was just right
3. What is your opinion regarding the way the questions in this section were written?
The questions were mostly easy to understand
The questions were mostly difficult to understand
No opinion
4. Do you feel that this section helped you express your opinion regarding most problems
that you face in your day-to-day activities?
Mostly Yes
Mostly No
Not Sure
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Appendix H: VFQ Items

NEI-VFQ Scoring Algorithm – August 2002
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Appendix I: Cover Letter for the Neurologist Survey

March, 2006
Dear Dr.
We are conducting a survey to determine neurologists’ opinions regarding the use of healthrelated quality of life (HRQoL) information in the routine care of patients with multiple sclerosis
(MS). We are also interested in your opinion regarding two HRQoL questionnaires designed for use in
patients with MS (printed on colored paper) which have been included with this mailing.
It is our understanding that you may be involved in providing direct medical care to patients
with MS in an outpatient setting. We are contacting a random sample from a nationwide selection of
neurologists to ask them their views about HRQoL assessment in patients with MS, and whether or
not they use HRQoL information in clinical practice.
Your input is essential for us to understand what neurologists feel about HRQoL assessment
in patients with MS. Results from our study will allow us to identify the areas where efforts are
needed to facilitate translation of HRQoL findings into usable information for clinical practice.
Furthermore, your opinion regarding the specific enclosed questionnaires will aid in determining
suitability of their use in the routine care of patients with MS.
It will only take a few minutes to complete the attached questionnaire and your responses will
be kept as confidential as legally possible. On receiving your completed questionnaire, responses will
be combined with responses from other neurologists and analyzed and the results of this study will be
only reported in aggregate format. The survey is voluntary, however, we hope you will share your
experiences and opinions about MS-related HRQoL information.
If you choose to participate, please mail the completed survey back to us in the self-addressed
business reply envelope included alongside. This research is being conducted as part of a larger
doctoral dissertation study in Pharmaceutical Sciences at West Virginia University. If you need any
help completing this survey or have any questions, please contact Vivek Pawar at (304) 685-7812 or
Lesley-Ann Miller, PhD at (304) 293-0228. Thank you in advance for providing this information.
Sincerely
_________________

__________________

Vivek Pawar, MS
Doctoral Candidate

Lesley-Ann Miller
Assistant Professor
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Appendix J: Neurologist Survey
HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Neurologist Survey
Are you directly involved in the routine care of patients with multiple sclerosis?
No --- Please stop here and return this survey in the enclosed business reply envelope. Thank you for your time.
Yes --- Please continue with the next question
INSTRUCTIONS: Please spend a few minutes to look through the HRQoL questionnaire printed on the blue paper
followed by the questionnaire printed on the yellow paper (enclosed) before you begin answering the questions.
We would like your opinion regarding the enclosed HRQoL questionnaires. Kindly CIRCLE ({) the desired response.
First, about the blue questionnaire…
a. Do you think that using the blue questionnaire in your patients with MS will provide additional useful information,
compared to what you normally have available from conventional physical exams & clinical testing methods?
Not Sure

Mostly No
1

2

3

4

Mostly Yes
5

6

7

b. What do you think about the length of the blue questionnaire?
Too Short
1

Too Long

Just Right
2

3

4

5

6

7

c. From the perspective of patients with MS, what is your opinion regarding the way the questions are worded?
Not Sure

Mostly Easy to Understand
1

2

3

4

Mostly Difficult to Understand
5

6

7

Now, about the yellow questionnaire….
d. Do you think that using the yellow questionnaire in your patients with MS will provide additional useful information,
compared to what you normally have available from conventional physical exams & clinical testing methods?
Not Sure

Mostly No
1

2

3

4

Mostly Yes
5

6

7

e. What do you think about the length of the yellow questionnaire?
Just Right

Too Short
1

2

3

4

Too Long
5

6

7

f. From the perspective of a patient with MS, what is your opinion regarding the way the questions are worded?
Not Sure

Mostly Easy to Understand
1

2

3

4

Mostly Difficult to Understand
5
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6

7

INSTRUCTIONS: The following questions will ask your opinion regarding HRQoL assessment in routine care of
patients with MS. Kindly CIRCLE ({) the desired response
1)

a. How important is it to collect HRQoL information in the routine care of patients with multiple sclerosis?
Not at all important 1

2)

2

3

4

5

6

7 Very important

a. HRQoL information may help address problems which the patients with MS will not bring up or think of
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Knowing about problems which patients with MS will not bring up or would not think of is…
Extremely Undesirable 1
3)

2

3

4

5

6

7 Extremely Desirable

a. Assessing HRQoL information will make the patients feel like I am concerned about their overall well-being
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. For patients with MS to feel that I am concerned about their overall well-being is
Extremely Undesirable 1
4)

2

3

4

5

6

7 Extremely Desirable

a. HRQoL information will help me understand the impact that MS is having on an individual’s life
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Knowing what kind of impact MS is having on the life of my patient with MS is…
Extremely Undesirable 1
5)

2

3

4

5

6

7 Extremely Desirable

a. HRQoL information can provide subjective information about the patient over and above the information
provided by standard objective tests
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Having a subjective assessment of my patient’s condition in addition to standard objective tests is
Extremely Undesirable 1
6)

2

3

4

5

6

7 Extremely Desirable

a. HRQoL information can be used to monitor changes or responses to treatment in patients with MS
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Monitoring changes or responses to treatment using HRQoL information in patients with MS is
Extremely Undesirable 1
7)

2

3

4

5

6

7 Extremely Desirable

a. HRQoL information assessment in patients with MS can facilitate shared clinical decision making
Strongly Disagree 1

2

3

4
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5

6

7 Strongly Agree

b. Making shared clinical decisions with MS patients is
Extremely Undesirable 1
8)

2

3

4

5

6

7 Extremely Desirable

a. Use of HRQoL questionnaires will lengthen the consultation with the patient
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Lengthening consultation time with patients with MS to collect HRQoL information is…
Extremely Undesirable 1
9)

2

3

4

5

6

7 Extremely Desirable

a. I feel confident that I could assess HRQoL information from patients with MS if I wanted to
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Assessing HRQoL information from patients with MS is __________ for me
Easy
10)

1

2

3

4

5

6

7 Difficult

a. The decision whether or not to assess HRQoL information from patients with MS is beyond my control
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Whether I assess HRQoL information from patients with MS is entirely upto me
Strongly Disagree 1
11)

2

3

4

5

6

7 Strongly Agree

a. The American Academy of Neurology recommends that I should assess HRQoL in patients with MS
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. What the American Academy of Neurology thinks regarding my decision about HRQoL assessment in patients
with MS is important to me
Not at all
12)

1

2

3

4

5

6

7 Very Much

a. Other neurologists believe that HRQoL information should be assessed in patients with MS
Strongly Disagree 1

2

3

4

5

6

7 Strongly Agree

b. Doing what other neurologists believe regarding HRQoL assessment in patients with MS is important to me
Not at all

1

2

3

4

5

6

7 Very Much

I intend to assess HRQoL information from patients with MS
Strongly Disagree 1

2

3

4
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5

6

7 Strongly Agree

INSTRUCTIONS: The following questions will ask your opinion regarding HRQoL information in general. Kindly
CIRCLE ({) the desired response
Strongly
Disagree

Not
Sure

Strongly
Agree

1) I do not understand how HRQoL information
would be used in routine care of patients with MS

1

2

3

4

5

6

7

2) HRQoL information facilitates better
communication with patients

1

2

3

4

5

6

7

3) HRQOL is not relevant to neurologists

1

2

3

4

5

6

7

4) HRQoL information allows for identification
and prioritization of problems

1

2

3

4

5

6

7

5) There are no benefits of using HRQoL
information in patients with MS

1

2

3

4

5

6

7

6) HRQoL information can be used to screen for
hidden problems (e.g. psychological)

1

2

3

4

5

6

7

7) Scoring HRQoL questionnaires is difficult

1

2

3

4

5

6

7

8) HRQoL information requires too much
resources or time

1

2

3

4

5

6

7

9) HRQoL information is not trustworthy

1

2

3

4

5

6

7

10) HRQoL information can be used to really
treat the “whole” patient

1

2

3

4

5

6

7

Are there any other factors which influence your decision whether or not to use HRQoL information in patients with MS?
____________________________________________________________________________________________
____________________________________________________________________________________________
____________________________________________________________________________________________
INSTRUCTIONS: Please indicate whether you currently assess HRQoL information using formal standardized
questionnaires in routine care of MS patients with MS? Kindly CHECK (9) your response
Yes

No
I am thinking of using HRQoL questionnaires in my practice within the next month
I am thinking of using HRQoL questionnaires in my practice within the next 6 months
I am aware of HRQoL questionnaires, but have not thought about using them in my practice
I am unaware of any HRQoL questionnaires and of how to use them in my practice
I have been using HRQoL questionnaires in my practice for more than six months
I have been using HRQoL questionnaires in my practice for less than six months
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INSTRUCTIONS: Please indicate whether you have used in clinical practice or heard of the following HRQoL
questionnaires. Kindly CHECK (9) your response
I have heard of

I have used
Medical Outcomes Survey Short Form (SF-36)
Multiple Sclerosis Quality of Life 54 (MSQOL-54)
Functional Assessment of Multiple Sclerosis (FAMS)
Multiple Sclerosis Quality of Life Inventory (MSQLI)
Multiple Sclerosis Impact Scale (MSIS-29)
Hamburg Quality of Life Assessment in Multiple Scleroris (HAQUAMS)
Sickness Impact Profile (SIP)
Other- _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

INSTRUCTIONS: This section will ask information about you and your practice. Kindly CHECK (9) your response
1. Please indicate your gender:

Male

Female

2. Please indicate your age-group:
30 years or younger
31 to 40 years
41 to 50 years
51 to 60 years
61 years and older
3. Your primary practice site is:
Hospital based

University-affiliated hospital

Solo, Office-based

Group, office based

Others, Please Specify: _________________________________________________________
4. Approximately how many patients with MS do you personally see per week? _________ patients
5. Have you ever participated in a MS-related clinical trial with a HRQoL component?

Yes

No

6. Please indicate the year in which you received your board certification in neurology: __________
7. How many years have you been in practice as a neurologist?
Currently a resident
5 years or fewer
6-10 years
10 years or more
Additional comments regarding HRQoL assessment in patients with MS in clinical practice:
______________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
THANK YOU FOR YOUR INPUT!
Kindly return this questionnaire to us in the enclosed business reply envelope.
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